GPR39 protein antagonists

JP2024542036APending Publication Date: 2024-11-13VASOCARDEA INC
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2024525728
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-26
Filing Date
2022-10-25
Publication Date
2024-11-13

Smart Images

  • Figure 2024542036000001_ABST
    Figure 2024542036000001_ABST
Patent Text Reader

Abstract

Novel compounds that act as antagonists to human GPR39 protein are disclosed. Pharmaceutical compositions and methods of use for antagonists to human GPR39 protein are disclosed. In particular, methods of using the antagonists in the treatment of diseases or conditions including cardiovascular diseases, endocrine and hormonal diseases, cancer diseases, metabolic diseases, gastrointestinal and liver diseases, hematological diseases, neurological diseases, and respiratory diseases are disclosed herein. [Formula 1] TIFF2024542036000457.tif34170
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 63 / 272,076, filed October 26, 2021, the complete disclosure of which is incorporated herein by reference in its entirety.

[0002] The present disclosure relates to novel compounds that act as antagonists to the human GPR39 protein. Additionally, the present disclosure relates to pharmaceutical compositions and methods of using antagonists to the human GPR39 protein in the treatment of diseases or conditions, including cardiovascular diseases, endocrine and hormonal disorders, cancer diseases, metabolic diseases, gastrointestinal and liver diseases, hematological diseases, neurological diseases, and respiratory diseases. [Background technology]

[0003] The use of GPR39 antagonists has been described for treating pain sensitivity, including hyperalgesia, and for suppressing appetite (US Pat. No. 5,629,999 - Jin et al.).

[0004] The use of GPR39 agonists and / or antagonists in enhancing glucose regulation and treating disorders of glucose metabolism in diseases such as diabetes and metabolic syndrome is described in patent application WO 02 / 044999 - Moreaux et al. - Janssen Pharmaceutica NV.

[0005] Non-Patent Document 1 discloses the conclusion that GPR39 receptor antagonists may be useful for diseases affecting gastric motility, including functional dyspepsia and diabetic gastroparesis, and / or diseases affecting colorectal motility, such as irritable bowel syndrome, diarrhea, or chronic constipation.

[0006] Non-patent document 2 addresses the role of the obestatin / GPR39 system in regulating motility, EMT, and invasion of gastric adenocarcinoma cells.

[0007] GPR39 antagonists are also discussed in Non-Patent Document 3, particularly their use in treating breast cancer, including ER-negative breast cancer.

[0008] The use of GPR39 antagonists in the treatment of various cancers is discussed in US Pat. No. 6,213,999 (Claassen et al.).

[0009] Inge Depoortere, in Non-Patent Document 4, discloses the use of GPR39 antagonists in the treatment of movement disorders such as functional dyspepsia, paresis, and chronic constipation.

[0010] Non-Patent Document 5 discusses the potential use of GPR antagonists in promoting or enhancing colonic epithelial function and tight junction barrier integrity, including treating ulcerative colon diseases such as ulcerative colitis and diarrheal pathologies. [Prior art documents] [Patent documents]

[0011] [Patent Document 1] U.S. Patent Publication No. 2009 / 0298756 [Patent Document 2] International Publication No. WO2007 / 141322 [Patent Document 3] U.S. Patent Publication No. 2004 / 0071708 [Non-patent literature]

[0012] [Non-Patent Document 1] Altered Gastrointestinal and Metabolic Function in the GPR39-Obestatin Receptor-Knockout Mouse,Gastroenterology,Moechars et al.,Oct.2006,Vol.131,Issue 4,pp.1131-1141 [Non-patent document 2] The role of the obestatin / GPR39 system in human gastric adenocarcinomas,Alen et al.,Oncotarget 2016,7:5957-5971 [Non-patent document 3] Enhanced ZnR / GPR39 Activity in Breast Cancer,an Alternative Trigger of Signaling Leading to Cell Growth,Ventura-Bixenshpaner et al.,Scientific Reports(2018)8:8119 [Non-patent document 4] GI functions of GPR39: novel biology,Current Opinion in Pharmacology,2012,12:647-652 [Non-Patent Document 5] The zinc sensing receptor,ZnR / GPR39,controls proliferation and differentiation of colonocytes and thereby tight junction formation in the colon,Cohen et al.,Cell Death and Disease(2014)5,e1307 Summary of the Invention [Problem to be solved by the invention]

[0013] [Means for solving the problem]

[0014] A compound of formula (IA), or a pharmaceutically acceptable salt thereof: [ka] During the ceremony, X1 is selected from the group consisting of: [ka] n a is an integer selected from the group of 0, 1, and 2; n b is an integer selected from the group of 0, 1, 2, 3, and 4, However, n a +n b The total must be between 2 and 4, or or X1 and Z1 together form a fused ring system of formula (Ia), [ka] R a is selected from the group of hydrogen and C1-C3 alkyl; X2 is selected from the group consisting of: [ka] Wavy lines in each case [ka] represents the bond to which each X1 and X2 moiety is attached; Y1 is selected from the group of C and N; Y2 is selected from the group of C, N, S, and O, with the proviso that when Y2 is O, R4 is absent, and when Y2 is S, R4 is absent or present one or two times; However, provided that two or more of Y1 and Y2 are not C, n c is an integer selected from the group of 1, 2, and 3; n d is an integer selected from the group of 1, 2, and 3, However, n c +n dThe total must be between 2 and 6. Z1, Z2, and Z3 are each independently selected from the group of C and N, provided that Z1, Z2, and Z3 are not R2 or a non-hydrogen R 2’ If it is bonded to, it must be C, R1 is C1-C6 alkyl, -(CH2) n1 -C3-C6 cycloalkyl, -NR x R y , phenyl, and benzyl, wherein said C1-C6 alkyl group and said -(CH2) n1 the ring of the —C3-C6 cycloalkyl, phenyl, and benzyl groups is substituted with 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; R x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; n1 is an integer selected from the group of 0, 1, 2, and 3; R2 is a carbocyclic and monocyclic heterocyclic ring, or a ring bonded through a carbon atom and containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from the group of N, S, and O, any of the foregoing being C1-C6 alkyl, —O—C1-C6 alkyl, —(CH2) n1 -C3-C6 cycloalkyl, -CF3, halogen, oxo, cyano, -O-(CH2) n2 -C3-C6 cycloalkyl, -C(=O)OH, -C(=O)-O-C1-C6 alkyl, -S(=O)2-C1-C6 alkyl, -C(=O)-NR x R y , -N(R x )(S(=O)2-C1-C6 alkyl), -(CH2) n1-heterocyclyl (including a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from the group N, S, and O), and phenyl, wherein R x and R y are each independently selected from the group of H and C1-C6 alkyl substituted with 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl, with the proviso that —(CH2) n1 provided that R2 is not pyridinyl when not substituted at least once by -C3-C6 cycloalkyl or phenyl; R2 ’ is selected from the group of hydrogen, OH, halogen, C1-C6 alkyl, and —CF3; R3 occurs one or more times and is independently selected from the group consisting of: a) hydrogen, halogen, cyano, or OH; b) —CO2H or —CO2—(C1-C6 alkyl); c) C1-C6 alkyl or —O—C1-C6 alkyl substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen, CF3, and OH; d) phenyl, benzyl, C3-C6 cycloalkyl, and —CH2—C3-C6 cycloalkyl, wherein each ring of said phenyl, benzyl, C3-C6 cycloalkyl, and —CH2—C3-C6 cycloalkyl group is substituted with 0, 1, 2, or 3 substituents selected from OH, halogen, cyano, and C1-C6 alkyl, and said C1-C6 alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen, —CF3, and OH; e) a 5- or 6-membered heterocyclic ring containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, wherein the 5- or 6-membered heterocyclic ring is substituted with 0, 1, 2, or 3 substituents selected from OH, halogen, benzyl, and C1-C6 alkyl, and the C1-C6 alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen and OH; and f) two R3 form a bridge between carbon atoms, said atoms of said bridge comprising 1, 2, or 3 atoms independently selected from the group of carbon, N, O, and S; R4 occurs once or twice and is selected from H, halogen, oxo, C1-C6 alkyl, -(CH2) n2 -C3-C6 cycloalkyl, -O-(CH2) n2 -C3-C6 cycloalkyl, -C(=O)-O-C1-C6 alkyl, -S(=O)2-C1-C6 alkyl, -C(=O)-NR x R y , -N(R x )(S(═O)2-C1-C6 alkyl), phenyl, benzyl, or heterocyclic rings having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are independently selected from the group of N, O, and S; x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from halogen, OH, CF3, and —O—C1-C3 alkyl; When Y2 is carbon, R4 can also be -O-C1-C6 alkyl, or two R4 can form a spirocyclic carbocycle or spirocyclic heterocycle; R4 C1-C6 alkyl, -C(=O)-O-C1-C6 alkyl, and -O-C1-C6 alkyl group, and the -(CH2) n2 -C3-C6 cycloalkyl and -O-(CH2) n2the rings of the -C3-C6 cycloalkyl, phenyl, and benzyl groups each independently have halogen, CF3, OH, 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are substituted by 0, 1, 2, or 3 substituents selected from the group of heterocyclic rings selected from the group of N, O, and S, substituted or unsubstituted phenyl, and -O-C1-C3 alkyl; R5 is selected from the group consisting of H and C1-C6 alkyl, and the C1-C6 alkyl group of R5 is selected from halogen, -CF3, -NR x R y and OH, R x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; R6 is H, C1-C6 alkyl, a heterocyclic ring having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, phenyl, and benzyl, and the C1-C6 alkyl group of R6 is selected from the group of halogen, -CF3, -NR x R y and OH, and the rings of the phenyl and benzyl groups of R6 and the heterocyclic ring are substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group C1-C6 alkyl, —O—C1-C6 alkyl, halogen, —CF3, and OH, wherein R x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from halogen, OH, CF3, and —O—C1-C3 alkyl; Provided is a compound, or a pharmaceutically acceptable salt thereof, wherein n2 in each instance is an integer selected from the group of 0, 1, 2, and 3.

[0015] A compound of formula (IB), or a pharmaceutically acceptable salt thereof: [ka] During the ceremony, X1 is selected from the group consisting of: [ka] n a is an integer selected from the group of 0, 1, and 2; n b is an integer selected from the group of 0, 1, 2, 3, and 4, However, n a +n b The total must be between 2 and 4, or or X1 and Z1 together form a fused ring system of formula (Ia), [ka] R a is selected from the group of hydrogen and C1-C3 alkyl; X2 is selected from the group consisting of: [ka] Wavy lines in each case [ka] represents the bond to which each X1 and X2 moiety is attached; Y1 is selected from the group of C and N; Y2 is selected from the group of C, N, S, and O, with the proviso that when Y2 is O, R4 is absent, and when Y2 is S, R4 is absent or present one or two times; However, provided that two or more of Y1 and Y2 are not C, n c is an integer selected from the group of 1, 2, and 3; n d is an integer selected from the group of 1, 2, and 3, However, n c +n d The total must be between 2 and 6. Z1, Z2, and Z3 are each independently selected from the group of C and N, with the proviso that Z1, Z2, and Z3 are C when attached to R2 or a non-hydrogen R2'; R1 is C1-C6 alkyl, -(CH2) n1 -C3-C6 cycloalkyl, -NR x R y , phenyl, and benzyl, wherein said C1-C6 alkyl group and said -(CH2) n1 the ring of the —C3-C6 cycloalkyl, phenyl, and benzyl groups is substituted with 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; R x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; n1 is an integer selected from the group of 0, 1, 2, and 3; R2 is selected from the group of phenyl, pyridinyl, and a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system bonded through a carbon atom and containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 0, 1, 2, 3, or 4 additional ring heteroatoms selected from the group of N, S, and O, any of the foregoing being selected from C1-C6 alkyl, —O—C1-C6 alkyl, —(CH2) n1 -C3-C6 cycloalkyl, -CF3, halogen, oxo, cyano, -O-(CH2) n2-C3-C6 cycloalkyl, -C(=O)OH, -C(=O)-O-C1-C6 alkyl, -S(=O)2-C1-C6 alkyl, -C(=O)-NR x R y , -N(R x )(S(=O)2-C1-C6 alkyl), -(CH2) n1 -heterocyclyl (including a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from the group N, S, and O), and phenyl, wherein R x and R y are each independently selected from the group of H and C1-C6 alkyl substituted with 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl, with the proviso that —(CH2) n1 provided that R2 is not pyridinyl when not substituted at least once by -C3-C6 cycloalkyl or phenyl; R2' is selected from the group of OH, halogen, C1-C6 alkyl, and -CF3; R3 occurs one or more times and is independently selected from the group consisting of: g) hydrogen, halogen, cyano, or OH; h) —CO2H or —CO2—(C1-C6 alkyl), i) C1-C6 alkyl or —O—C1-C6 alkyl substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen, CF3, and OH; j) phenyl, benzyl, C3-C6 cycloalkyl, and —CH2—C3-C6 cycloalkyl, wherein each ring of said phenyl, benzyl, C3-C6 cycloalkyl, and —CH2—C3-C6 cycloalkyl group is substituted with 0, 1, 2, or 3 substituents selected from OH, halogen, cyano, and C1-C6 alkyl, and said C1-C6 alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen, —CF3, and OH; k) a 5- or 6-membered heterocyclic ring containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, wherein the 5- or 6-membered heterocyclic ring is substituted with 0, 1, 2, or 3 substituents selected from OH, halogen, benzyl, and C1-C6 alkyl, and the C1-C6 alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen and OH; and l) two R3 form a bridge between carbon atoms, said atoms of said bridge comprising 1, 2, or 3 atoms independently selected from the group of carbon, N, O, and S; R4 occurs once or twice and is selected from H, halogen, oxo, C1-C6 alkyl, -(CH2) n2 -C3-C6 cycloalkyl, -O-(CH2) n2 -C3-C6 cycloalkyl, -C(=O)-O-C1-C6 alkyl, -S(=O)2-C1-C6 alkyl, -C(=O)-NR x R y , -N(R x )(S(═O)2-C1-C6 alkyl), phenyl, benzyl, or heterocyclic rings having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are independently selected from the group of N, O, and S; x and R yeach is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from halogen, OH, CF3, and —O—C1-C3 alkyl; When Y2 is carbon, R4 can also be -O-C1-C6 alkyl, or two R4 can form a spirocyclic carbocycle or spirocyclic heterocycle; R4 C1-C6 alkyl, -C(=O)-O-C1-C6 alkyl, and -O-C1-C6 alkyl group, and the -(CH2) n2 -C3-C6 cycloalkyl and -O-(CH2) n2 the rings of the -C3-C6 cycloalkyl, phenyl, and benzyl groups each independently have halogen, CF3, OH, 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are substituted by 0, 1, 2, or 3 substituents selected from the group of heterocyclic rings selected from the group of N, O, and S, substituted or unsubstituted phenyl, and -O-C1-C3 alkyl; R5 is selected from the group consisting of H and C1-C6 alkyl, and the C1-C6 alkyl group of R5 is selected from halogen, -CF3, -NR x R y and OH, R x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; R6 is H, C1-C6 alkyl, a heterocyclic ring having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, phenyl, and benzyl, and the C1-C6 alkyl group of R6 is selected from the group of halogen, -CF3, -NR x R yand OH, and the rings of the phenyl and benzyl groups of R6 and the heterocyclic ring are substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group C1-C6 alkyl, —O—C1-C6 alkyl, halogen, —CF3, and OH, wherein R x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from halogen, OH, CF3, and —O—C1-C3 alkyl; Further provided is a compound, or a pharmaceutically acceptable salt thereof, wherein n2 in each instance is an integer selected from the group of 0, 1, 2, and 3.

[0016] A compound of formula (IC), or a pharmaceutically acceptable salt thereof: [ka] During the ceremony, X1 is selected from the group consisting of: [ka] n a is an integer selected from the group of 0, 1, and 2; n b is an integer selected from the group of 0, 1, 2, 3, and 4, However, n a +n b The total must be between 2 and 4, or or X1 and Z1 together form a fused ring system of formula (Ia), [ka] R a is selected from the group of hydrogen and C1-C3 alkyl; X2 is selected from the group consisting of: [ka] Wavy lines in each case [ka] represents the bond to which each X1 and X2 moiety is attached; Y1 is selected from the group of C and N; Y2 is selected from the group of C, N, S, and O, with the proviso that when Y2 is O, R4 is absent, and when Y2 is S, R4 is absent or present one or two times; However, provided that two or more of Y1 and Y2 are not C, n c is an integer selected from the group of 1, 2, and 3; n d is an integer selected from the group of 1, 2, and 3, However, n c +n d is 2, 3, 5, or 6, Z1, Z2, and Z3 are each independently selected from the group of C and N, with the proviso that Z1, Z2, and Z3 are C when attached to R2 or a non-hydrogen R2'; R1 is C1-C6 alkyl, -(CH2) n1 -C3-C6 cycloalkyl, -NR x R y , phenyl, and benzyl, wherein said C1-C6 alkyl group and said -(CH2) n1 the ring of the —C3-C6 cycloalkyl, phenyl, and benzyl groups is substituted with 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; R x and R yeach is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; n1 is an integer selected from the group of 0, 1, 2, and 3; R2 is selected from the group of phenyl, pyridinyl, and a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system bonded through a carbon atom and containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 0, 1, 2, 3, or 4 additional ring heteroatoms selected from the group of N, S, and O, any of the foregoing being selected from C1-C6 alkyl, —O—C1-C6 alkyl, —(CH2) n1 -C3-C6 cycloalkyl, -CF3, halogen, oxo, cyano, -O-(CH2) n2 -C3-C6 cycloalkyl, -C(=O)OH, -C(=O)-O-C1-C6 alkyl, -S(=O)2-C1-C6 alkyl, -C(=O)-NR x R y , -N(R x )(S(=O)2-C1-C6 alkyl), -(CH2) n1 -heterocyclyl (including a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from the group N, S, and O), and phenyl, wherein R x and R y are each independently selected from the group of H and C1-C6 alkyl substituted with 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl, with the proviso that —(CH2) n1 provided that R2 is not pyridinyl when not substituted at least once by -C3-C6 cycloalkyl or phenyl; R2' is selected from the group of hydrogen, OH, halogen, C1-C6 alkyl, and -CF3; R3 occurs one or more times and is independently selected from the group consisting of: m) hydrogen, halogen, cyano, or OH; n) —CO2H or —CO2—(C1-C6 alkyl), o) C1-C6 alkyl or —O—C1-C6 alkyl substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen, CF3, and OH; p) phenyl, benzyl, C3-C6 cycloalkyl, and —CH2—C3-C6 cycloalkyl, wherein each ring of said phenyl, benzyl, C3-C6 cycloalkyl, and —CH2—C3-C6 cycloalkyl group is substituted with 0, 1, 2, or 3 substituents selected from OH, halogen, cyano, and C1-C6 alkyl, and said C1-C6 alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen, —CF3, and OH; q) a 5- or 6-membered heterocyclic ring containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, wherein the 5- or 6-membered heterocyclic ring is substituted with 0, 1, 2, or 3 substituents selected from OH, halogen, benzyl, and C1-C6 alkyl, and the C1-C6 alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen and OH; and r) two R3 form a bridge between carbon atoms, said atoms of said bridge comprising 1, 2, or 3 atoms independently selected from the group of carbon, N, O, and S; R4 occurs once or twice and is selected from H, halogen, oxo, C1-C6 alkyl, -(CH2) n2 -C3-C6 cycloalkyl, -O-(CH2) n2 -C3-C6 cycloalkyl, -C(=O)-O-C1-C6 alkyl, -S(=O)2-C1-C6 alkyl, -C(=O)-NR x R y , -N(R x)(S(═O)2-C1-C6 alkyl), phenyl, benzyl, or heterocyclic rings having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are independently selected from the group of N, O, and S; x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from halogen, OH, CF3, and —O—C1-C3 alkyl; When Y2 is carbon, R4 can also be -O-C1-C6 alkyl, or two R4 can form a spirocyclic carbocycle or spirocyclic heterocycle; R4 C1-C6 alkyl, -C(=O)-O-C1-C6 alkyl, and -O-C1-C6 alkyl group, and the -(CH2) n2 -C3-C6 cycloalkyl and -O-(CH2) n2 the rings of the -C3-C6 cycloalkyl, phenyl, and benzyl groups each independently have halogen, CF3, OH, 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are substituted by 0, 1, 2, or 3 substituents selected from the group of heterocyclic rings selected from the group of N, O, and S, substituted or unsubstituted phenyl, and -O-C1-C3 alkyl; R5 is selected from the group consisting of H and C1-C6 alkyl, and the C1-C6 alkyl group of R5 is selected from halogen, -CF3, -NR x R y and OH, R x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; R6 is H, C1-C6 alkyl, a heterocyclic ring having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, phenyl, and benzyl, and the C1-C6 alkyl group of R6 is selected from the group of halogen, -CF3, -NR x R y and OH, and the rings of the phenyl and benzyl groups of R6 and the heterocyclic ring are substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group C1-C6 alkyl, —O—C1-C6 alkyl, halogen, —CF3, and OH, wherein R x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from halogen, OH, CF3, and —O—C1-C3 alkyl; Also provided is a compound, or a pharmaceutically acceptable salt thereof, wherein n2 in each instance is an integer selected from the group of 0, 1, 2, and 3.

[0017] A compound of formula (ID), or a pharmaceutically acceptable salt thereof: [ka] During the ceremony, X1 is selected from the group consisting of: [ka] n a is an integer selected from the group of 0, 1, and 2; n b is an integer selected from the group of 0, 1, 2, 3, and 4, However, n a +n b The total must be between 2 and 4, or or X1 and Z1 together form a fused ring system of formula (Ia), [ka] R a is selected from the group of hydrogen and C1-C3 alkyl; X2 is selected from the group consisting of: [ka] Wavy lines in each case [ka] represents the bond to which each X1 and X2 moiety is attached; Y1 is selected from the group of C and N; Y2 is selected from the group of C, N, S, and O, with the proviso that when Y2 is O, R4 is absent, and when Y2 is S, R4 is absent or present one or two times; However, provided that two or more of Y1 and Y2 are not C, n c is an integer selected from the group of 1, 2, and 3; n d is an integer selected from the group of 1, 2, and 3, However, n c +n d The total must be between 2 and 6. Z1, Z2, and Z3 are each independently selected from the group of C and N, with the proviso that Z1, Z2, and Z3 are C when attached to R2 or a non-hydrogen R2'; R1 is C1-C6 alkyl, -(CH2) n1 -C3-C6 cycloalkyl, -NR x R y , phenyl, and benzyl, wherein said C1-C6 alkyl group and said -(CH2) n1the ring of the —C3-C6 cycloalkyl, phenyl, and benzyl groups is substituted with 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; R x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; n1 is an integer selected from the group of 0, 1, 2, and 3; R2 is selected from the group of phenyl, pyridinyl, and a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system bonded through a carbon atom and containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 0, 1, 2, 3, or 4 additional ring heteroatoms selected from the group of N, S, and O, any of the foregoing being selected from C1-C6 alkyl, —O—C1-C6 alkyl, —(CH2) n1 -C3-C6 cycloalkyl, -CF3, halogen, oxo, cyano, -O-(CH2) n2 -C3-C6 cycloalkyl, -C(=O)OH, -C(=O)-O-C1-C6 alkyl, -S(=O)2-C1-C6 alkyl, -C(=O)-NR x R y , -N(R x )(S(=O)2-C1-C6 alkyl), -(CH2) n1 -heterocyclyl (including a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from the group N, S, and O), and phenyl, wherein R x and R y are each independently selected from the group of H and C1-C6 alkyl substituted with 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl, with the proviso that —(CH2) n1provided that R2 is not pyridinyl when not substituted at least once by -C3-C6 cycloalkyl or phenyl; R2' is selected from the group of hydrogen, OH, halogen, C1-C6 alkyl, and -CF3; R3 occurs one or more times and is independently selected from the group consisting of: s) hydrogen, halogen, cyano, or OH; t) -CO2H or -CO2-(C1-C6 alkyl), u) C1-C6 alkyl or —O—C1-C6 alkyl substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen, CF3, and OH; v) phenyl, benzyl, C3-C6 cycloalkyl, and —CH2—C3-C6 cycloalkyl, wherein each ring of said phenyl, benzyl, C3-C6 cycloalkyl, and —CH2—C3-C6 cycloalkyl group is substituted with 0, 1, 2, or 3 substituents selected from OH, halogen, cyano, and C1-C6 alkyl, and said C1-C6 alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen, —CF3, and OH; w) a 5- or 6-membered heterocyclic ring containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, wherein the 5- or 6-membered heterocyclic ring is substituted with 0, 1, 2, or 3 substituents selected from OH, halogen, benzyl, and C1-C6 alkyl, and the C1-C6 alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen and OH; and x) two R3 form a bridge between carbon atoms, said atoms of said bridge comprising 1, 2, or 3 atoms independently selected from the group of carbon, N, O, and S; R4 occurs once or twice and is selected from H, halogen, oxo, C1-C6 alkyl, -(CH2) n2 -C3-C6 cycloalkyl, -O-(CH2) n2-C3-C6 cycloalkyl, -C(=O)-O-C1-C6 alkyl, -S(=O)2-C1-C6 alkyl, -C(=O)-NR x R y , -N(R x )(S(═O)2-C1-C6 alkyl), phenyl, benzyl, or heterocyclic rings having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are independently selected from the group of N, O, and S; x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from halogen, OH, CF3, and —O—C1-C3 alkyl; When Y2 is carbon, R4 can also be -O-C1-C6 alkyl, or two R4 can form a spirocyclic carbocycle or spirocyclic heterocycle; R4 C1-C6 alkyl, -C(=O)-O-C1-C6 alkyl, and -O-C1-C6 alkyl group, and the -(CH2) n2 -C3-C6 cycloalkyl and -O-(CH2) n2 the rings of the -C3-C6 cycloalkyl, phenyl, and benzyl groups each independently have halogen, CF3, OH, 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are substituted by 0, 1, 2, or 3 substituents selected from the group of heterocyclic rings selected from the group of N, O, and S, substituted or unsubstituted phenyl, and -O-C1-C3 alkyl; R5 is selected from the group consisting of H and C1-C6 alkyl, and the C1-C6 alkyl group of R5 is selected from halogen, -CF3, -NR x R y and OH, R x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; R6 is H, C1-C6 alkyl, a heterocyclic ring having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, phenyl, and benzyl, and the C1-C6 alkyl group of R6 is selected from the group of halogen, -CF3, -NR x R y and OH, and the rings of the phenyl and benzyl groups of R6 and the heterocyclic ring are substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group C1-C6 alkyl, —O—C1-C6 alkyl, halogen, —CF3, and OH, wherein R x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from halogen, OH, CF3, and —O—C1-C3 alkyl; Also provided is a compound, or a pharmaceutically acceptable salt thereof, wherein n2 in each instance is an integer selected from the group of 0, 1, 2, and 3.

[0018] A compound of formula (IE), or a pharmaceutically acceptable salt thereof: [ka] During the ceremony, X1 is selected from the group consisting of: [ka] n a is an integer selected from the group of 0, 1, and 2; n b is an integer selected from the group of 0, 1, 2, 3, and 4, However, n a +n b The total must be between 2 and 4, or or X1 and Z1 together form a fused ring system of formula (Ia), [ka] R a is selected from the group of hydrogen and C1-C3 alkyl; X2 is selected from the group consisting of: [ka] Wavy lines in each case [ka] represents the bond to which each X1 and X2 moiety is attached; Y1 is selected from the group of C and N; Y2 is selected from the group of C, N, S, and O, with the proviso that when Y2 is O, R4 is absent, and when Y2 is S, R4 is absent or present one or two times; However, provided that two or more of Y1 and Y2 are not C, n c is an integer selected from the group of 1, 2, and 3; n d is an integer selected from the group of 1, 2, and 3, However, n c +n d The total must be between 2 and 6. Z1, Z2, and Z3 are each independently selected from the group of C and N, with the proviso that Z1, Z2, and Z3 are C when attached to R2 or a non-hydrogen R2'; R1 is C1-C6 alkyl, -(CH2) n1 -C3-C6 cycloalkyl, -NR x R y , phenyl, and benzyl, wherein said C1-C6 alkyl group and said -(CH2) n1the ring of the —C3-C6 cycloalkyl, phenyl, and benzyl groups is substituted with 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; R x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; n1 is an integer selected from the group of 0, 1, 2, and 3; R2 is selected from the group of phenyl, pyridinyl, and a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system bonded through a carbon atom and containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 0, 1, 2, 3, or 4 additional ring heteroatoms selected from the group of N, S, and O, any of the foregoing being selected from C1-C6 alkyl, —O—C1-C6 alkyl, —(CH2) n1 -C3-C6 cycloalkyl, -CF3, halogen, oxo, cyano, -O-(CH2) n2 -C3-C6 cycloalkyl, -C(=O)OH, -C(=O)-O-C1-C6 alkyl, -S(=O)2-C1-C6 alkyl, -C(=O)-NR x R y , -N(R x )(S(=O)2-C1-C6 alkyl), -(CH2) n1 -heterocyclyl (including a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from the group N, S, and O), and phenyl, with the proviso that -(CH) n1 provided that R2 is not pyridinyl when not substituted at least once by -C3-C6 cycloalkyl or phenyl; R2' is selected from the group of hydrogen, OH, halogen, C1-C6 alkyl, and -CF3; R3 occurs one or more times and is independently selected from the group consisting of: y) hydrogen, halogen, cyano, or OH; z) —CO2H or —CO2—(C1-C6 alkyl), aa) C1-C6 alkyl or —O—C1-C6 alkyl substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group halogen, CF3, and OH; bb) phenyl, benzyl, C3-C6 cycloalkyl, and —CH2—C3-C6 cycloalkyl, wherein each ring of said phenyl, benzyl, C3-C6 cycloalkyl, and —CH2—C3-C6 cycloalkyl group is substituted with 0, 1, 2, or 3 substituents selected from OH, halogen, cyano, and C1-C6 alkyl, and said C1-C6 alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen, —CF3, and OH; cc) a 5- or 6-membered heterocyclic ring containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, wherein the 5- or 6-membered heterocyclic ring is substituted with 0, 1, 2, or 3 substituents selected from OH, halogen, benzyl, and C1-C6 alkyl, and the C1-C6 alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen and OH; and dd) two R3 form a bridge between carbon atoms, said atoms of said bridge comprising 1, 2, or 3 atoms independently selected from the group of carbon, N, O, and S; R4 occurs once or twice and is halogen; R5 is selected from the group consisting of H and C1-C6 alkyl, and the C1-C6 alkyl group of R5 is selected from halogen, -CF3, -NR x R y and OH, R x and R yeach is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from the group of halogen, OH, CF3, and —O—C1-C3 alkyl; R6 is H, C1-C6 alkyl, a heterocyclic ring having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, phenyl, and benzyl, and the C1-C6 alkyl group of R6 is selected from the group of halogen, -CF3, -NR x R y and OH, and the rings of the phenyl and benzyl groups of R6 and the heterocyclic ring are substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group C1-C6 alkyl, —O—C1-C6 alkyl, halogen, —CF3, and OH, wherein R x and R y each is independently selected from the group of H and C1-C6 alkyl substituted by 0, 1, 2, or 3 substituents selected from halogen, OH, CF3, and —O—C1-C3 alkyl; n2 in each instance is an integer selected from the group of 0, 1, 2, and 3; However, the compound may be N-[4-(4,4-difluoropiperidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide, (4,4-difluoropiperidin-1-yl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[3-(trifluoromethyl)pyrazol-1-yl]phenyl]methanone, [2-(3-cyclopropylpyrazol-1-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl Still further provided is a compound, or a pharmaceutically acceptable salt thereof, provided that the compound is not N-[4-(4-fluoropiperidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide, N-(4,4-difluoropiperidin-1-yl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-(3-propan-2-ylpyrazol-1-yl)phenyl]methanone, N-[4-(4-fluoropiperidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide, or N-[4-(4-fluoropiperidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide. DETAILED DESCRIPTION OF THE INVENTION

[0019] Within the scope of compounds of formula (IA), (IB), (IC), (ID), and (IE), or pharmaceutically acceptable salts thereof, there are three additional embodiments including compounds of formula (I'), or pharmaceutically acceptable salts thereof, compounds of formula (I"), or pharmaceutically acceptable salts thereof, and compounds of formula (I""), or pharmaceutically acceptable salts thereof, respectively; [ka] wherein, in each instance, X1, X2, R2, Z1, Z2, Z3, and all other variables and provisos, if present, are as defined above for formula (IA), (IB), (IC), (ID), or (IE).

[0020] It is also understood that within the scope of formula (I) there exist separate and independent embodiments based on the above definitions of X1 and X2, which include compounds of formulae (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), and (I-7), respectively, or pharmaceutically acceptable salts thereof; [ka] wherein, in each instance, X, R, if present, a , R1, R2, R3, R4, Y1, Y2, Z1, Z2, Z3, n a , n b All variables, including n1, n2, and the provisos, are as defined above for formula (IA), (IB), (IC), (ID), or (IE).

[0021] It is also understood that within the scope of formulas (IA), (IB), (IC), (ID), and (IE) there exist separate and independent embodiments based on the above definitions of X1 and X2, which include compounds of the following formulae (Ia) to (I-11), or pharmaceutically acceptable salts thereof: [ka] TIFF2024542036000030.tif248161TIFF2024542036000031.tif252159TIFF2024542036000032.tif207160TIFF2024542036000033.tif71142 wherein in each instance, if present, R a , R1, R2, R3, R4, R5, R6, Y1, Y2, Z1, Z2, Z3, n a , n b All variables, including n1, n2, and the provisos, are as defined above for formula (IA), (IB), (IC), (ID), or (IE).

[0022] Other separate embodiments provide compounds of each of the above formulas (IA), (IB), (IC), (ID), and (IE), formulas (I'), (I''), and (I'''), formulas (I-1) to (I-7), and formulas (Ia) to (I-11), or a pharmaceutically acceptable salt thereof, wherein in each embodiment, Z1, Z2, and Z3 are each C; a , R1, R2, R3, R4, R5, R6, Y1, Y2, n a , n b , n1, n2, and the proviso are as defined above for the corresponding formula (IA), (IB), (IC), (ID), or (IE) to (I-11).

[0023] Other separate embodiments provide compounds of each of the above formulas (IA), (IB), (IC), (ID), and (IE), formulas (I'), (I''), and (I'''), formulas (I-1) to (I-7), and formulas (Ia) to (I-11), or a pharmaceutically acceptable salt thereof, wherein in each embodiment, Z1, Z2, and Z3 are each N and R a , R1, R2, R3, R4, R5, R6, Y1, Y2, n a , n b , n1, n2, and the proviso are as defined above for the corresponding formula (IA), (IB), (IC), (ID), or (IE) to (I-11).

[0024] Further separate embodiments provide compounds of each of the above formulas (IA), (IB), (IC), (ID), and (IE), formulas (I'), (I''), and (I'''), formulas (I-1) to (I-7), and formulas (Ia) to (I-11), or a pharmaceutically acceptable salt thereof, wherein in each embodiment, Z1 and Z2 are each C, Z3 is N, and R a , R1, R2, R3, R4, R5, R6, Y1, Y2, n a , n b , n1, n2, and the proviso are as defined above for the corresponding formula (IA), (IB), (IC), (ID), or (IE) to (I-11).

[0025] Further separate embodiments provide compounds of each of the above formulas (IA), (IB), (IC), (ID), and (IE), formulas (I'), (I''), and (I'''), formulas (I-1) to (I-7), and formulas (Ia) to (I-11), or a pharmaceutically acceptable salt thereof, wherein in each embodiment, Z1 and Z3 are each C, Z2 is N, and R a , R1, R2, R3, R4, R5, R6, Y1, Y2, n a , n b , n1, n2, and the proviso are as defined above for the corresponding formula (IA), (IB), (IC), (ID), or (IE) to (I-11).

[0026] Further separate embodiments provide compounds of each of the above formulas (IA), (IB), (IC), (ID), and (IE), formulas (I'), (I''), and (I'''), formulas (I-1) to (I-7), and formulas (Ia) to (I-11), or a pharmaceutically acceptable salt thereof, wherein in each embodiment, Z1 and Z3 are each N, Z2 is C, and R a , R1, R2, R3, R4, R5, R6, Y1, Y2, n a , n b , n1, n2, and the proviso are as defined above for the corresponding formula (IA), (IB), (IC), (ID), or (IE) to (I-11).

[0027] Further separate embodiments provide compounds of each of the above formulas (IA), (IB), (IC), (ID), and (IE), formulas (I'), (I''), and (I'''), formulas (I-1) to (I-7), and formulas (Ia) to (I-11), or a pharmaceutically acceptable salt thereof, wherein in each embodiment, Z1 and Z2 are each N, Z3 is C, and R a , R1, R2, R3, R4, R5, R6, Y1, Y2, n a , n b , n1, n2, and the proviso are as defined above for the corresponding formula (IA), (IB), (IC), (ID), or (IE) to (I-11).

[0028] Further separate embodiments provide compounds of each of the above formulas (IA), (IB), (IC), (ID), and (IE), formulas (I'), (I''), and (I'''), formulas (I-1) to (I-7), and formulas (Ia) to (I-11), or a pharmaceutically acceptable salt thereof, wherein in each embodiment, Z2 and Z3 are each N, Z1 is C, and R a , R1, R2, R3, R4, R5, R6, Y1, Y2, n a , n b , n1, n2, and the proviso are as defined above for the corresponding formula (IA), (IB), (IC), (ID), or (IE) to (I-11).

[0029] In each of the embodiments herein of Formula (IA), Formula (I'), (I''), and (I'''), Formulas (I-1) through (I-7), and Formulas (Ia) through (I-jj), or a pharmaceutically acceptable salt thereof, above, there are further embodiments in which R2 is selected from the group consisting of: [ka] During the ceremony, R7 occurs once or twice and is selected from the group consisting of hydrogen, -OH, halogen, -C1-C6 alkyl, -O-C1-C6 alkyl, -(CH2) n1 -C3-C6 cycloalkyl, -(CH2) n1 -C3-C6 heterocycle (containing at least one heteroatom selected from O, N, and S), cyano, -O-(CH2) n2 -C3-C6 cycloalkyl, -C(=O)OH, -C(=O)-O-C1-C6 alkyl, -S(=O)2-C1-C6 alkyl, -C(=O)-NR x R y , -N(R x)(S(═O)2-C1-C6 alkyl), and —CF3, wherein any of said alkyl groups is further substituted with 0, 1, 2, 3, or 4 substituents selected from halogen and —OH, and n1 is an integer selected from the group of 0, 1, 2, and 3.

[0030] In each of the embodiments herein of Formula (IA), Formula (I'), (I''), and (I'''), Formulas (I-1) through (I-7), and Formulas (Ia) through (I-jj), or a pharmaceutically acceptable salt thereof, above, there are further embodiments in which R2 is selected from the group consisting of: [ka] TIFF2024542036000036.tif55148 During the ceremony, R7 occurs once or twice and is selected from the group consisting of hydrogen, -OH, halogen, -C1-C6 alkyl, -O-C1-C6 alkyl, -(CH2) n1 -C3-C6 cycloalkyl, -(CH2) n1 -C3-C6 heterocycle (containing at least one heteroatom selected from O, N, and S), cyano, -O-(CH2) n2 -C3-C6 cycloalkyl, -C(=O)OH, -C(=O)-O-C1-C6 alkyl, -S(=O)2-C1-C6 alkyl, -C(=O)-NR x R y , -N(R x )(S(═O)2-C1-C6 alkyl), and —CF3, wherein any of said alkyl groups is further substituted with 0, 1, 2, 3, or 4 substituents selected from halogen and —OH, and n1 is an integer selected from the group of 0, 1, 2, and 3.

[0031] In each of the embodiments herein of formula (IA), formula (I'), (I''), and (I'''), formulas (I-1) to (I-7), and formulas (Ia) to (I-jj), or pharmaceutically acceptable salts thereof, above, R2 is [ka] There are still further embodiments selected from the group consisting of:

[0032] In each of the embodiments herein of formulas (IB), (IC), (ID), and (IE), formulas (I'), (I''), and (I'''), formulas (I-1) through (I-7), and formulas (Ia) through (I-11), or a pharmaceutically acceptable salt thereof, there are further embodiments in which R2 is selected from the group consisting of: [ka] During the ceremony, R7 and R8, at each instance, are independently selected from hydrogen, halogen, C1-C6 alkyl, -O-C1-C6 alkyl, -CF3, and phenyl, provided that only one of R7 and R8 may be phenyl. In embodiments herein, when the R2 group is a bicyclic or spirocyclic ring, it is understood that R7 and R8 may be bonded to any available ring carbon or nitrogen atom in either ring, and that R7 and R8 may be bonded to ring atoms in the same or different rings.

[0033] In each of the embodiments herein of formulas (IB), (IC), (ID), and (IE), formulas (I'), (I''), and (I'''), formulas (I-1) through (I-7), and formulas (Ia) through (I-11), or a pharmaceutically acceptable salt thereof, there still exist further embodiments wherein R2 is selected from the group consisting of: [ka] wherein R7 and R8, at each instance, are independently selected from hydrogen, halogen, C1-C6 alkyl, —O—C1-C6 alkyl, —CF3, and phenyl, provided that only one of R7 and R8 may be phenyl.

[0034] Also provided are separate embodiments that include compounds of each of Formula (IB), (IC), (ID), and (IE), Formula (I'), (I"), and (I"'), Formula (I-1) through (I-7), and Formula (Ia) through (I-11), or a pharmaceutically acceptable salt thereof, with separate embodiments including compounds of each formula where R2 is defined above. For example, there are provided compounds of Formula (IB), (IC), (ID), or (IE), or a pharmaceutically acceptable salt thereof, where R2 is the azepane ring of group a) substituted by variables R7 and R8. Another embodiment includes compounds of Formula (IB), (IC), (ID), or (IE), where R2 is the azabicyclo[3.10.0]hexanyl ring of group b) substituted by variables R7 and R8. This pattern continues to define the remainder of the embodiments, each having a distinct referenced R2 group from the list above.

[0035] In each of the above embodiments of the compounds of formula (IB), (IC), (ID), and (IE), formula (I'), (I''), and (I'''), formula (I-1) to (I-7), and formula (Ia) to (I-11), or a pharmaceutically acceptable salt thereof, Z1, Z2, Z3, R a , R1, R3, R4, R5, R6, Y1, Y2, n a , n b , n1, n2, and the provisos are as defined above for the corresponding formulas (IB), (IC), (ID), and (IE), formulas (I'), (I''), and (I'''), formulas (I-1) through (I-7), and formulas (Ia) through (I-11), and R2 is selected from the group consisting of: [ka] Further embodiments exist wherein R7 and R8 are each independently selected from hydrogen, halogen, C1-C6 alkyl, -O-C1-C6 alkyl, halogen, and -CF3.

[0036] In each of the above embodiments of the compounds of formula (IB), (IC), (ID), and (IE), formula (I'), (I''), and (I'''), formula (I-1) to (I-7), and formula (Ia) to (I-11), or a pharmaceutically acceptable salt thereof, Z1, Z2, Z3, R a , R1, R3, R4, R5, R6, Y1, Y2, n a , n b Each variable, including n1, n2, and the provisos, are as defined above for the corresponding Formula (I), Formulas (I-1) to (I-7), and Formulas (Ia) to (I-11), and R2 is selected from the group consisting of: [ka] Further embodiments exist wherein R7 and R8 are each independently selected from hydrogen, halogen, C1-C6 alkyl, -O-C1-C6 alkyl, and -CF3.

[0037] In each of the above embodiments of the compounds of formula (IB), (IC), (ID), and (IE), formula (I'), (I''), and (I'''), formula (I-1) to (I-7), and formula (Ia) to (I-11), or a pharmaceutically acceptable salt thereof, Z1, Z2, Z3, R a , R1, R3, R4, R5, R6, Y1, Y2, n a , n b Each variable, including n1, n2, and the provisos, are as defined above for the corresponding Formula (I), Formulas (I-1) to (I-7), and Formulas (Ia) to (I-11), and R2 is selected from the group consisting of: [ka] Further embodiments exist wherein R7 and R8 are each independently selected from hydrogen, halogen, C1-C6 alkyl, -O-C1-C6 alkyl, and -CF3.

[0038] In each of the above embodiments of the compounds of Formula (I), Formulas (I-1) to (I-7), and Formulas (Ia) to (I-11), or pharmaceutically acceptable salts thereof, Z1, Z2, Z3, R a , R1, R3, R4, R5, R6, Y1, Y2, n a , n b Each variable, including n1, n2, and the provisos, are as defined above for the corresponding Formula (I), Formulas (I-1) to (I-7), and Formulas (Ia) to (I-11), and R2 is selected from the group consisting of: [ka] Further embodiments exist wherein R7 and R8 are each independently selected from hydrogen, halogen, C1-C6 alkyl, -O-C1-C6 alkyl, and -CF3.

[0039] In each of the above embodiments of the compounds of Formula (I), Formulas (I-1) to (I-7), and Formulas (Ia) to (I-11), or pharmaceutically acceptable salts thereof, Z1, Z2, Z3, R a , R1, R3, R4, R5, R6, Y1, Y2, n a , n b Each variable, including n1, n2, and the provisos, are as defined above for the corresponding Formula (I), Formulas (I-1) to (I-7), and Formulas (Ia) to (I-11), and R2 is selected from the group consisting of: [ka] Further embodiments exist wherein R7 and R8 are each independently selected from hydrogen, halogen, C1-C6 alkyl, -O-C1-C6 alkyl, and -CF3.

[0040] In some embodiments herein, R7 and R8 are selected from hydrogen, halogen, -CF3, C1-C4 alkyl, and C1-C4 alkoxy. In other embodiments, R7 and R8 are selected from hydrogen, halogen, -CF3, C1-C3 alkyl, and C1-C3 alkoxy. In still further embodiments, hydrogen, F, Cl, -CF3, C1-C3 alkyl, and C1-C3 alkoxy.

[0041] In each of the embodiments of the compounds and salts herein that include an R3 moiety, there are further embodiments within the same range, except that R3 occurs 1 to 3 times. In each of the embodiments of the compounds and salts herein that include an R3 moiety, there are further embodiments within the same range, except that R3 occurs 1 to 2 times. In each of the embodiments of the compounds and salts herein that include an R3 moiety, there are further embodiments within the same range, except that R3 occurs only once. In each of the embodiments of the compounds and salts herein that include an R3 moiety, there are further embodiments within the same range, except that R3 is selected from the group of hydrogen, C1-C4 alkyl, C3-C6 cycloalkyl, —CF3, —C1-C4 alkyl-OH, phenyl, pyrazolyl, and thiophenyl, where the phenyl, pyrazolyl, and thiophenyl ring are substituted with 0, 1, 2, or 3 substituents selected from the group of halogen, OH, —CF3, C1-C4 alkyl, and C1-C4 alkoxy.

[0042] In each of the embodiments of the compounds and salts herein that include an R3 moiety, there are additional embodiments within the same scope, except that R3 is selected from the group of phenyl, pyrazolyl, and thiophenyl, substituted with 0, 1, 2, or 3 substituents selected from the group of halogen, OH, —CF3, C1-C4 alkyl, and C1-C4 alkoxy.

[0043] Each compound of Formula (IA), (IB), (IC), (ID), and (IE), and all other formulae and specifically named compounds herein, also includes pharmaceutically acceptable salts, pharmaceutically acceptable co-crystals, pharmaceutically acceptable esters, pharmaceutically acceptable solvates, hydrates, isomers (including optical isomers, racemates, or other mixtures thereof), tautomers, isotopes, polymorphs, and pharmaceutically acceptable prodrugs of such compounds.

[0044] The compounds of the present disclosure may have asymmetric centers and can be prepared as racemic mixtures or as individual enantiomers. Individual enantiomers can be obtained by asymmetric synthesis or by resolving racemic or non-racemic mixtures of intermediates at appropriate stages in the synthesis. Individual enantiomers can also be obtained by resolving the compounds by conventional means, such as crystallization in the presence of a resolving agent, or chromatography, for example, using a chiral high-pressure liquid chromatography (HPLC) column. Individual enantiomers, as well as racemic and non-racemic mixtures of enantiomers, are within the scope of the present disclosure, and all of these are intended to be included within the structures shown herein unless specifically indicated otherwise.

[0045] How to use Hypertension is the most common chronic disease, affecting 1.13 billion people worldwide and resulting in 10 million deaths annually. Despite the availability of antihypertensive drugs that have successfully lowered blood pressure (BP) in millions of patients, there remains a significant unmet need. Only half of hypertensive patients achieve control of their BP, and current antihypertensive drugs fail to normalize BP in the majority of patients. Treatment-resistant hypertension (TRH), also known as resistant hypertension, is on the rise due to the rise of diabetes and obesity, which account for 75% of hypertension risk and are responsible for most cases of TRH. Identifying new targets and developing new strategies to prevent and treat hypertension and its complications remains a high public health and medical priority.

[0046] Methods for inhibiting the activity of GPR39 protein in a subject are provided, comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of formula (IA), (IB), (IC), (ID), or (IE), or a pharmaceutically acceptable salt thereof.

[0047] However, in certain embodiments, the method comprises administering to a subject in need thereof a pharmaceutically effective amount of a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any sub-formula of formula (IA), (IB), (IC), (ID), or (IE), of any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0048] Provided is a method of treating hypertension in a human in need thereof, comprising administering to the human a pharmaceutically effective amount of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing. In one embodiment, the hypertension treated is primary hypertension, which may also be referred to as essential hypertension.

[0049] In another embodiment, the hypertension being treated is secondary hypertension, including, but not limited to, sleep apnea, blocked renal arteries, abnormal levels of hormones, enzymes, growth factors, or other agents that control systemic or local blood pressure (including, but not limited to, renin, angiotensin I and II, and aldosterone, angiotensin-converting enzyme, catecholamines, thrombin, prostaglandins, natriuretic peptides, vasopressin, adreomedrin, substance P, calcitonin gene-related peptide, kallikrein, kininogens, kinins, kinin-degrading enzymes, phosducin, adipokines, and leptin), adrenal gland disease, thyroid abnormalities (including, but not limited to, hyperthyroidism, hypothyroidism, Cushing's disease, pheochromocytoma, and excess growth hormone), and large animal stenoses, including stenoses.

[0050] In one embodiment, the hypertension being treated is treatment-resistant or refractory hypertension.

[0051] In yet another embodiment, the hypertension being treated is a hypertensive urgency.

[0052] In another embodiment, the hypertension being treated is malignant hypertension, which may also be referred to as a hypertensive emergency or hypertensive crisis.

[0053] In an additional embodiment, the hypertension being treated is isolated systolic hypertension.

[0054] In a further embodiment, the hypertension being treated is salt-sensitive hypertension.

[0055] In another embodiment, the hypertension being treated is pulmonary hypertension.

[0056] Current treatments for stroke involve dissolving or removing blood clots involved in vascular obstruction. However, despite patent large vessels, small vessels remain impaired in a significant proportion of patients, ranging from 30 to 50%, which can lead to ineffective treatment. The compounds described herein can be combined with current stroke therapies to improve outcomes for the majority of patients.

[0057] Thus, there is provided a method of treating stroke in a human in need thereof, comprising administering to the human a pharmaceutically effective amount of a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0058] Vascular dementia is a small vessel disease in the brain that impairs blood flow and oxygen supply to brain cells, leading to neuronal dysfunction. Small vessel disease dementia is the second leading cause of dementia after Alzheimer's disease and is the leading cause in individuals over 70 years of age and in developing countries. Provided is a method for treating dementia due to small vessel disease in a human in need thereof, comprising administering to the human a pharmaceutically effective amount of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0059] Given their effects on microvascular mitigation and protection, the compounds and compositions herein can also be used in methods for treating conditions associated with microvascular dysfunction and microvascular disease, each method comprising administering to a subject in need thereof a pharmaceutically effective amount of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing. This includes methods for treating microvascular complications associated with or caused by diabetes. In one embodiment, the diabetes in question is type 1 diabetes mellitus. In another embodiment, the diabetes in question is type 2 diabetes mellitus. This also includes methods for treating microvascular complications associated with or caused by the pre-diabetic state known as prediabetes.

[0060] Also provided is a method of treating heart failure in a human, comprising administering to a human in need thereof a pharmaceutically effective amount of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0061] Included are methods for treating microvascular angina, cerebral small vessel disease (cSVD), vascular cognitive impairment (VCI), systemic microvascular endothelial dysfunction (alone or presenting with infective endocarditis), and chronic kidney disease.

[0062] Peripheral arterial disease is primarily a small vessel disease and is generally ineffective with large vessel surgery and stent placement, but small vessel disease cannot be cured.

[0063] Provided herein is a method of treating peripheral arterial disease in a human, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0064] The compounds herein may also be used to treat pre-eclampsia, a pregnancy complication characterized by high blood pressure and signs of damage to other organ systems, most often the liver and kidneys. Provided herein is a method of treating pre-eclampsia in humans, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0065] The compounds of the present invention are also useful for treating myocardial infarction, and are particularly useful when there is no-reflow phenomenon.Despite the restoration of coronary blood flow to myocardium, the destruction or blockage of coronary microvasculature can significantly reduce the blood flow to infarcted area, and no-reflow phenomenon exists.In this case, the flow to microcirculation can occur in one-third of patients with myocardial infarction.

[0066] Thus, there is provided a method of treating myocardial infarction in humans, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0067] Also provided is a method of treating myocardial infarction in the presence of a no-reflow phenomenon in a human, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0068] The compounds of the invention may also be used in the setting of chronic coronary artery disease, in which approximately one-third of patients continue to have angina due to microvascular dysfunction despite the aorta being bypassed or stented.

[0069] Thus, there is provided a method of treating chronic coronary artery disease in humans, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0070] Also provided is a method of treating microvascular dysfunction associated with chronic coronary artery disease in humans, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0071] The compounds of the present invention may also be used for a condition referred to as Syndrome X, in which subjects experience cardiac microvascular dysfunction or constriction resulting in angina pectoris despite normal epicardial coronary artery activity as diagnosed by angiography. Thus, there is provided a method of treating Syndrome X in humans, comprising administering to a mammal in need thereof a pharmaceutically effective amount of a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0072]

[0009] Provided are methods of treating breast cancer in a human in need thereof, comprising administering to the human a pharmaceutically effective amount of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, the breast cancer treated in this manner is ER-negative breast cancer.

[0073] Also provided is a method of treating gastric adenocarcinoma in a human, comprising administering to a human in need thereof a pharmaceutically effective amount of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0074] Also provided is a method of promoting or enhancing colonic epithelial function and tight junction barrier integrity in a human, comprising administering to a human in need thereof a pharmaceutically effective amount of a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0075] Also provided is a method of treating ulcerative colon disease in a human, comprising administering to a human in need thereof a pharmaceutically effective amount of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing. In one embodiment, the ulcerative colon disease being treated is ulcerative colitis. In another embodiment, the ulcerative colon disease being treated is Crohn's disease. In yet another embodiment, the ulcerative colon disease being treated is irritable bowel syndrome (IBS), which may also be referred to as colitis, enteritis, ileitis, or proctitis.

[0076] Also provided is a method of treating inflammatory bowel disease (IBD) in a human, comprising administering to a human in need thereof a pharmaceutically effective amount of a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0077] Also provided is a method of treating diarrhea in a human, comprising administering to a human in need thereof a pharmaceutically effective amount of a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing.

[0078] Because microvascular complications can inhibit uniform delivery of anesthetic agents, in some embodiments, the compounds herein can be used in methods of distributing and improving the effectiveness of local, regional, or systemic delivery of anesthetic agents. Thus, also provided is a method of enhancing the delivery of an anesthetic agent to a human experiencing a microvascular complication, comprising administering to a human in need thereof a pharmaceutically effective amount of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt of any of the foregoing, is administered to a human prior to administration of an anesthetic agent.

[0079] Pharmaceutical Compositions Also provided herein are pharmaceutical compositions comprising a pharmaceutically effective amount of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt or co-crystal of any of the foregoing, and a pharmaceutically acceptable carrier or excipient. Additional pharmaceutical compositions each comprise a pharmaceutically effective amount of a compound of Formulas (I'), (I"), (I'", (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), and (I-7), and a compound selected from each of Formulas (Ia) through (I-11), and a compound specifically named herein, and a pharmaceutically acceptable carrier or excipient.

[0080] Further provided herein is the use of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt or co-crystal of any of the foregoing, in the preparation of a medicament. Additional uses include a pharmaceutically effective amount of a compound selected from each of Formulas (I'), (I"), (I'",), (I-1), (I-2), (I-3), (I-4), (I-5), (I-6), and (I-7), and formulas (Ia) through (I-11), and including the compounds specifically named herein, respectively, for use in the preparation of a medicament.

[0081] The term "carrier" refers to an excipient or vehicle, including, but not limited to, diluents, disintegrants, precipitation retardants, surfactants, glidants, binders, lubricants, etc. Pharmaceutically acceptable carriers are generally described herein and in "Remington's Pharmaceutical Sciences" by E.W. Martin. Examples of carriers include, but are not limited to, aluminum monostearate, aluminum stearate, carboxymethylcellulose, sodium carboxymethylcellulose, crospovidone, glyceryl isostearate, glyceryl monostearate, hydroxyethylcellulose, hydroxyethylcellulose, hydroxymethylcellulose, hydroxyoctacosanyl hydroxystearate, hydroxypropylcellulose, hydroxypropylmethylcellulose, lactose, lactose monohydrate, magnesium stearate, mannitol, microcrystalline cellulose, poloxamer 124, poloxamer 181, poloxamer 182, poloxamer 188, poloxamer 237, poloxamer 407, povidone, silicon dioxide, colloidal silicon dioxide, silicone, silicone adhesive 4102, and silicone emulsion. However, it should be understood that the carrier selected for a pharmaceutical composition, and the amount of such carrier in the composition, may vary depending on the method of formulation (e.g., dry granulation, solid dispersion).

[0082] Some examples of suitable excipients for oral formulations include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methylcellulose. Additionally, the formulation may contain lubricants such as talc, magnesium stearate, and mineral oil, wetting agents, emulsifying and suspending agents, preservatives such as methyl and propylhydroxybenzoates, sweeteners, and flavorings.

[0083] As used herein, a "pharmaceutically acceptable excipient" is a pharmaceutically acceptable vehicle, including, but not limited to, any and all carriers, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

[0084] The pharmaceutical compositions may be administered in either single or multiple doses by any of the accepted modes of administration for agents having similar utilities described in these patents and patent applications incorporated by reference, including, for example, rectal, buccal, intranasal, and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, as an inhalant, or via an impregnated or coated device such as a stent or a cylindrical polymer inserted into an artery.

[0085] One mode of administration is parenteral, particularly by injection. Forms in which a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt or cocrystal thereof, can be incorporated for administration by injection include sesame oil, corn oil, cottonseed oil, or peanut oil, as well as aqueous or oil suspensions or emulsions with elixirs, mannitol, dextrose, or sterile aqueous solutions, and similar pharmaceutical vehicles. Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils can also be used. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.

[0086] Sterile injectable solutions are prepared by incorporating the compound according to the present disclosure in the required amount in an appropriate solvent with various other ingredients as enumerated above, as needed, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients and the other required ingredients from those enumerated above into a sterile vehicle containing a basic dispersion medium. For sterile powders for preparing sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying techniques, which yield a powder of the active agent and any additional desired ingredients from a previously sterile-filtered solution thereof. In some embodiments, for parenteral administration, a sterile injectable solution containing a therapeutically effective amount, e.g., 0.1 to 1000 mg, of a compound of formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt or cocrystal thereof, is prepared. However, it will be understood that the amount of compound actually administered will normally be determined by a physician in light of the relevant circumstances, including the condition to be treated, the selected route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual subject, the severity of the subject's symptoms, etc.

[0087] Oral administration is another route for administration of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any sub-formula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt or co-crystal thereof. Administration may be via a capsule or an enteric-coated tablet, or the like. In making a pharmaceutical composition comprising a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any sub-formula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt or co-crystal thereof, the active ingredient is typically diluted with an excipient and / or enclosed within such a carrier, which may be in the form of a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material (as described above), which acts as a vehicle, carrier, or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments, for example, containing up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.

[0088] In some embodiments, for parenteral administration, each dosage unit contains 0.1 mg to 1 g, 0.1 mg to 700 mg, or 0.1 mg to 100 mg of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt or co-crystal thereof. In some embodiments, a therapeutically or pharmaceutically effective amount of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt thereof, contains about 0.1 mg to about 500 mg per dose and is administered once or twice daily. In some embodiments, the individual doses are selected from 1 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 75 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, and 500 mg per dose.

[0089] It will be understood, however, that the amount of compound actually administered in any of the dosage units described herein will normally be determined by a physician in light of the relevant circumstances, including the condition to be treated, the selected route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual subject, the severity of the subject's symptoms, and the like.

[0090] Products and Kits Compositions (e.g., including formulations and unit dosages) comprising a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt or co-crystal thereof, can be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. Thus, also provided are articles of manufacture, e.g., containers containing unit dosage forms of a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt or co-crystal thereof, as well as labels containing instructions for use of these compounds. In some embodiments, the article of manufacture is a container containing a compound of Formula (IA), (IB), (IC), (ID), or (IE), a compound of any subformula of Formula (IA), (IB), (IC), (ID), or (IE), any of the compounds specifically named herein, or a pharmaceutically acceptable salt or cocrystal thereof, and at least one pharmaceutically acceptable vehicle. The article of manufacture can be a bottle, vial, ampoule, single-use disposable applicator, etc., containing a pharmaceutical composition provided herein. The container can be formed from a variety of materials, such as glass or plastic, and in one aspect, also contains a label on or associated with the container indicating directions for use in the treatment of cancer or an inflammatory condition. It should be understood that the active ingredient can be packaged in any material that can improve chemical and physical stability, such as an aluminum foil bag. In some embodiments, the disease or condition indicated on the label can include, for example, treatment of cancer.

[0091] definition Terms such as "microvascular tone," "microcirculatory tone," "microcirculatory vascular tone," and "arteriolar tone" refer to the degree of constriction experienced by microcirculatory vessels relative to their maximally dilated state. The microcirculation may be defined anatomically as blood vessels having a diameter between about 250 μm and about 100 μm, including particularly those having a diameter between about 200 μm and about 150 μm, and includes arterioles, capillaries, and venules (post-capillary venules). Collectively, these vessels may be referred to as "microvessels," "microcirculatory vessels," and the like. In embodiments herein, it is a goal to provide compounds, compositions, and methods for relaxing microvessels in a subject, reducing vascular resistance, protecting the microvessels themselves, and reducing or eliminating end-organ damage associated with microvascular resistance, particularly that found in the eye, kidney, and heart, as well as damage to nerve sheaths associated with microvessels. In some embodiments, the microcirculation is defined as blood vessels with a diameter of less than 200 μm. In the human body, approximately 90% of the blood volume resides in these vessels, including arteries, capillaries, and venules. The diameter of arterioles ranges from approximately 50 to 200 μm. Some venules contain vascular smooth muscle, and some capillaries are surrounded by pericytes, both contractile cells that constrict and relax these vessels, thus allowing for more or less delivery of blood and oxygen to cells and removal of cellular waste products. The size of these arterioles is tightly regulated to meet the oxygen demand of the cells they supply.

[0092] "Coronary microvascular disease" is a heart disease that affects the walls and inner lining of the small blood vessels that branch off from the larger coronary arteries. Coronary microvascular disease may also be referred to as "cardiac syndrome X" or "non-obstructive coronary artery disease." In the heart or elsewhere, it may also be referred to as "small artery disease," "small vessel disease," or "arteriolosclerosis."

[0093] Such small vessel disease is often seen in primary hypertension, stroke, and hypertensive renal disease. Renal pathology typically involves afferent and interlobular arteries and can include intimal thickening, vascular smooth muscle cell proliferation, and extracellular matrix deposition, increasing the media-to-lumen ratio. Areas of vascular smooth muscle cells can then be replaced by fibrosis and cell loss.

[0094] "Microvascular angina" refers to a form of chest pain caused by abnormalities of the heart's microvasculature, including, but not limited to, abnormal relaxation or spasm of the microvasculature.

[0095] As used herein, "heterocycle" or "heterocyclic group" refers to a chemical ring containing carbon atoms and at least one ring heteroatom selected from O, S, and N, including saturated, unsaturated, partially saturated, and aromatic rings.

[0096] Examples of three-membered heterocycles as found in the definitions of R3 and R4 herein include, by way of example and not limitation, aziridinyl, azirinyl, oxiranyl, and thiiranyl groups.

[0097] Examples of 4-membered heterocycles as found in the definitions of R3 and R4 herein include, by way of example and without limitation, azetidinyl, dihydro-1λ4-azetyl, azetyl, 1,3-diazetidinyl, and oxetanyl groups.

[0098] Examples of 5-membered heterocycles as found in the definitions of R and R herein include, by way of example and not limitation, thiazolyl, tetrahydrothiophenyl, sulfur-oxidized tetrahydrothiophenyl, furanyl, thienyl, pyrrolyl, dihydropyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, pyrrolidinyl, 2-pyrrolidonyl, dihydropyrrolidinyl, pyrrolinyl, tetrahydrofuranyl, triazinyl, thienyl, 2H-pyrrolyl, isothiazolyl, isoxazolyl, imidazolinyl, imidazolinyl, pyrazolinyl, pyrazolinyl, and oxazolinyl groups.

[0099] Examples of 6-membered heterocycles as found in the definitions of R3 and R4 herein include, but are not limited to, pyridyl, dihydropyridyl, tetrahydropyridyl (piperidyl), pyrimidinyl, piperidinyl, thiadiazinyl, thiazinyl, 2H,6H-1,5,2-dithiazinyl, pyranyl, pyrazinyl, pyridazinyl, piperazinyl, thienyl, thiopyran, dithiazinyl, morpholinyl, thiomorpholinyl, groups, by way of example only.

[0100] Examples of 7-membered heterocycles herein include, by way of example and not limitation, borepinyl, azepanyl, azepinyl, oxepanyl, oxepinyl, thiepanyl, diazepanyl, diazepinyl, and thiazepinyl groups.

[0101] Examples of 8-membered heterocycles herein include, by way of example and not limitation, azocinyl, azocinyl, oxocanyl, oxocinyl, thiocanyl, and thiocinyl groups.

[0102] Examples of 9-membered heterocycles herein include, but are not limited to, monocyclic heterocycles such as, by way of example, azonanyl, azoninyl, oxonanyl, oxoninyl, thionanyl, and thionyl groups, and fused heterocycles such as, by way of example, indolyl, indolinyl, isoindolyl, indolizinyl, indazolyl, azaindolyl, benzimidazolyl, azaidazolyl, pyrazolopyrimidinyl, purinyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, benzo[d]isoxazolyl, benzo[d]oxazolyl, benzo[c][1,2,5]thiadiazolyl, benzo[d]thiazolyl, benzisothiazolyl, adenyl, and guanyl groups.

[0103] Examples of 10-membered heterocycles herein include, by way of example only, decahydroisoquinolinyl, decahydroquinolinyl, tetrahydroquinolinyl, quinolinyl, dihydroquinolinyl, isoquinolinyl, quinoxalinyl, quinolidinyl, phthalazinyl, quinazolinyl, cinnolinyl, chromenyl, isochromenyl, naphthyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[4,3-d]pyrimidinyl, pyrido[3,4-b]pyrazinyl, pyrido[2,3-b]pyrazinyl, pteridinyl, benzo[e][1,2]oxazinyl, benzo[e][1,3]oxazinyl, benzo[b][1,4]oxazinyl, quinolinyl, thienopyrimidinyl (including thieno[3,2-d]pyrimidinyl), and isoquinolinolinyl groups.

[0104] It should be understood that the general term heterocycle referred to herein includes each isomeric form of heterocycle, such as the term "dithianyl" which includes 1,2 dithianyl, 1,3-dithianyl, and 1,4-dithianyl groups, the term "thiadiazinyl" which includes 1,2,5-thiadiazinyl and 1,3,4-thiadiazinyl groups, the term "azaindolyl" which includes 4-azaindolyl, 5-azaindolyl, 6-azaindolyl, and 7-azaindolyl groups, and "benzothiophenyl" which includes benzo[b]thiophenyl and benzo[c]thiophenyl groups.

[0105] Similarly, generic heterocyclic ring names include variations in one or more points of unsaturation. For example, the term "dihydropyrrolyl" refers to "2,3-dihydro-1H-pyrrolyl" and "2,5-dihydro-1H-pyrrolyl" groups.

[0106] The term "alkyl" refers to a straight or branched chain hydrocarbon. For example, an alkyl group may have 1 to 6 carbon atoms (i.e., C1-C6 alkyl or C 1-6Examples of suitable alkyl groups include methyl (Me, —CH), ethyl (Et, —CHCH), 1-propyl (n-Pr, n-propyl, —CHCHCH), 2-propyl (i-Pr, i-propyl, —CH(CH)), 1-butyl (n-Bu, n-butyl, —CHCHCHCHCH), 2-methyl-1-propyl (i-Bu, i-butyl, —CHCH(CH)), 2-butyl (s-Bu, s-butyl, —CHCH(CH)), 2-methyl-1-propyl (i-Bu, i-butyl, —CHCH(CH)), 2-butyl (s-Bu, s-butyl, — CH(CH3)CH2CH3), 2-methyl-2-propyl (t-Bu, t-butyl, --C(CH3)3), 1-pentyl (n-pentyl, --CH2CH2CH2CH2CH3), 2-pentyl (--CH(CH3)CH2CH2CH3), 3-pentyl (--CH(CH2CH3)2), 2-methyl-2-butyl (-C(CH3)2CH2CH3), 3-methyl-2-butyl (--CH(CH3)CH(CH3)2), 3-methyl-1 -butyl (--CH2CH2CH(CH3)2), 2-methyl-1-butyl (-CH2CH(CH3)CH2CH3), 1-hexyl (--CH2CH2CH2CH2CH2CH2CH3), 2-hexyl (--CH(CH3)CH2CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)C These include, but are not limited to, 4-methyl-2-pentyl (-CH(CH)CHCH(CH)), 3-methyl-3-pentyl (-C(CH)(CHCH)), 2-methyl-3-pentyl (-CH(CHCH)CH(CH)), 2,3-dimethyl-2-butyl (-C(CH)CH(CH)), and 3,3-dimethyl-2-butyl (-CH(CH)C(CH)).

[0107] The term "alkoxy" refers to a group having the formula "-O-alkyl", where an alkyl group, as defined above, is attached to the parent molecule through an oxygen atom. The alkyl portion of the alkoxy group has 1 to 6 carbon atoms (i.e., C1-C6 alkoxy or C 1-6The alkoxy group may have a specific number of carbon chain atoms, such as alkoxy. Examples of suitable alkoxy groups include, but are not limited to, methoxy (-O-CH or --OMe), ethoxy (-OCHCH or --OEt), t-butoxy (-O--C(CH) or --OtBu), and the like.

[0108] The term "carbocycle" or "carbocyclic group" refers to a chemical ring containing only carbon atoms, including saturated, unsaturated, partially saturated, and aromatic rings.

[0109] The term "cycloalkyl" refers to a saturated ring having from 3 to 6 carbon atoms as a single ring, including cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl groups.

[0110] The term "halogen" refers to an atom selected from the group of the elements chlorine, fluorine, bromine, and iodine.

[0111] The term "oxo" refers to a double-bonded oxygen "=O".

[0112] The terms "therapeutically effective amount" and "pharmaceutically effective amount" refer to an amount sufficient to effect treatment, as defined below, when administered to a subject (e.g., a mammal such as a human) in need of such treatment. A therapeutically effective amount or a pharmaceutically effective amount varies depending on the subject and disease state being treated, the subject's weight and age, the severity of the disease state, the method of administration, etc., which can be readily determined by one of ordinary skill in the art. For example, a "therapeutically effective amount" or a "pharmaceutically effective amount" of a compound of formula (IA), (IB), (IC), (ID), or (IE), or a pharmaceutically acceptable salt or cocrystal thereof, is an amount sufficient to antagonize the expression or activity of GPR39, thereby treating a subject (e.g., a human) suffering from an indication or improving or alleviating existing symptoms of the indication. For example, a therapeutically effective amount or a pharmaceutically effective amount can be an amount sufficient to alleviate the symptoms of a disease or condition that responds to inhibition of GPR39 activity.

[0113] "Treatment" or "treating" is an approach for obtaining beneficial or desired results, including clinical results. Beneficial or desired results can include one or more of the following: (i) inhibiting a disease or condition (e.g., reducing one or more symptoms resulting from a disease or condition and / or lessening the severity of the disease or condition); (ii) delaying or preventing the onset of one or more clinical symptoms associated with a disease or condition (e.g., stabilizing a disease or condition, preventing or delaying the worsening or progression of a disease or condition, and / or preventing or delaying the spread (e.g., metastasis) of a disease or condition); and / or (iii) causing regression of clinical symptoms (e.g., ameliorating a disease state, providing partial or complete remission of a disease or condition, enhancing the effect of another drug, delaying disease progression, improving quality of life, and / or prolonging survival).

[0114] The terms "inhibiting" or "inhibition" refer to a decrease, e.g., a significant decrease, in the baseline activity of a biological activity or process. "Inhibition of GPR39 activity" refers to a decrease in GPR39 activity as a direct or indirect response to the presence of a compound of Formula (IA), (IB), (IC), (ID), or (IE), or a pharmaceutically acceptable salt or cocrystal thereof, compared to the activity of GPR39 in the absence of such compound or a pharmaceutically acceptable salt or cocrystal thereof. The decrease in activity may result from the direct interaction of the compound with GPR39, or from the interaction of the compound(s) described herein with one or more other factors that in turn affect the expression and / or activity of GPR39. For example, the presence of the compound(s) may decrease GPR39 activity by directly binding to GPR39, by causing (directly or indirectly) another factor to reduce GPR39 expression or activity, or by (directly or indirectly) reducing the amount of GPR39 protein present in a cell or organism. In some embodiments, the inhibition of GPR39 activity can be compared to the same subject before treatment, or to other subjects not receiving treatment. The term "inhibitor" is understood to refer to a compound or agent that provides the desired inhibitory activity when administered to a human in need thereof in a pharmaceutically or therapeutically effective dose.

[0115] "Delaying" the onset of a disease or condition means postponing, inhibiting, slowing, decelerating, stabilizing, and / or postponing the onset of a disease or condition. This delay can be of varying lengths of time, depending on the disease or condition being treated and / or the subject's medical history. A method of "delaying" the onset of a disease or condition is a method that reduces the probability of the onset of a disease or condition in a given time frame and / or reduces the severity of the disease or condition in a given time frame compared to not using the method. Such comparisons are typically based on clinical studies using a statistically significant number of subjects. The onset of a disease or condition may be detectable using standard methods such as regular physical examinations, mammography, imaging, or biopsy. Onset may also refer to the progression of a disease or condition, including development, recurrence, and onset, which may not be initially detected.

[0116] As used herein, the singular terms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly dictates otherwise. Also, as used herein, the term "comprises" means "includes." Thus, "including A or B" means including A, B, or A and B.

[0117] Numerical values ​​should be understood to include values ​​that are the same when reduced to the same number of significant figures and numerical values ​​that differ from the numerical value by less than the experimental error of conventional measurement techniques of the type described in this application to determine the value.

[0118] All ranges disclosed and / or claimed herein are inclusive of the recited endpoints and are independently combinable (e.g., "2 to 10" and the range "2 to 10" include the endpoints 2 and 10, and all intermediate values ​​3, 4, 5, 6, 7, 8, and 9).

[0119] By "significant" is meant any detectable change that is statistically significant in a standard parametric test of statistical significance, such as the Student's T-test, where p<0.05.

[0120] "Pharmaceutically acceptable salts" include, for example, salts with inorganic acids and salts with organic acids. Examples of salts include hydrochloride, phosphate, diphosphate, hydrobromide, sulfate, sulfinate, nitrate, malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate (mesylate), benzenesulfonate (besylate), p-toluenesulfonate (tosylate), 2-hydroxyethylsulfonate, benzoate, salicylate, stearate, and alkanoate (acetate, HOOC--(CH)). n --COOH (wherein n is 0-4), etc. Additionally, if the compounds described herein are obtained as acid addition salts, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, addition salts, particularly pharmaceutically acceptable addition salts, can be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, following conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methods that can be used to prepare non-toxic pharmaceutically acceptable addition salts.

[0121] The term "crystalline form" and related terms herein refer to various crystalline modifications of a given substance, including, but not limited to, polymorphs, solvates, hydrates, co-crystals, and other molecular complexes, as well as salts, solvates of salts, hydrates of salts, other molecular complexes of salts, and polymorphs thereof. Crystalline forms of a substance can be obtained by several methods, as known in the art. Such methods include, but are not limited to, melt recrystallization, melt cooling, solvent recrystallization, recrystallization in confined spaces such as nanopores or capillaries, recrystallization on surfaces or templates such as polymers, recrystallization in the presence of additives such as co-crystal pair molecules, desolvation, dehydration, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, sublimation, grinding, and solvent drop grinding.

[0122] As used herein, the term "co-crystal" or "co-crystal salt" refers to a crystalline material consisting of two or more solids at room temperature, each of which has unique physical properties such as structure, melting point, heat of fusion, hygroscopicity, solubility, and stability. Co-crystals or co-crystal salts can be prepared according to co-crystallization methods known per se. The term co-crystal (or co-crystal) or co-crystal salt also refers to a multi-component system in which there is a compound of formula (IA), (IB), (IC), (ID), or (IE) and host API (active pharmaceutical ingredient) molecule(s), such as guest (or co-former) molecule(s). In certain embodiments, the pharmaceutically acceptable co-crystal of a compound of formula (IA), (IB), (IC), (ID), or (IE) with a co-former molecule is a crystalline form selected from a malonic acid co-crystal, a succinic acid co-crystal, a decanoic acid co-crystal, a salicylic acid co-crystal, a vanillic acid co-crystal, a maltol co-crystal, or a glycolic acid co-crystal. Cocrystals may have improved properties compared to the parent form (i.e., the free molecule, the zwitterion, etc.) or a salt of the parent compound. Improved properties may include increased solubility, increased dissolution, increased bioavailability, increased dose response, decreased hygroscopicity, crystalline forms of normally amorphous compounds, crystalline forms of compounds that are difficult or unsaltable, reduced morphological diversity, more desirable morphologies, etc.

[0123] As used herein, the terms "isotope" and "isotopic" in reference to compounds disclosed herein mean that one or more atoms of a compound have been replaced with an isotope of such one or more atoms. An "isotope" refers to any of two or more forms of a chemical element having the same number of protons in the nucleus but a different number of neutrons in the nucleus. For example, an isotopic compound includes a compound in which one or more hydrogen atoms (H) have been replaced with one or more deuterium atoms (D). In this example, deuterium is an isotope of hydrogen, and replacing a hydrogen atom with deuterium (at one or more positions) makes the resulting compound an isotopic compound. For example, with respect to Formula (IA), (IB), (IC), (ID), or (IE), replacing two methyl groups in the isopropyl moiety (-CH(CH)) with a fully deuterated methyl group (-CH(CD)) can be an isotopic compound of Formula (IA), (IB), (IC), (ID), or (IE). In addition to replacing hydrogen with deuterium, other stable (non-radioactive) isotope substitutions include replacing carbon-12 with carbon-13, and unstable (radioactive) isotopes include replacing hydrogen with tritium, replacing carbon-12 with carbon-14, replacing iodine-127 with iodine-123 or iodine-125, etc. Accordingly, all references herein to isotopic compounds of formula (IA), (IB), (IC), (ID), or (IE), as well as to various embodiments thereof, refer to compounds having one or more isotopic substitutions, including but not limited to, the replacement of one or more hydrogen atoms with one or more deuterium atoms, and any occurrence(s) in the compound. To this end, the isotopic compounds disclosed herein offer improved advantages over their non-isotopic forms. To this end, isotopic modifications provide a means for improving existing drugs and / or as a tool in the design of new drugs. For example, isotopic drug design has proven successful in the context of deuterium (D) kinetic isotope effects.Due to the two-fold higher mass of D compared to H, the CD bond is much more resistant to oxidation processes (such as the ability to be catalyzed by CYP 450 or other enzymes involved in metabolism) while retaining very similar steric properties. Therefore, isosteric substitution of HD usually preserves the pharmacodynamics of the compound while improving its pharmacokinetics, affecting half-life and / or area under the curve values, and ultimately the dose and / or administration regimen. For example, drug exposure can be enhanced by isotopic modification and / or reduced clearance. Such advantages are provided to the compounds disclosed herein by their isotopic derivatization.

[0124] Terms such as "subject" and "patient" refer to an animal, such as a mammal, that has been or will be the object of treatment, observation, or experiment. The methods described herein may be useful in both human therapy and veterinary applications. In some embodiments, the subject is a mammal, in some embodiments, the subject is a human, and in some embodiments, the subject is selected from a cat and a dog. A "subject in need thereof" or a "human in need thereof" refers to a subject, such as a human, that may have or is suspected of having a disease or condition that would benefit from a particular treatment, e.g., treatment with a compound of Formula (IA), (IB), (IC), (ID), or (IE), or a pharmaceutically acceptable salt or cocrystal thereof, as described herein. This includes subjects who may be determined to be at risk for or susceptible to such a disease or condition, such that treatment may prevent the onset of the disease or condition.

[0125] The term "prediabetes" or "prediabetic state" refers to a condition in which a subject's blood glucose level is not high enough to be considered diabetes, but may be a precursor to type 2 diabetes. A prediabetic state may be defined in a subject whose fasting blood glucose level is 100 mg / dL or higher but less than 126 mg / dL (the diagnostic level for diabetes). Hemoglobin A1c (HbA1c) level is another laboratory test for diabetes. An HbA1c level of 6.5% or higher is characteristic of diabetes, while a level of 5.7% to 6.4% suggests prediabetes. [Example]

[0126] Measurement of intracellular calcium responses in PC3 cells expressing endogenous human GPR39 receptors Human prostate adenocarcinoma (PC3) cells endogenously expressing the human GPR39 receptor were seeded into black-walled, clear-base 384-well plates at a density of 7,500 cells per well in DMEM (low glucose) supplemented with 10% heat-inactivated fetal bovine serum and 1% Pen / Strep and grown overnight at 37°C and 5% CO. After washing with assay buffer (20 mM HEPES, 137 mM NaCl, 5.4 mM KCl, 10 mM glucose, 0.8 mM MgSO, 1.3 mM CaCl, 0.3 mM NaHPO, 0.4 mM KHPO, 4.2 mM NaHCO, pH 7.4), the cells were incubated with a calcium-6 probe (Molecular Devices) for 2 hours at 37°C and then equilibrated for 30 minutes at room temperature on a metal block. Fluorescence was measured in real time by a fluorescence imaging plate reader (FLIPR TETRA, Molecular Devices) (excitation wavelength at 470–495 nm, emission wavelength at 515–575 nm).

[0127] Compounds of the invention were serially diluted 1000-fold in pure DMSO, plated in 384-well plates, and then diluted 200-fold in assay buffer containing 150 μM ZnCl (30 μM final concentration) and 1.1% DMSO (0.32% final concentration).

[0128] A double-addition FLIPR protocol was used, involving the first addition of compound diluted 200-fold in assay buffer containing 150 μM ZnCl and 1.1% DMSO, followed 10 minutes later by the second addition of a submaximal concentration of the hGPR39 receptor agonist, C3 (Tocris, TC-G1008), with an EC90 (concentration producing 90% of the maximal response) value of 1.5 μM.

[0129] Fluorescence was monitored throughout the assay.2+ Peak stimulation (subtracted from baseline) was expressed as a percentage of maximal inhibition of the EC90 C3 response and plotted against the concentration of test compound. Curve fitting and IC50 estimation was performed using a four-parameter logistic model using XLfit software.

[0130] Compound potencies were reported as functional pKi (-Log10Ki) obtained using the modified Cheng-Prusoff relationship (Cheng, Y., Prusoff, WH 1973.).

[0131] fKi = IC50 / (1 + [L] / EC50), where IC50 is the concentration of antagonist required to inhibit 50% of the maximal response, [L] is the concentration of agonist used (EC90), and EC50 is the concentration of agonist required to induce 50% of the maximal response (obtained in each experimental plate).

[0132] The fpKi data are shown in Table 1 below. An fpKi less than 5.2 is reported as "+ / -". An fpKi in the range of 5.2-5.9 is reported as "+". An fpKi of 6.0-6.5 is reported as "++". An fpKi of 6.6-7.2 is reported as "+++". An fpKi of 7.3 or greater is reported as "++++". [Table 1] TIFF2024542036000046.tif254140TIFF2024542036000047.tif120140

[0133] synthesis The compounds described herein can be prepared by methods known in the art and are exemplified by the following non-limiting illustrations.

[0134] Unless otherwise noted, all reactions are typically carried out under an inert atmosphere (e.g., under nitrogen). The following abbreviations are used in this document: EtOAc, AcOEt, EA = ethyl acetate Et2O = diethyl ether CH3CN = acetonitrile MeOH = methanol THF = tetrahydrofuran rt(RT)=room temperature DMSO = dimethyl sulfoxide DMF = N,N'-dimethylformamide DCM = dichloromethane EtOH = ethanol RP = reverse phase FA = formic acid Cy, cHex = cyclohexane TEA = triethylamine DIPEA = N,N-diisopropylethylamine Boc2O = di-tert-butyl dicarbonate TFA = trifluoroacetic acid HATU = 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide Hexafluorophosphate AcOH = acetic acid SCX cartridge = strong cation exchange cartridge FC = flash chromatography ss=saturated solution ON = overnight [ka]

[0135] Step 1 Compounds of formula II can be obtained from compounds of formula I (commercially available from Enamine) by SNAr displacement with pyrrolidine in a suitable aprotic solvent, such as CHCN, typically at 80° C. The reaction takes about 1 hour to complete.

[0136] Step 2 Compounds of formula III can be obtained by nitro reduction of compounds of formula II under catalytic hydrogenation conditions, typically using Pd / C in a suitable solvent such as acetic acid, at room temperature. The reaction takes about 4 hours to complete.

[0137] Step 3 The compound of formula IV can be obtained by coupling reaction between the compound of formula III and a suitable commercially available acyl chloride, such as cyclopropanecarbonyl chloride, in the presence of an organic base, such as TEA. The reaction is typically carried out at room temperature in a suitable solvent, such as DCM. The reaction takes about 12 hours to complete.

[0138] Step 4 Compounds of formula V can be obtained from compounds of formula IV by hydrolysis, for example, using LiOH, in a suitable mixture of solvents such as MeOH / THF / HO, typically at 50° C. The reaction takes about 36 hours to complete.

[0139] Step 5 Compounds of formula VI can be obtained from compounds of formula V by coupling with an appropriate amine in the presence of a coupling agent (e.g., HATU) and an organic base (e.g., DIPEA). The reaction is typically carried out at room temperature in a suitable solvent such as DMF. The reaction takes about 3 to about 12 hours to complete.

[0140] Scheme 1. Preparation of Compound II: Methyl 4-nitro-2-pyrrolidin-1-ylbenzoate [ka] To a solution of methyl 2-fluoro-4-nitrobenzoate (5.0 g, 25.11 mmol) in MeCN (50 mL) was added pyrrolidine (5.36 g, 75.32 mmol), and the reaction was stirred at 80° C. for 1 hour. After this time, the reaction was cooled to room temperature and then concentrated in vacuo. The residue was taken up in water and filtered. The solid was dried in vacuo to give the product of formula methyl 4-nitro-2-pyrrolidin-1-ylbenzoate, which was used in the next step without further purification. Yield: 6g 1 H NMR(400MHz,DMSO-d6) δ7.64(d,1H),7.49(d,1H),7.44(dd,1H),3.86(s,3H),3.26-3.20(m,4H),1.95-1.90(m,4H);LC-MS:251.05(MH+).

[0141] Scheme 1. Preparation of Compound III: Methyl 4-amino-2-pyrrolidin-1-ylbenzoate [ka] To a solution of methyl 4-nitro-2-pyrrolidin-1-ylbenzoate (4.75 g, 18.98 mmol) in acetic acid (190 mL) was added Pd—C 10% (2.02 g, 1.9 mmol). The reaction was stirred at room temperature under an H atmosphere for 4 hours. After this time, the mixture was filtered through a Celite pad, washed with MeOH, and the solvent was evaporated under vacuum. The residue was taken up in saturated NaHCO solution and extracted three times with AcOEt. The combined organic fractions were washed with brine, dried over NaSO, filtered, and concentrated under vacuum to give the product of formula methyl 4-amino-2-pyrrolidin-1-ylbenzoate, which was used in the next step without further purification. Yield: 3.95g 1H NMR(400MHz,DMSO-d6) δ7.29(d,1H),6.02-5.88(m,2H),5.47(s,2H),3.67(s,3H),3.16-2.99(m,4H),2.00-1.71(m,4H);LC-MS:m / z 221.39(MH+).

[0142] Scheme 1. Preparation of Compound IV: Methyl 4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoate [ka] A solution of methyl 4-amino-2-pyrrolidin-1-ylbenzoate (5.75 g, 26.1 mmol) and N,N-diisopropylethylamine (9.09 mL, 52.21 mmol) in dry DCM (145.57 mL) was cooled to 0 °C and stirred for 10 min. After this time, cyclopropanecarbonyl chloride (3.08 mL, 33.94 mmol) was added dropwise, and the reaction mixture was allowed to reach room temperature and stirred overnight. The next day, the reaction mixture was diluted with DCM and washed with saturated NaHCO solution. The organic phase was washed with brine, dried on a phase separator, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (eluting with 9:1 cHex / AcOEt to 9:1 cHex / AcOEt) to give the product of formula methyl 4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoate. Yield: 5.6g 1 H NMR(400MHz,DMSO-d6) δ10.22(s,1H),7.41(d,1H),7.22(d,1H),6.92(dd,1H),3.75(s,3H),3.11( q,4H),1.92-1.83(m,4H),1.83-1.75(m,1H),0.83-0.76(m,4H);LC-MS:m / z 289.12(MH+).

[0143] Scheme 1. Preparation of Compound V: 4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoic acid [ka] To a solution of methyl 4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoate (5.0 g, 17.34 mmol) in THF (150 mL) / MeOH (20 mL) was added a 6N solution of NaOH (5.78 mL, 34.68 mmol). The reaction was stirred at 50° C. overnight.

[0144] The next day, additional sodium hydroxide solution 6N (5.78 mL, 34.68 mmol) was added, followed by 10 mL of MeOH, and the reaction was stirred at 50° C. for 1 day. After this time, the reaction was cooled to room temperature and concentrated in vacuo. The aqueous solution was washed with DCM (3×), acidified with HCl 12N to pH=1, and extracted five times with AcOEt. The combined organic fractions were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was taken up in Et2O, filtered, and the solid was washed with Et2O and dried in vacuo to give the product of formula 4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoic acid, which was used in the next step without further purification. Yield: 2.5g 1 H NMR(400MHz,DMSO-d6) δ13.10(s,1H),10.25(s,1H),7.52(d,1H),7.34(d,1H),6.99(dd,1H),3.21- 3.04(m,4H),2.01-1.78(m,4H),1.79(tt,1H),0.86-0.73(m,4H);LC-MS:m / z 275.08(MH+).

[0145] Preparation: N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide [ka] Example 1 To a solution of 4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoic acid (46.58 mg, 0.170 mmol) and (HATU)[dimethylamino(3-triazolo[4,5-b]pyridinyloxy)methylidene]-dimethylammonium hexafluorophosphate (96.85 mg, 0.250 mmol) and N,N-diisopropylethylamine (0.09 mL, 0.510 mmol) in DMF (2 mL) was added a solution of 2-phenylpyrrolidine (25.0 mg, 0.170 mmol) in DMF (1 mL). The reaction mixture was stirred overnight at room temperature. After the reaction was complete, the mixture was diluted with saturated NaHCO3 solution and extracted three times with AcOEt. The combined organic fractions were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by FC on an NH column (eluting with cHex / AcOEt 8:2 to cHex / AcOEt 2:8) to give the product of formula N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide (see Example 1). Yield: 34.2 mg 1 H NMR(400MHz,DMSO-d6) δ10.14-9.87(m,1H),7.38-7.27(m,3H),7.26-7.12(m,2H),7.09-6.92(m,3H),5.17-4.78(m,1H ),3.61(d,2H),3.08(d,4H),2.39-2.17(m,1H),2.04-1.62(m,8H),0.84-0.62(m,4H);LC-MS:m / z 404.3(MH+).

[0146] Preparation: N-[4-(3-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide [ka] Example 2 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that 3-phenylpyrrolidine was used instead of 2-phenylpyrrolidine. The title compound was obtained in a yield of 38% (26 mg). 1 H NMR(400MHz,DMSO-d6) δ10.08(d,1H),7.39-7.18(m,5H),7.10-6.97(m,2H),6.96-6.85(m,1H),3.99-3.65(m,2H) ,3.38(d,3H),3.26-2.99(m,4H),2.25(d,1H),2.08-1.70(m,6H),0.77(dtd,4H);LC-MS:m / z 404.3(MH+).

[0147] Preparation: N-[4-(2-oxa-7-azaspiro[3.4]octane-7-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide [ka] Example 3 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that 2-oxa-6-azaspiro[3.4]octane was used instead of 2-phenylpyrrolidine. The title compound was obtained in a yield of 61% (40 mg). 1 H NMR(400MHz,DMSO-d6) δ10.08(s,1H),7.10-7.02(m,1H),6.99-6.86(m,2H),4.57(d,1H),4.49-4.38(m,3H),3.65(s,1H), 3.41(s,2H),3.11(d,5H),2.12(dt,2H),1.89-1.81(m,4H),1.77(qd,1H),0.77(dt,4H);LC-MS:m / z 370.2(MH+).

[0148] Preparation: N-[4-[(trans)-2,6-dimethylmorpholine-4-carbonyl]-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide [ka] Example 4 The synthesis of the title compound was carried out in a similar manner to the synthesis of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that trans-2,6-dimethylmorpholine was used instead of 2-phenylpyrrolidine. The title compound was obtained as a racemic mixture in 50% yield (33 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 10.09(s,1H),7.06(s,1H),6.99-6.88(m,2H),4.11-3.67(m,3H),3.41-2.72(m,7H),1.95-1. 80(m,4H),1.80-1.70(m,1H),1.32-1.09(m,3H),0.99(dd,3H),0.82-0.69(m,4H);LC-MS:m / z 372.23(MH+).

[0149] Preparation: N-[4-(2,6-dimethyl-1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide [ka] Example 5 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that 2,6-dimethyl-1,4-thiazinane 1,1-dioxide hydrochloride was used instead of 2-phenylpyrrolidine. The title compound was obtained in a yield of 44% (34 mg). 1H NMR(400MHz,DMSO-d6) δ10.13(d,1H),7.28-6.72(m,3H),4.79(d,1H),3.83(dd,1H),3.48-3.38(m,1H),3.25-2 .76(m,7H),1.97-1.65(m,5H),1.25(t,3H),1.06(dd,3H),0.81-0.74(m,4H);LC-MS:m / z 420.2(MH+).

[0150] Preparation: N-[4-(8-oxa-3-azabicyclo[3.2.1]octane-3-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide [ka] Example 6 The title compound was synthesized in the same manner as in Example 1, except that 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride was used instead of 2-phenylpyrrolidine. The title compound was obtained in a yield of 44% (34 mg). 1 H NMR(400MHz,DMSO-d6) δ10.09(s,1H),7.06(dd,1H),7.00-6.82(m,2H),4.47-4.00(m,3H),3.24-2.82(m,7H),1.98-1.44(m,9H),0.77(dt,4H);LC-MS:m / z 370.2(MH+).

[0151] Preparation: N-[4-(3-oxa-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide [ka] Example 7 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that 3-oxa-3-azabicyclo[3.2.1]octane hydrochloride was used instead of 2-phenylpyrrolidine. The title compound was obtained in a yield of 13% (9 mg). 1 H NMR(400MHz,DMSO-d6) δ10.13(s,1H),7.33-6.83(m,3H),4.53(s,1H),3.84-3.41(m,5H),3.23-2.94(m,4H),1.97-1.70(m,9H),0.82-0.67(m,4H);LC-MS:m / z 370.2(MH+).

[0152] Preparation: N-[4-(6-oxa-3-azabicyclo[3.1.1]heptane-3-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide [ka] Example 8 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that 6-oxa-3-azabicyclo[3.1.1]heptane hydrochloride was used instead of 2-phenylpyrrolidine. The title compound was obtained in a yield of 75% (49 mg). 1 H NMR(400MHz,DMF-d7) δ10.07(s,1H),7.07(d,1H),7.01-6.85(m,2H),4.53(d,2H),3.84(d,1H),3.61-3.44 (m,2H),3.26(s,2H),3.24-2.93(m,5H),1.94-1.56(m,5H),0.77(dd,4H);LC-MS:m / z 356.2(MH+)

[0153] Preparation: N-[4-(3-azabicyclo[3.1.1]heptane-3-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide [ka] Example 9 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that 3-oxa-8-azabicyclo[3.2.1]octane hydrochloride was used instead of 2-phenylpyrrolidine. The title compound was obtained in a yield of 78% (50 mg). 1 H NMR(400MHz,DMSO-d6) δ10.06(s,1H),7.05(s,1H),6.93(s,2H),3.73-3.34(m,4H),3.29-3.01(m,6H),2.39-2.32 (m,1H),2.17-2.04(m,2H),1.97-1.68(m,4H),1.33-1.13(m,2H),0.78(dd,4H);LC-MS:m / z 354.2(MH+)

[0154] Preparation: tert-butyl N-[1-[4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoyl]piperidin-4-yl]-N-methylcarbamate [ka] Example 10 The synthesis of the title compound was carried out in a similar manner to the synthesis of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that 4-N-BOC-4-N-methyl-aminopiperidine was used instead of 2-phenylpyrrolidine. The title compound was obtained in quantitative yield (140 mg). LC-MS: m / z 471.49(MH+)

[0155] Preparation: tert-butyl N-[1-[4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoyl]piperidin-4-yl]carbamate [ka] Example 11 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that N-(4-piperidinyl)carbamic acid tert-butyl ester was used instead of 2-phenylpyrrolidine. The title compound was obtained in quantitative yield (140 mg). LC-MS: m / z 457.48(MH+)

[0156] Preparation: tert-butyl 4-[4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoyl]-3-[2-(trifluoromethyl)phenyl]piperazine-1-carboxylate [ka] Example 12 The title compound was synthesized in a similar manner to the synthesis of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that tert-butyl 3-[2-(trifluoromethyl)phenyl]piperazine-1-carboxylate was used instead of 2-phenylpyrrolidine. The title compound was obtained as a racemic mixture in a yield of 19% (24 mg). LC-MS: m / z 587.30(MH+).

[0157] Preparation: tert-butyl 3-(3-cyanophenyl)-4-[4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoyl]piperazine-1-carboxylate [ka] Example 13 The title compound was synthesized in a similar manner to the synthesis of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that tert-butyl 3-(3-cyanophenyl)piperazine-1-carboxylate was used instead of 2-phenylpyrrolidine. The title compound was obtained as a racemic mixture in a yield of 47% (55 mg). LC-MS: m / z 544.27(MH+).

[0158] Preparation: tert-butyl 4-[4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)piperazine-1-carboxylate [ka] Example 14 The synthesis of the title compound was carried out in a similar manner to the synthesis of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that tert-butyl 3-(4,5-dimethyl-1,3-thiazol-2-yl)piperazine-1-carboxylate was used instead of 2-phenylpyrrolidine. The title compound was obtained as a racemic mixture in 60% yield (73 mg). LC-MS: m / z 554.25(MH+)

[0159] Preparation: tert-butyl 4-[4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoyl]-3-(4-methylphenyl)piperazine-1-carboxylate [ka] Example 15 The title compound was synthesized in a manner similar to that of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that tert-butyl 3-(4-methylphenyl)piperazine-1-carboxylate was used instead of 2-phenylpyrrolidine. The title compound was obtained as a racemic mixture in 70% yield (96 mg).

[0160] Preparation: tert-butyl 3-(3-chloro-5-methylphenyl)-4-[4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoyl]piperazine-1-carboxylate [ka] Example 16 The title compound was synthesized in the same manner as in Example 1, except that tert-butyl 3-(3-chloro-5-methylphenyl)piperazine-1-carboxylate was used instead of 2-phenylpyrrolidine. The title compound was obtained as a racemic mixture in 90% yield (130 mg). LC-MS: m / z 567.29 (MH+).

[0161] Preparation: tert-butyl 4-[4-(cyclopropanecarbonylamino)-2-pyrrolidin-1-ylbenzoyl]-3-(3-methylphenyl)piperazine-1-carboxylate [ka] Example 17 The title compound was synthesized in a manner similar to that of the compound N-[4-(2-phenylpyrrolidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide in Example 1, except that tert-butyl 3-(3-methylphenyl)piperazine-1-carboxylate was used instead of 2-phenylpyrrolidine. The title compound was obtained as a racemic mixture in quantitative yield (150 mg). LC-MS: m / z 533.33(MH+). [ka]

[0162] Step 1 Compounds of formula II can be obtained by forming the acyl chloride of compounds of formula I (commercially available from Enamine) by treatment with a suitable chlorinating agent, such as SOCl, followed by coupling with 1-methyl-3-phenylpiperazine (commercially available from Enamine) in the presence of a suitable organic base, such as DIPEA, typically at 90° C. The reaction is typically carried out at room temperature in a suitable solvent, such as DCM. The reaction takes about 12 hours to complete.

[0163] Step 2 Compounds of formula II can be obtained from compounds of formula II by SNAr displacement with pyrrolidine in a suitable aprotic solvent, such as DMSO, typically at 120° C. The reaction takes about 36 hours to complete.

[0164] Step 3 Compounds of formula IV can be obtained from compounds of formula III by the Buchwald reaction with an appropriate heteroarylaniline in the presence of a suitable palladium precatalyst, such as tBuBrettPhos Pd G3, and a suitable base, such as K3PO4. The reaction is typically carried out at 120°C in a suitable solvent, such as 1-butanol. The reaction takes about 12 hours to about 24 hours to complete.

[0165] Step 4 Compounds of formula V can be obtained by Suzuki coupling between compounds of formula III and an appropriate commercially available boronic acid in the presence of a suitable catalyst, such as palladium tetrakistriphenylphosphine, a suitable inorganic base, Na2CO3, in a suitable solvent, 1,2-dimethoxyethane, typically at 95° C. The reaction takes about 2 days to complete.

[0166] Scheme 2. Preparation of Compound II: (2-Fluoro-4-iodophenyl)-(4-methyl-2-phenylpiperazin-1-yl)methanone [ka] A mixture of 2-fluoro-4-iodobenzoic acid (2.0 g, 7.52 mmol) and thionyl dichloride (10.97 mL, 150.37 mmol) was heated to reflux for 2.5 hours. After this time, the reaction was cooled to room temperature and then concentrated under vacuum. The mixture was stripped three times with cyclohexane to remove excess thionyl dichloride. The residue was suspended in dry DCM (40 mL) and triethylamine (3.14 mL, 22.56 mmol) was added, followed by 1-methyl-3-phenylpiperazine (1.33 g, 7.52 mmol). The reaction mixture was stirred overnight at room temperature. The next day, the mixture was diluted with DCM and washed with saturated NaHCO3 solution. The combined organic phase was dried on a phase separator and concentrated under vacuum to give the product of formula (2-fluoro-4-iodophenyl)-(4-methyl-2-phenylpiperazin-1-yl)methanone as a racemic mixture. The product was used in the next step without further purification. Yield: 3.2g 1 H NMR(400MHz,DMSO-d6) δ7.75(dd,2H),7.47(d,2H),7.42-7.20(m,4H),4.74-3.64(m,1H),3.55-3.34(m,1H),3.2 5-2.57(m,2H),2.36-2.24(m,1H),2.18(d,3H),2.07-1.83(m,1H),0.97(t,1H);LC-MS:m / z 425.05(MH+).

[0167] Scheme 2. Preparation of Compound III: (4-iodo-2-pyrrolidin-1-ylphenyl)-(4-methyl-2-phenylpiperazin-1-yl)methanone [ka] To a solution of (2-fluoro-4-iodophenyl)-(4-methyl-2-phenylpiperazin-1-yl)methanone (2.79 g, 6.56 mmol) in DMSO (50 mL) was added pyrrolidine (1.64 mL, 19.69 mmol), and the reaction mixture was stirred at 120 °C overnight. After 16 h, additional pyrrolidine (0.55 mL, 6.56 mmol) was added, and the reaction was stirred for 1 day. The next day, the reaction was cooled to room temperature, diluted with water, and the aqueous phase was extracted three times with AcOEt. The combined organic phases were washed with brine, dried over Na SO , filtered, and concentrated in vacuo. The residue was purified by reverse-phase flash chromatography using acidic conditions (elution from 5:95 CHCN / HO + 0.1% HCOOH to 95:5 CHCN / HO + 0.1% HCOOH). Pure fractions were collected and concentrated in vacuo. The residue was taken up in saturated NaHCO3 solution and extracted three times with AcOEt. The combined organic fractions were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to give the product of formula (4-iodo-2-pyrrolidin-1-ylphenyl)-(4-methyl-2-phenylpiperazin-1-yl)methanone. Yield: 1.0g 1 H NMR(400MHz,DMSO) δ7.73(d,1H),7.53-7.14(m,4H),7.10-6.76(m,2H),6.68(d,1H),5.84-5.57(m,1H),4 .77-4.29(m,1H),3.14-2.58(m,7H),2.43-1.99(m,7H),1.75-1.49(m,2H);LC-MS:m / z 476.1(MH+).

[0168] Preparation: [4-[(3-methyl-1,2-oxazol-5-yl)amino]-2-pyrrolidin-1-ylphenyl]-(4-methyl-2-phenylpiperazin-1-yl)methanone [ka] Example 18 A mixture of (4-iodo-2-pyrrolidin-1-ylphenyl)-(4-methyl-2-phenylpiperazin-1-yl)methanone (150.0 mg, 0.320 mmol), 3-methyl-5-isoxazolamine (37.15 mg, 0.380 mmol), potassium phosphate tripotassium (66.98 mg, 0.320 mmol), and tBuBrettPhos Pd G3 (26.96 mg, 0.030 mmol) in 1-butanol (1.2 mL) was degassed by N2-vacuum cycle. The reaction was stirred at 120 °C for 24 h. After this time, the reaction was cooled to room temperature, diluted with MeOH, and purified by SCX, eluting first with MeOH and then with NH3 IN in MeOH. The basic fractions were collected and concentrated in vacuo. The residue was purified by reverse-phase flash chromatography using acidic conditions (elution from 5:95 CHCN / HO+0.1% HCOOH to 95:5 CHCN / HO+0.1% HCOOH). Pure fractions were collected and concentrated in vacuo. The residue was taken up in saturated NaHCO solution and extracted three times with AcOEt. The combined organic fractions were washed with brine, dried over NaSO, filtered, and concentrated in vacuo to give the product of formula [4-[(3-methyl-1,2-oxazol-5-yl)amino]-2-pyrrolidin-1-ylphenyl]-(4-methyl-2-phenylpiperazin-1-yl)methanone as a racemic mixture. Yield: 16 mg 1H NMR(400MHz,DMSO-d6) δ9.75(d,1H),7.83-7.14(m,6H),6.97(ddd,1H),6.78-6.66(m,1H),6.61-6.35(m,1H),3.5 5-3.30(m,2H),3.10-2.55(m,7H),2.37-2.10(m,7H),1.94(s,4H),1.67(d,1H);LC-MS:m / z 446.48(MH+).

[0169] Preparation: (4-methyl-2-phenylpiperazin-1-yl)-[2-pyrrolidin-1-yl-4-([1,2,4]triazolo[1,5-a]pyridin-2-ylamino)phenyl]methanone [ka] Example 19 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [4-[(3-methyl-1,2-oxazol-5-yl)amino]-2-pyrrolidin-1-ylphenyl]-(4-methyl-2-phenylpiperidin-1-yl)methanone in Example 18, except that [1,2,4]triazolo[1,5-a]pyridin-2-amine was used instead of 3-methyl-5-isoxazolamine. The title compound was obtained in a yield of 16% (25 mg). 1 H NMR(500MHz,DMSO-d6) δppm 9.52(br d,1H),8.74(d,1H),7.84-6.50(m,11H),5.93-4.61(m,1H),4.54-3.36(m,2H),3.30-3.17(m,2H),3.06(br s,4H),2.44-2.09(m,4H),2.09-1.51(m,5H);LC-MS:m / z 482.24(MH+).

[0170] Preparation: (4-methyl-2-phenylpiperazin-1-yl)-[4-[(5-methyl-1,3,4-thiadiazol-2-yl)amino]-2-pyrrolidin-1-ylphenyl]methanone [ka] Example 20 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [4-[(3-methyl-1,2-oxazol-5-yl)amino]-2-pyrrolidin-1-ylphenyl]-(4-methyl-2-phenylpiperidin-1-yl)methanone in Example 18, except that 5-methyl-1,3,4-thiadiazol-2-amine was used instead of 3-methyl-5-isoxazolamine. The title compound was obtained in a yield of 39% (56 mg). 1 H NMR(400MHz,DMSO-d6) δ10.18(d,1H),7.76-7.68(m,1H),7.54-7.17(m,5H),7.15-6.99(m,1H),6.94-6.81(m,1H),5.90-4.27(m,1H) ,3.43(d,1H),3.12-2.53(m,8H),2.37(dt,1H),2.22(d,4H),2.07-1.84(m,4H),1.81-1.55(m,2H);LC-MS:m / z 463.2(MH+).

[0171] Preparation: (4-methyl-2-phenylpiperazin-1-yl)-[4-(1H-pyrazol-4-yl)-2-pyrrolidin-1-ylphenyl]methanone [ka] Example 21 A mixture of 2M aqueous solution of (4-bromo-2-pyrrolidin-1-ylphenyl)-(4-methyl-2-phenylpiperazin-1-yl)methanone (50.0 mg, 0.120 mmol), 1H-pyrazole-4-boronic acid (14.37 mg, 0.130 mmol), and Na2CO3 (0.18 mL, 0.350 mmol) in 1,2-dimethoxyethane (1.052 mL) was degassed by five nitrogen / vacuum cycles. Palladium tetrakistriphenylphosphine (6.74 mg, 0.010 mmol) was then added and the vessel was sealed. The reaction mixture was again degassed by five nitrogen / vacuum cycles and then heated to 95 °C for 2 days. After this time, the mixture was purified directly by reverse-phase flash chromatography using acidic conditions (eluting with 5:95 CHCN / HO+0.1% HCOOH to 50:50 CHCN / HO+0.1% HCOOH), and then purified by SCX, washing first with MeOH and then eluting with NH3 IN in MeOH. The basic fractions were collected and concentrated in vacuo to give the product of formula (4-methyl-2-phenylpiperazin-1-yl)-[4-(1H-pyrazol-4-yl)-2-pyrrolidin-1-ylphenyl]methanone. Yield: 14 mg 1 H NMR(400MHz,DMSO-d6) δ12.91(bs,1H),8.29-8.15(m,1H),7.98-7.85(m,1H),7.74(d,1H),7.60-7.15(m,4H),7.08-6.80(m,3H),5.98-4.3 7(m,1H),3.52-3.39(m,2H),3.16-2.61(m,5H),2.44-2.13(m,5H),2.05-1.90(m,3H),1.83-1.63(m,2H);LC-MS:m / z 416.18(MH+). [ka]

[0172] Step 1 Compounds of formula II can be obtained from compounds of formula I (commercially available from Enamine) by coupling with an appropriate amine in the presence of a coupling agent, such as HATU, and an organic base, such as DIPEA. The reaction is typically carried out at room temperature in a suitable solvent, such as DMF. The reaction takes about 3 to about 12 hours to complete. Alternatively, compounds of formula II can be obtained by forming an acyl chloride of compounds of formula I (commercially available from Enamine) by treatment with a suitable chlorinating agent, such as SOCl, typically at 90° C., followed by coupling with an appropriate amine in the presence of a suitable organic base, such as TEA. The reaction is typically carried out at room temperature in a suitable solvent, such as DCM. The reaction takes about 1 to about 12 hours to complete.

[0173] Step 2 Compounds of formula III can be obtained by nitro reduction of compounds of formula II using Zn powder in a suitable solvent, such as AcOH, typically at room temperature. The reaction takes about 3 to about 12 hours to complete. Alternatively, compounds of formula III can be obtained by reduction of compounds of formula II using tin(III) chloride dehydrate in a suitable solvent, such as EtOH, typically at 80°C. The reaction takes about 12 hours to complete.

[0174] Step 3 The compound of formula IV can be obtained by coupling reaction between the compound of formula III and a suitable commercially available acyl chloride, such as cyclopropanecarbonyl chloride, in the presence of an organic base, such as TEA. The reaction is typically carried out at room temperature in a suitable solvent, such as DCM. The reaction takes about 3 hours to complete.

[0175] Step 4 Compounds of formula V can be obtained by Suzuki coupling between compounds of formula IV and the desired heteroarylboronic ester or heteroarylboronic acid in the presence of a suitable precatalyst, such as XPhos Pd G2, a suitable base, such as K3PO4, in a suitable solvent, such as a mixture of 1,2-dimethoxyethane / water, typically at 100° C. The reaction takes about 3 to 12 hours to complete.

[0176] Step 5 Compounds of formula VI can be obtained by Miyaura coupling between compounds of formula IV, the desired aryl bromide, and bis(pinacolato)diboron in a suitable solvent, such as 1,4 dioxane, in the presence of a suitable catalyst, such as PdCl(dppf)·CHCl, and a suitable base, such as AcOK, typically at 100° C. The reaction takes about 12 hours to complete.

[0177] Step 6 Compounds of formula V can be obtained by Suzuki coupling between compounds of formula VI and commercially available heteroaryl halides in a suitable solvent, 1,2-dimethoxyethane, in the presence of a suitable catalyst, e.g., palladium tetrakistriphenylphosphine, a suitable inorganic base, Na2CO3, typically at 95° C. The reaction takes about 12 hours to complete.

[0178] Scheme 3, Preparation of compound (II)*a: (2-bromo-4-nitrophenyl)-(4,4-difluoropiperidin-1-yl)methanone [ka] To a solution of [dimethylamino(3-triazolo[4,5-b]pyridinyloxy)methylidene]-dimethylammonium hexafluorophosphate, HATU (2.32 g, 6.1 mmol), 2-bromo-4-nonthrobenzoic acid (1.0 g, 4.06 mmol), and N,N-diisopropylethylamine (3.15 g, 24.39 mmol) in DMF (25 mL) was added 4,4-difluoropiperidine hydrochloride (768.7 mg, 4.88 mmol). The reaction was stirred at room temperature for 3 hours. After this time, saturated aqueous NaHCO was added to the reaction mixture, and the aqueous phase was extracted with EtOAc (3 times). The organic portion was collected, washed with brine, and residual water was removed by adding NaSO. The solvent was filtered and evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (eluting with 100% cHex to 25:75 AcOEt / cHex) to give the product of formula (2-bromo-4-nitrophenyl)-(4,4-difluoropiperidin-1-yl)methanone. Yield: 1.2g 1 H NMR(400MHz,DMSO) δ8.51(d,1H),8.32(dd,1H),7.77(d,1H),3.89(dt,1H),3.68(ddd,1H),3.25(t,2H),2.32-1.88(m,4H);LC-MS:m / z 349.0,351.0(MH+)

[0179] Scheme 3, Preparation of compound (II)*b: (2-bromo-4-nitrophenyl)-(4-propylpiperazin-1-yl)methanone [ka] A mixture of 2-bromo-4-nitrobenzoic acid (1.5 g, 6.1 mmol) and thionyl dichloride (8.9 mL, 121.95 mmol) was heated to 90° C. and stirred for 2 hours. The reaction was cooled to room temperature and then concentrated in vacuo. The mixture was stripped three times with cyclohexane to remove excess thionyl dichloride. The residue was taken up in DCM (10 mL) and added to a solution of triethylamine (5.96 mL, 42.68 mmol) and 1-propylpiperazine dihydrobromide (1.77 g, 6.1 mmol) in DCM (75 mL). The reaction mixture was stirred at room temperature for 1 hour, then it was diluted with DCM, washed with saturated NaHCO solution, brine, dried over NaSO, filtered, and concentrated in vacuo to give the product of formula (2-bromo-4-nitrophenyl)-(4-propylpiperazin-1-yl)methanone. The product was used in the next step without further purification. Yield: 2.2g 1 H NMR(400MHz,DMSO) δ8.49(d,1H),8.29(dd,1H),7.65(d,1H),3.65(qdd,2H),3.18-3.05(m,2H),2.49-2. 38(m,2H),2.37-2.31(m,2H),2.30-2.24(m,2H),1.44(h,2H),0.86(t,3H);LC-MS:m / z 256.05,358.07(MH+).

[0180] Scheme 3, Preparation of compound (II)*c: (2-bromo-4-nitrophenyl)-(1,1-dioxo-1,4-thiazinan-4-yl)methanone [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound (2-bromo-4-nitrophenyl)-(4-propylpiperazin-1-yl)methanone, except that 1,4-thiazinane 1,1-dioxide hydrochloride was used instead of 1-propylpiperazine dihydrobromide. The title compound was obtained in 74% (3.3 g) yield. 1H NMR(400MHz,DMSO) δ8.52(d,1H),8.36(dd,1H),7.89(d,1H),4.50-4.36(m,1H),3.74(ddd,1H),3. 60-3.51(m,2H),3.42(d,1H),3.28-3.23(m,1H),3.12-3.05(m,2H);LC-MS:m / z 362.87,364.94(MH+).

[0181] Scheme 3, Preparation of compound (II)*d: (2-bromo-4-nitrophenyl)-(4-methyl-2-phenylpiperazin-1-yl)methanone [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound (2-bromo-4-nitrophenyl)-(4-propylpiperazin-1-yl)methanone, except that 1-methyl-3-phenylpiperazine was used instead of 1-propylpiperazine dihydrobromide. The title compound was obtained in 100% (1.8 g) yield. 1 H NMR(400MHz,DMSO) δ8.50(td,1H),8.37-8.09(m,1H),7.89-7.17(m,6H),5.95-5.71(m,1H),4.47(d,1H),3.50 (dd,1H),3.17-2.57(m,2H),2.40(td,1H),2.30-1.90(m,4H);LC-MS:404.01,405.96(MH+).

[0182] Scheme 3, Preparation of compound (III)*a: (4-amino-2-bromophenyl)-(4,4-difluoropiperidin-1-yl)methanone [ka] To a solution of (2-bromo-4-nitrophenyl)-(4,4-difluoropiperidin-1-yl)methanone (1.17 g, 3.35 mmol) in AcOH (28 mL) was added zinc (2.19 g, 33.51 mmol), and the reaction mixture was stirred at room temperature for 24 hours. The reaction was filtered and concentrated in vacuo. The residue was taken up in saturated NaHCO3 solution and extracted with AcOEt (3 times). The combined organic fractions were washed with brine, dried over Na2SO4, filtered, and the solvent was evaporated. The crude was purified by FC on silica gel (eluting with 80:20 cHex / EtOAc to 4:6 cHex / EtOAc) to give the product of formula (4-amino-2-bromophenyl)-(4,4-difluoropiperidin-1-yl)methanone. Yield: 650mg 1 H NMR(400MHz,DMSO-d6) δ7.00(d,1H),6.80(d,1H),6.57(dd,1H),5.62(s,2H),3.86-3.73(m,2H),3.67-3.55(m,2H),2.13-1.91(m,4H);LC-MS:m / z 319.25,321.25(MH+).

[0183] Scheme 3, Preparation of compound (III)*b: (4-amino-2-bromophenyl)-(1,1-dioxo-1,4-thiazinan-4-yl)methanone [ka] A mixture of (2-bromo-4-nitrophenyl)-(1,1-dioxo-1,4-thiazinan-4-yl)methanone (1.2 g, 3.3 mmol) and tin(III) chloride dihydrate (2.26 g, 9.91 mmol) in ethanol (24 mL) was heated to reflux for 8 hours. After this time, the mixture was cooled to room temperature, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluting with 100% DCM to 95:5 DCM / MeOH as eluent) to give the product of formula (4-amino-2-bromophenyl)-(1,1-dioxo-1,4-thiazinan-4-yl)methanone. Yield: 1.0g 1 H NMR(400MHz,DMSO-d6) δ7.10(d,1H),6.80(d,1H),6.57(dd,1H),5.75(s,2H),7H),4.27(s,1H),3.40(d,7H);LC-MS:m / z 332.93,334.9(MH+).

[0184] Scheme 3, Preparation of compound (III)*c: (4-amino-2-bromophenyl)-(4-propylpiperazin-1-yl)methanone [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound (4-amino-2-bromophenyl)-(4,4-difluoropiperidin-1-yl)methanone, except that (2-bromo-4-nitrophenyl)-(4,4-difluoropiperidin-1-yl)methanone was replaced with (2-bromo-4-nitrophenyl)-(4-propylpiperazin-1-yl)methanone. The title compound was obtained in a yield of 88% (1.7 g). 1 H NMR(400MHz,DMSO) δ6.91(d,1H),6.79(d,1H),6.56(dd,1H),5.57(s,2H),3.57(s,2H),3.15(s ,2H),2.35(d,3H),2.29-2.14(m,3H),1.43(h,2H),0.85(t,3H);LC-MS:m / z 326.04,327.99(MH+).

[0185] Scheme 3, Preparation of compound (III)*d: (4-amino-2-bromophenyl)-(4-methyl-2-phenylpiperazin-1-yl)methanone [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of the compound (4-amino-2-bromophenyl)-(4,4-difluoropiperidin-1-yl)methanone, except that (2-bromo-4-nitrophenyl)-(4,4-difluoropiperidin-1-yl)methanone was replaced with (2-bromo-4-nitrophenyl)-(4-methyl-2-phenylpiperazin-1-yl)methanone. The title compound was obtained in a yield of 91% (850 mg). 1 H NMR(400MHz,DMSO) δ7.57(d,1H),7.30(d,5H),6.80(td,2H),5.75(s,1H),5.60(s,2H),4.95-4.27(m,1H),3.4 5(d,1H),3.23-2.87(m,2H),2.77-2.57(m,1H),2.38-2.13(m,3H),1.89(s,1H);LC-MS:m / z 374.09,376.08(MH+).

[0186] Scheme 3, Preparation of compound (IV)*a: N-[3-bromo-4-(4,4-difluoropiperidine-1-carbonyl)phenyl]cyclopropanecarboxamide [ka] To a cooled mixture of N,N-diisopropylethylamine (0.69 mL, 4.09 mmol) and (4-amino-2-bromophenyl)-(4,4-difluoropiperidin-1-yl)methanone (652.0 mg, 2.04 mmol) in DCM (20 mL) was added cyclopropanecarbonyl chloride (0.22 mL, 2.45 mmol) dropwise at 0 °C. The mixture was stirred at room temperature for 1 h. After this time, the mixture was diluted with DCM, washed with saturated NaHCO solution, and dried on a phase separator. The solvent was evaporated, and the crude was purified by FC on silica gel (eluting with 100% DCM to 95:5 DCM / MeOH) to give the product of formula N-[3-bromo-4-(4,4-difluoropiperidine-1-carbonyl)phenyl]cyclopropanecarboxamide. Yield: 830mg 1H NMR(400MHz,DMSO) δ10.47(s,1H),8.03(d,1H),7.56(dd,1H),7.33(d,1H),3.82(s,1H),3.66(d,1H) ,3.24(t,2H),2.17-1.85(m,4H),1.82-1.71(m,1H),0.87-0.80(m,4H);LC-MS:m / z 387.16,389.16(MH+).

[0187] Scheme 3, Preparation of compound (IV)*b: N-[3-bromo-4-(4-propylpiperazine-1-carbonyl)phenyl]cyclopropanecarboxamide [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound N-[3-bromo-4-(4,4-difluoropiperidine-1-carbonyl)phenyl]cyclopropanecarboxamide, except that (4-amino-2-bromophenyl)-(4,4-difluoropiperidin-1-yl)methanone was replaced with (4-amino-2-bromophenyl)-(4-propylpiperazin-1-yl)methanone. The title compound was obtained in a yield of 96% (2.0 g). 1 H NMR(400MHz,DMSO) δ10.45(s,1H),8.02(d,1H),7.55(dd1H),7.24(d,1H),3.61(d,2H),3.12(td,2 LC-MS:m / z 394.10,396.04(MH+).

[0188] Scheme 3, Preparation of compound (IV)*c: N-[3-bromo-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound N-[3-bromo-4-(4,4-difluoropiperidine-1-carbonyl)phenyl]cyclopropanecarboxamide, except that (4-amino-2-bromophenyl)-(4,4-difluoropiperidin-1-yl)methanone was replaced with (4-amino-2-bromophenyl)-(1,1-dioxo-1,4-thiazinane-4-yl)methanone. The title compound was obtained in a yield of 43% (1.6 g). 1 H NMR(400MHz,DMSO) δ10.49(s,1H),8.04(d,1H),7.59(dd,1H),7.46(d,1H),4.35(s,1H),3.75(s,1 H),3.56(s,3H),3.23(s,2H),3.06(s,1H),1.78(p,1H),0.84(d,4H);LC-MS:m / z 401.27,403.27(MH+).

[0189] Scheme 3, Preparation of compound (IV)*d: N-[3-bromo-4-(4-methyl-2-phenylpiperazine-1-carbonyl)phenyl]cyclopropanecarboxamide [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound N-[3-bromo-4-(4,4-difluoropiperidine-1-carbonyl)phenyl]cyclopropanecarboxamide, except that (4-amino-2-bromophenyl)-(4,4-difluoropiperidin-1-yl)methanone was replaced with (4-amino-2-bromophenyl)-(4-methyl-2-phenylpiperazin-1-yl)methanone. The title compound was obtained in a yield of 69% (3.9 g). 1H NMR(400MHz,DMSO-d6) δ10.44(d,1H),8.14-7.94(m,1H),7.58(d,2H),7.31(dt,5H),5.84-5.52(m,1H),3.47(d,1H), 3.17-2.57(m,2H),2.46-2.12(m,4H),2.11-1.60(m,2H),1.08(dt,1H),0.82(d,4H);LC-MS:m / z 442.12,444.14(MH+).

[0190] Preparation: N-[4-(4,4-difluoropiperidine-1-carbonyl)-3-(1-methylpyrazol-3-yl)phenyl]cyclopropanecarboxamide [ka] Example 22 A mixture of 1-methyl-1H-pyrazole-3-boronic acid pinacol ester (83.83 mg, 0.400 mmol), N-[3-bromo-4-(4,4-difluoropiperidine-1-carbonyl)phenyl]cyclopropanecarboxamide (120.0 mg, 0.310 mmol), X-Phos amonobiphenyl palladium chloride precatalyst (24.35 mg, 0.030 mmol), and tripotassium phosphate (197.35 mg, 0.930 mmol) in water (0.3 mL) / 1,2-dimethoxyethane (3 mL) was degassed under nitrogen flux for 5 min and then heated to 100 °C overnight. The next day, the reaction was cooled to room temperature, diluted with water, and extracted with EtOAc (3 times). The organic layers were collected together, washed with brine, dried over Na2SO4, filtered, and dissolved. The solvent was removed under vacuum. The residue was purified by FC on silica gel (eluting with 90:10 DCM / EtOAc to 20:80 DCM:AcOEt) and again by reversed-phase flash chromatography using acidic conditions (eluting with 5:95 CHCN / H2O + 0.1% HCOOH to 50:50 CH3CN / H2O + 0.1% HCOOH). Pure fractions were collected and concentrated under vacuum. The residue was taken up in saturated NaHCO3 solution and extracted three times with AcOEt. The combined organic fractions were washed with brine, dried over Na2SO4, filtered, and concentrated under vacuum to give the product of formula N-[4-(4,4-difluoropiperidine-1-carbonyl)-3-(1-methylpyrazol-3-yl)phenyl]cyclopropanecarboxamide. Yield: 22 mg 1 H NMR(400MHz,DMSO) δ10.36(s,1H),7.95(d,1H),7.73(d,1H),7.63(dd,1H),7.20(d,1H),6.35(d,1H),3.85(s,4H),3.51(dd d,1H),3.13(tt,2H),2.13-1.89(m,2H),1.79(tt,2H),1.60-1.47(m,1H),0.85-0.75(m,4H);LC-MS:m / z 389.2(MH+)

[0191] Preparation: N-[4-(4,4-difluoropiperidine-1-carbonyl)-3-(1-propan-2-ylpyrazol-3-yl)phenyl]cyclopropanecarboxamide [ka] Example 23 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(4,4-difluoropiperidine-1-carbonyl)-3-(1-methylpyrazol-3-yl)phenyl]cyclopropanecarboxamide in Example 22, except that 1-isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole was used instead of 1-methyl-1H-pyrazole-3-boronic acid pinacol ester. The title compound was obtained in a yield of 42% (54 mg). 1 H NMR(400MHz,DMSO) δ10.36(s,1H),7.91(d,1H),7.80(d,1H),7.65(dd,1H),7.21(d,1H),6.34(d,1H),4.51(hept,1H),3.93-3.82(m,1H) ,3.51(ddd,1H),3.20-3.02(m,2H),2.14-1.66(m,4H),1.42(dd,6H),1.36-1.21(m,1H),0.85-0.75(m,4H);LC-MS:m / z 417.3(MH+).

[0192] Preparation: N-[3-(1-propan-2-ylpyrazol-3-yl)-4-(4-propylpiperazine-1-carbonyl)phenyl]cyclopropanecarboxamide [ka] Example 24 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(4,4-difluoropiperidine-1-carbonyl)-3-(1-methylpyrazol-3-yl)phenyl]cyclopropanecarboxamide in Example 22, except that N-[3-bromo-4-(4,4-difluoropiperidine-1-carbonyl)phenyl]cyclopropanecarboxamide and 1-methyl-1H-pyrazole-3-boronic acid pinacol ester were replaced with N-[3-bromo-4-(4-propylpiperazine-1-carbonyl)phenyl]cyclopropanecarboxamide and 1-isopropyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, respectively. The title compound was obtained in a yield of 38% (61 mg). 1 H NMR(400MHz,DMSO) δ10.34(s,1H),7.91(d,1H),7.78(d,1H),7.64(dd,1H),7.13(d,1H),6.30(d,1H),4.52(hept,1H),3.62-3.43(m,2H),3.06-2.96(m, LC-MS:m / z 424.3(MH+).

[0193] Preparation: N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-(5-methylthiophen-2-yl)phenyl]cyclopropanecarboxamide [ka] Example 25 4,4,5,5-Tetramethyl-2-(5-methyl-2-thiophenyl)-1,3,2-dioxaborolane (72.61 mg, 0.320 mmol), N-[3-bromo-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide (100.0 mg, 0.250 mmol), X-Phos amonobiphenyl palladium chloride precatalyst (19.58 mg, 0.020 mmol), and tripotassium phosphate (158.69 mg, 0.750 mmol) were suspended in a mixture of water (0.3 mL) and 1,2-dimethoxyethane (3.3 mL). The resulting suspension was degassed under nitrogen flux for 5 min and then heated to 90 °C overnight. The next day, the reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3×). The organic layers were collected together, washed with brine, dried over NaSO, filtered, and the solvent was removed under vacuum. The crude material was purified by reverse-phase flash chromatography using acidic conditions (elution from 5:95 CHCN / HO+0.1% HCOOH to 60:40 CHCN / HO+0.1% HCOOH) to give the product of formula N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-(5-methylthiophen-2-yl)phenyl]cyclopropanecarboxamide. Yield: 23 mg 1 H NMR(400MHz,DMSO) δ10.42(s,1H),7.83(d,1H),7.59(dd,1H),7.35(d,1H),6.94(d,1H),6.84(dt,1H),4.06-3.98(m,1H),3.97-3.90(m,1H),3.53-3. 44(m,1H),3.33(d,1H),3.10-2.97(m,2H),2.50(d,1H),2.47(d,3H),2.28(d,1H),1.84-1.73(m,1H),0.85-0.78(m,4H);LC-MS:m / z 419.1(MH+).

[0194] Preparation: N-[3-(5-cyanothiophen-2-yl)-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide [ka] Example 26 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-(5-methylthiophen-2-yl)phenyl]cyclopropanecarboxamide in Example 25, except that (5-cyanothiophen-2-yl)boronic acid was used instead of 4,4,5,5-tetramethyl-2-(5-methyl-2-thiophenyl)-1,3,2-dioxaborolane. The title compound was obtained in a yield of 11% (11 mg). 1 H NMR(400MHz,DMSO-d6) δ10.53(s,1H),7.95(dd,2H),7.72(dd,1H),7.53(d,1H),7.26(d,1H),4.27(s,1 LC-MS:m / z 430.2(MH+).

[0195] Preparation: N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-[2-(trifluoromethyl)-1,3-thiazol-5-yl]phenyl]cyclopropanecarboxamide [ka] Example 27 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-(5-methylthiophen-2-yl)phenyl]cyclopropanecarboxamide in Example 25, except that 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)-1,3-thiazole was used instead of 4,4,5,5-tetramethyl-2-(5-methyl-2-thiophenyl)-1,3,2-dioxaborolane. The title compound was obtained in a yield of 55% (62 mg). 1H NMR(400MHz,DMSO-d6) δ10.56(s,1H),8.13(q,1H),7.97(d,1H),7.74(dd,1H),7.61(d,,1H),4.37( s,1H),3.57(s,3H),3.30(s,4H),1.80(p,1H),0.88-0.81(m,4H);LC-MS:m / z 474.1(MH+).

[0196] Preparation: N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-(1-propan-2-ylpyrazol-3-yl)phenyl]cyclopropanecarboxamide [ka] Example 28 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-(5-methylthiophen-2-yl)phenyl]cyclopropanecarboxamide in Example 25, except that 1-propan-2-yl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole was used instead of 4,4,5,5-tetramethyl-2-(5-methyl-2-thiophenyl)-1,3,2-dioxaborolane. The title compound was obtained in a yield of 37% (38 mg). 1 H NMR(400MHz,DMSO-d6) δ10.38(s,1H),7.91(d,1H),7.84(d,1H),7.66(dd,1H),7.28(d,1H),6.38(d,1H),4.52(p,1H),4.09(s,1H),3.97-3.86( LC-MS:m / z 431.2(MH+).

[0197] Preparation: N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-[5-(trifluoromethyl)thiophen-2-yl]phenyl]cyclopropanecarboxamide [ka] Example 29 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-(5-methylthiophen-2-yl)phenyl]cyclopropanecarboxamide in Example 25, except that [5-(trifluoromethyl)thiophen-2-yl]boronic acid was used instead of 4,4,5,5-tetramethyl-2-(5-methyl-2-thiophenyl)-1,3,2-dioxaborolane. The title compound was obtained in a yield of 11% (12 mg). 1 H NMR(400MHz,DMSO-d6) δ10.54(s,1H),7.96(d,1H),7.76-7.68(m,2H),7.51(d,1H),7.22(dq,1H),4.21(s,1H),3.74(s,1 LC-MS:m / z 473.1(MH+).

[0198] Preparation: N-[4-(4-methyl-2-phenylpiperazine-1-carbonyl)-3-(1-propan-2-ylpyrazol-3-yl)phenyl]cyclopropanecarboxamide [ka] Example 30 A mixture of X-Phos aminobiphenyl palladium chloride precatalyst (10.94 mg, 0.010 mmol), potassium phosphate tripotassium (88.68 mg, 0.420 mmol), 1-propan-2-yl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (32.88 mg, 0.140 mmol), and N-[3-bromo-4-(4-methyl-2-phenylpiperazine-1-carbonyl)phenyl]cyclopropanecarboxamide (80.0 mg, 0.140 mmol) in water (0.195 mL) / 1,2-dimethoxyethane (1.945 mL) was degassed for 5 minutes and then stirred overnight at 100° C. The next day, the mixture was diluted with water and extracted three times with EtOAc. The combined organic phase was washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The residue was purified by reverse-phase flash chromatography using basic conditions (elution from 5:95 CH3CN / HO+0.1% NH4OH to 40:60 CH3CN / HO+0.1% NH4OH) and again by NH column flash chromatography (elution from 100% DCM to 60:40 DCM / EtOAc) to give the product of formula N-[4-(4-methyl-2-phenylpiperazine-1-carbonyl)-3-(1-propan-2-ylpyrazol-3-yl)phenyl]cyclopropanecarboxamide as a racemic mixture. Yield: 24 mg 1 H NMR(400MHz,DMSO-d6) δ ppm 10.42-10.28(m,1H),8.00-6.93(m,10H),6.47-5.66(m,3H),4.70-4.30(m,3H),3.41-3.33(m ,1H),3.10-2.55(m,4H),2.41-1.72(m,2H),1.56-1.00(m,5H),0.86-0.75(m,4H);LC-MS:m / z 472.28(MH+).

[0199] Preparation: N-[4-(4-methyl-2-phenylpiperazine-1-carbonyl)-3-[2-(trifluoromethyl)-1,3-thiazol-5-yl]phenyl]cyclopropanecarboxamide [ka] Example 31 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(4-methyl-2-phenylpiperazine-1-carbonyl)-3-(1-propan-2-ylpyrazol-3-yl)phenyl]cyclopropanecarboxamide in Example 30, except that 5-(tetramethyl-1,3,2-dioxaborolan-2-yl)-2-(trifluoromethyl)-1,3-thiazole was used instead of 1-propan-2-yl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole. The title compound was obtained as a racemic mixture in a yield of 14% (10 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 10.64-10.49(m,1H),8.38-7.12(m,8H),5.80-5.64(m,1H),4.43-4.32(m ,1H),3.35-3.28(m,2H),2.44-1.70(m,8H),0.88-0.72(m,4H);LC-MS:m / z 515.17(MH+).

[0200] Preparation: N-[4-(4-methyl-2-phenylpiperazine-1-carbonyl)-3-(2-methyl-1,3-thiazol-5-yl)phenyl]cyclopropanecarboxamide [ka] Example 32 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(4-methyl-2-phenylpiperazine-1-carbonyl)-3-(1-propan-2-ylpyrazol-3-yl)phenyl]cyclopropanecarboxamide in Example 30, except that 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3-thiazole was used instead of 1-propan-2-yl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole. The title compound was obtained as a racemic mixture in a yield of 47% (19 mg). 1 H NMR(400MHz,DMSO-d6) δ10.54-10.34(m,1H),7.94-7.60(m,2H),7.55-7.16(m,6H),5.73-5.64(m,1H),4.60-4.2 8(m,2H),3.12-2.53(m,5H),2.02(s,6H),1.17-0.90(m,1H),0.89-0.74(m,4H);LC-MS:m / z 461.25(MH+).

[0201] Preparation: N-[4-(4-methyl-2-phenylpiperazine-1-carbonyl)-3-[5-(trifluoromethyl)thiophen-2-yl]phenyl]cyclopropanecarboxamide [ka] Example 33 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(4-methyl-2-phenylpiperazine-1-carbonyl)-3-(1-propan-2-ylpyrazol-3-yl)phenyl]cyclopropanecarboxamide in Example 30, except that [5-(trifluoromethyl)thiophen-2-yl]boronic acid was used instead of 1-propan-2-yl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole. The title compound was obtained as a racemic mixture in a yield of 20% (11 mg). 1H NMR(400MHz,DMSO-d6) δ ppm 10.56-10.41(m,1H),8.04-7.15(m,10H),5.78-5.66(m,1H),4.55-4.28(m,1H),3.39-3.25(m,1H),3. 13-2.54(m,3H),2.41-2.27(m,1H),2.23-2.12(m,2H),2.05-1.73(m,1H),1.57-1.45(m,1H),0.83(br d,4H);LC-MS:m / z 514.29(MH+).

[0202] Preparation: N-[4-(4-methyl-2-phenylpiperazine-1-carbonyl)-3-(5-methylthiophen-2-yl)phenyl]cyclopropanecarboxamide [ka] Example 34 The synthesis of the title compound was carried out in a similar manner to the synthesis of the compound N-[4-(4-methyl-2-phenylpiperazine-1-carbonyl)-3-(1-propan-2-ylpyrazol-3-yl)phenyl]cyclopropanecarboxamide in Example 3.1, except that 4,4,5,5-tetramethyl-2-(5-methyl-2-thiophenyl)-1,3,2-dioxaborolane was used instead of 1-propan-2-yl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl). The title compound was obtained as a racemic mixture in 61% (38 mg) yield. 1 H NMR(400MHz,DMSO-d6) δ10.48-10.26(m,1H),7.90-7.56(m,2H),7.50-7.33(m,2H),7.25(dtd,4H),7.09-6.55(m,2H),5.86-4.17(m, LC-MS:m / z 460.18(MH+).

[0203] Preparation: N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxamide [ka] Example 35 A mixture of N-[3-bromo-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide (100.0 mg, 0.240 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (74.42 mg, 0.290 mmol), potassium acetate (72.64 mg, 0.730 mmol), and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (4.0 mg, 0 mmol) in 1,4-dioxane (2.442 mL) was degassed using Shlenk line techniques and stirred at 100° C. overnight. The next day, the reaction was cooled to room temperature, filtered through a pad of Celite, and washed with EtOAc. The solution was concentrated in vacuo to give the product of formula N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxamide, which was used in the next step without further purification. Yield: 100mg 1 H NMR(400MHz,DMSO) δ10.37(d,1H),7.81(dd,1H),7.70-7.60(m,1H),7.44(d,1H),3.57(s,8H), 1.84-1.77(m,1H),1.27(s,6H),1.07(s,6H),0.90-0.76(m,4H);LC-MS:m / z 449.21(MH+).

[0204] Preparation: N-[4-(2-oxa-7-azaspiro[3.5]nonane-7-carbonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxamide [ka] Example 36 The synthesis of the title compound was carried out in the same manner as the synthesis of compound N N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxamide in Example 3, except that N-[3-bromo-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide was used instead of N-[3-bromo-4-(2-oxa-7-azaspiro[3.5]nonane-7-carbonyl)phenyl]cyclopropanecarboxamide. The title compound was obtained in quantitative yield (80 mg). LC-MS: m / z 441.25(MH+)

[0205] Preparation: N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-[6-(trifluoromethyl)pyridin-2-yl]phenyl]cyclopropanecarboxamide [ka] Example 37 Palladium tetrakistriphenylphosphine (14.43 mg, 0.010 mmol) and N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxamide (112.0 mg, 0.250 mmol) were suspended in 1,2-dimethoxyethane (2.5 mL), followed by the addition of a 2 M aqueous solution of sodium carbonate (0.37 mL, 0.750 mmol). The mixture was degassed with five nitrogen / vacuum cycles, and 2-bromo-6-(trifluoromethyl)pyridine (62.1 mg, 0.270 mmol) was added. The reaction mixture was degassed again with five nitrogen / vacuum cycles and heated to 90 °C overnight. The next day, the reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 times). The organic layers were collected together, washed with brine, dried over NaSO, filtered, and the solvent was removed under vacuum. The mixture was purified by reverse-phase flash chromatography using acidic conditions (elution from 5:95 CHCN / HO+0.1% HCOOH to 35:65 CHCN / HO+0.1% HCOOH) to give the product of formula N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-[6-(trifluoromethyl)pyridin-2-yl]phenyl]cyclopropanecarboxamide. Yield: 22 mg 1 H NMR(400MHz,DMSO) δ10.52(s,1H),8.21(t,1H),8.04(d,1H),7.95(d,1H),7.89(dd,1H),7.75(dd,1 H),7.55(d,1H),4.37(s,1H),3.30(s,7H),1.81(p,1H),0.84(d,4H);LC-MS:m / z 468.17(MH+).

[0206] Preparation: N-[4-(2-oxa-7-azaspiro[3.5]nonane-7-carbonyl)-3-[6-(trifluoromethyl)pyridin-2-yl]phenyl]cyclopropanecarboxamide [ka] Example 38 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-[6-(trifluoromethyl)pyridin-2-yl]phenyl]cyclopropanecarboxamide in Example 37, except that N-[4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxamide was used instead of N-[4-(2-oxa-7-azaspiro[3.5]nonane-7-carbonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropanecarboxamide. The title compound was obtained in a yield of 23% (20 mg). 1 H NMR(400MHz,DMSO) δ10.49(s,1H),8.17(t,1H),7.98(d,1H),7.86(dd,2H),7.74(dd,1H),7.30(d,1H),4.44 -4.07(m,4H),3.30(s,4H),1.81(p,1H),1.76-1.37(m,4H),0.88-0.79(m,4H);LC-MS:m / z 460.20(MH+). [ka]

[0207] Step 1 Compounds of formula II can be obtained from compounds of formula I (commercially available from Astatech) by coupling with an appropriate amine in the presence of a coupling agent, such as HATU, and an organic base, such as DIPEA. The reaction is typically carried out at room temperature in a suitable solvent, such as DMF. The reaction takes about 3 to about 12 hours to complete.

[0208] Step 2 Compounds of formula III can be obtained by Suzuki coupling between compounds of formula II and the desired heteroarylboronic acid ester in a suitable solvent, such as a 1,2-dimethoxyethane / water mixture, in the presence of a suitable precatalyst, such as XPhos Pd G2, a suitable base, such as K3PO4, typically at 100° C. The reaction takes about 3 hours to about 12 hours to complete.

[0209] Step 3 Compounds of formula IV can be obtained by nitrile cyclization of compounds of formula III with ethanimidamide hydrochloride in the presence of a suitable catalyst, such as CuBr, a suitable base, such as CsCO, in a suitable solvent, such as DMSO, typically at 120° C. The reaction takes about 3 hours to about 12 hours to complete.

[0210] Step 4 Compounds of formula V can be obtained by nitrile cyclization of compounds of formula III with ethanimidamide hydrochloride in the presence of a suitable catalyst, such as CuBr, a suitable base, such as CsCO, in a suitable solvent, such as DMSO, typically at 120° C. The reaction takes about 3 hours to about 12 hours to complete.

[0211] Step 5 Compounds of formula IV can be obtained by Suzuki coupling between compounds of formula V and the desired heteroarylboronic acid ester in a suitable solvent, such as a mixture of 1,2-dimethoxyethane / water, in the presence of a suitable precatalyst, such as XPhos Pd G2, a suitable base, such as K3PO4, typically at 100° C. The reaction takes about 3 hours to about 12 hours to complete.

[0212] Scheme 4, Preparation of compound (II)*a: 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile [ka] To a solution of HATU (0.63 g, 1.66 mmol), 2-bromo-4-cyanobenzoic acid (250.0 mg, 1.11 mmol), and N,N-diisopropylethylamine (1.13 mL, 6.64 mmol) in DMF (7.374 mL) was added 4-methoxy-4-methyl-piperidine hydrochloride (219.87 mg, 1.33 mmol). The reaction was stirred at room temperature for 2.5 hours. After this time, saturated NaHCO solution was added to the reaction mixture, and the aqueous phase was extracted with EtOAc (x3). The organic portion was collected and washed with brine. Residual water was removed by adding NaSO, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (eluting with 95:5 cHex / AcOEt to 50:50 cHex / AcOEt) to give the product of formula 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile. Yield: 170mg 1 H NMR(400MHz,DMSO) δ8.27(t,1H),7.94(ddd,1H),7.62-7.50(m,1H),4.13(ddd,1H),3.22-3.02(m,5H),3.00-2. 89(m,1H),1.86-1.72(m,1H),1.68-1.57(m,1H),1.57-1.33(m,2H),1.12(d,3H);LC-MS:m / z 337.25,339.25(MH+).

[0213] Scheme 4, Preparation of compound (II)*b: 3-bromo-4-(4-tert-butylpiperidine-1-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 4-tert-butylpiperidine was used instead of 4-methoxy-4-methyl-piperidine hydrochloride. The title compound was obtained in 90% (346 mg) yield. 1H NMR(400MHz,DMSO-d6) δ8.30-8.25(m,1H),7.98-7.87(m,1H),7.66-7.47(m,1H),4.59(t,1H),3.23-3.11(m,1H),3.02-2 .91(m,1H),2.76-2.63(m,1H),1.90-1.50(m,2H),1.34-1.03(m,3H),0.89-0.81(m,9H);LC-MS:m / z 349.17,351.13(MH+).

[0214] Scheme 4, Preparation of compound (II)*c: 3-bromo-4-(4,4-difluoropiperidine-1-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 4,4-difluoropiperidine hydrochloride was used instead of 4-methoxy-4-methyl-piperidine hydrochloride. The title compound was obtained in 77% (500 mg) yield. 1 H NMR(400MHz,DMSO-d6) δ8.31(d,1H),7.98(dd,1H),7.66(d,1H),3.95-3.83(m,1H),3.78-3.61(m,1H),3.23(t2H),2.23-1.87(m,4H);LC-MS:m / z 329.25,331.25(MH+).

[0215] Scheme 4, Preparation of compound (II)*d: 3-bromo-4-(1-oxa-7-azaspiro[3.5]nonane-7-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 1-oxa-7-azaspiro[3.5]nonane was used instead of 4-methoxy-4-methyl-piperidine hydrochloride. The title compound was obtained in 74% (487 mg) yield. 1 H NMR(400MHz,DMSO-d6) δ ppm 8.27(d,1H),7.93(dt,1H),7.56(dd,1H),4.46-4.33(m,2H),3.73-3.51(m,2H),3.27(s,1H),2.99(s,2H),2.37(br d,2H),1.96-1.70(m,3H);LC-MS:m / z 335.09,337.06(MH+).

[0216] Scheme 4, Preparation of compound (II)*e: 3-bromo-4-(4-ethoxypiperidine-1-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 4-ethoxypiperidine hydrochloride was used instead of 4-methoxy-4-methyl-piperidine hydrochloride. The title compound was obtained in a yield of 56% (210 mg). 1 H NMR(400MHz,DMSO) δ8.28(t,1H),7.94(dd,1H),7.56(dd,1H),3.97(td,1H),3.54(tt,1H),3.46(qd,2H),3.35-3.31(m,1H), 3.19(ddt,1H),2.99(tdd,1H),1.89(s,1H),1.81-1.72(m,1H),1.58-1.31(m,2H),1.10(t,3H);LC-MS:m / z 337.35,339.35(MH+).

[0217] Scheme 4, Preparation of compound (II)*f: 3-bromo-4-(6,6-difluoro-2-azaspiro[3.3]heptane-2-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 6,6-difluoro-2-azaspiro[3.3]heptane hydrochloride was used instead of 4-methoxy-4-methyl-piperidine hydrochloride. The title compound was obtained in 50% (70 mg) yield. 1 H NMR(400MHz,DMSO-d6) δ8.30(d,1H),7.96(dd,1H),7.61(d,1H),4.19(s,2H),3.97(s,2H),2.96-2.78(m,4H);LC-MS:m / z 341.25,343.25(MH+)

[0218] Scheme 4, Preparation of Compound (II)*g: 3-Bromo-4-[4-(trifluoromethoxy)piperidine-1-carbonyl]benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 4-(trifluoromethoxy)piperidine hydrochloride was used instead of 4-methoxy-4-methyl-piperidine hydrochloride. The title compound was obtained in 62% (260 mg) yield. 1H NMR(400MHz,DMSO) δ8.29(dd,1H),7.96(ddd,1H),7.72-7.49(m,1H),4.74(dt,1H),4.02(td,1H),3.42(ddd d,1H),3.30-3.06(m,2H),2.09-1.97(m,1H),1.90(s,1H),1.84-1.56(m,2H);LC-MS:m / z 377.26,379.26(MH+).

[0219] Scheme 4, Preparation of compound (II)*h: 3-bromo-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 4-(trifluoromethoxy)piperidine hydrochloride was used instead of 4-methoxy-4-methyl-piperidine hydrochloride. The title compound was obtained in a yield of 78% (560 mg). 1 H NMR(400MHz,DMSO) δ8.29(dd,1H),7.95(ddd,1H),7.71-7.50(m,1H),4.60(t,1H),3.26(d,1H),3.09(dtd,1H) ,2.83(tdd1H),2.66(d,1H),1.94(t,1H),1.82-1.65(m,1H),1.55-1.29(m,2H);LC-MS:m / z 361.10,363.09(MH+).

[0220] Scheme 4, Preparation of compound (II)*i: 3-bromo-4-(4-fluoro-4-methylpiperidine-1-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 4-fluoro-4-methylpiperidine hydrochloride was used instead of 4-methoxy-4-methyl-piperidine hydrochloride. The title compound was obtained in a yield of 52% (186 mg). 1 H NMR(400MHz,DMSO) δ8.29(d,1H),7.95(ddd,1H),7.65-7.53(m,1H),4.26(d,1H),3.25-2.97( m,3H),1.94-1.79(m,1H),1.78-1.54(m,3H),1.42-1.28(m,3H);LC-MS:m / z 325.25,327.25(MH+).

[0221] Scheme 4, Preparation of Compound (II)*j: 3-Bromo-4-(4-methoxypiperidine-1-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 4-methoxypiperidine was used instead of 4-methoxy-4-methyl-piperidine hydrochloride. The title compound was obtained in 56% (200 mg) yield. 1 H NMR(400MHz,DMSO) δ8.28(d,1H),7.94(dt,1H),7.56(dd,1H),3.97-3.87(m,1H),3.49-3.33(m,2H),3.25(s,3H),3.18(qd, 1H),3.06-2.92(m,1H),1.95-1.84(m,1H),1.76(s,1H),1.59-1.34(m,2H);LC-MS:323.25,325.25(MH+).

[0222] Scheme 4, Preparation of compound (II) *k 3-bromo-4-(4-methylpiperidine-1-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 4-methylpiperidine was used instead of 4-methoxy-4-methyl-piperidine hydrochloride. The title compound was obtained in 78% (265 mg) yield. 1 H NMR(400MHz,DMSO) δ8.27(dd,1H),7.93(ddd,1H),7.60-7.46(m,1H),4.45(t,1H),3.14(d,1H),3.07-2.9 1(m,1H),2.78(tt,1H),1.76-1.45(m,3H),1.26-0.97(m,2H),0.91(d,3H);LC-MS:m / z 307.10,309.09(MH+).

[0223] Scheme 4, Preparation of compound (II)*l: 4-(6-azaspiro[2.5]octane-6-carbonyl)-3-bromobenzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 6-azaspiro[2.5]octane hydrochloride was used instead of 4-methoxy-4-methyl-piperidine hydrochloride. The title compound was obtained in 78% (550 mg) yield. 1 H NMR(400MHz,DMSO-d6) δ8.28(d,1H),7.94(dd,1H),7.57(d,1H),3.67(t,2H),3.16-3.05(m,2H),1.56-1.20(m,4H),0.51-0.24(m,4H);LC-MS:m / z 319.14,321.10(MH+).

[0224] Scheme 4, Preparation of compound (III)*a: 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile [ka] A mixture of 1-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (138.64 mg, 0.590 mmol), 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile (180.0 mg, 0.530 mmol), X-phos amonobiphenyl palladium chloride precatalyst (41.95 mg, 0.050 mmol), and tripotassium phosphate (339.92 mg, 1.6 mmol) in water (0.755 mL) / 1,2-dimethoxyethane (7.554 mL) was degassed under nitrogen flux for 5 min and then heated to 90° C. for 1 h. After this time, the reaction mixture was cooled to room temperature, diluted with water, and extracted with AcOEt (3×). The organic layers were collected together, washed with brine, dried over Na2SO4, filtered, and the solvent was removed under vacuum. The residue was purified by flash chromatography on silica gel (eluting with 100% cHex to 30:70 AcOEt / cHex) to give the product of formula 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile. Yield: 120mg 1 H NMR(400MHz,DMSO) δ8.23-8.05(m,1H),7.89-7.76(m,2H),7.44(dd,1H),6.69-6.50(m,1H),4.52(dp,1H),4.19- 4.08(m,1H),3.09-2.79(m,6H),1.75(t,1H),1.52-1.26(m,9H),1.10-0.95(m,3H);LC-MS:m / z 367.5(MH+).

[0225] Scheme 4, Preparation of compound (III)*b: 4-(4-tert-butylpiperidine-1-carbonyl)-3-(1-isopropylpyrazol-3-yl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 3-bromo-4-(4-tert-butylpiperidine-1-carbonyl)benzonitrile was used instead of 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile. The title compound was obtained in a yield of 91% (100 mg). 1 H NMR(400MHz,DMSO-d6) δ8.24-8.06(m,1H),7.87-7.76(m,2H),7.49-7.37(m,1H),6.64-6.47(m,1H),4.71-4.40(m,2H),3.28-3.01(m, LC-MS:m / z 379.36(MH+).

[0226] Scheme 4, Preparation of compound (III)*c: 3-(1-isopropylpyrazol-3-yl)-4-(1-oxa-7-azaspiro[3.5]nonane-7-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of compound 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile was replaced with 3-bromo-4-(1-oxa-7-azaspiro[3.5]nonane-7-carbonyl)benzonitrile. The title compound was obtained in a yield of 60% (65 mg). 1 H NMR(400MHz,DMSO-d6) δ8.16(dd,1H),7.86-7.80(m,2H),7.45(dd,1H),6.59(dd,1H),4.57-4.28(m,2H),3.71-3.50(m,2H),3.15-2.79( LC-MS:m / z 365.24(MH+).

[0227] Scheme 4, Preparation of compound (III)*d: 4-(4-ethoxypiperidine-1-carbonyl)-3-(1-isopropylpyrazol-3-yl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 3-bromo-4-(4-ethoxypiperidine-1-carbonyl)benzonitrile was used instead of 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile. The title compound was obtained in a yield of 79% (180 mg). 1H NMR(400MHz,DMSO) δ8.16(dd,1H),7.88-7.77(m,2H),7.44(t,1H),6.58(t,1H),4.53(dp,1H),4.00-3.84(m,1H),3.44(qd,2H),3.40-2.99(m ,3H),2.94-2.73(m,1H),1.88-1.75(m,1H),1.59-1.49(m,2H),1.43(td,6H),1.34-1.18(m,1H),1.07(dt,3H);LC-MS:m / z 367.3(MH+).

[0228] Scheme 4, Preparation of compound (III)*e: 4-(6,6-difluoro-2-azaspiro[3.3]heptane-2-carbonyl)-3-(1-isopropylpyrazol-3-yl)benzonitrile [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of compound 3- (1-isopropylpyrazol-3-yl) -4- (4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile, except that 3-bromo-4- (4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile was replaced with 3-bromo-4- (6,6-difluoro-2-azaspiro [3.3] heptane-2-carbonyl) benzonitrile. The title compound was obtained in a yield of 60% (52 mg). LC-MS: m / z 371.46(MH+)

[0229] Scheme 4, Preparation of compound (III)*f: 4-(4,4-difluoropiperidine-1-carbonyl)-3-(1-propan-2-ylpyrazol-3-yl)benzonitrile [ka] The synthesis of this compound was carried out in the same manner as the synthesis of compound 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile was replaced with 3-bromo-4-(4,4-difluoropiperidine-1-carbonyl)benzonitrile. The title compound was obtained in a yield of 100% (90 mg). 1 H NMR(400MHz,DMSO-d6) δ8.22-8.17(m,1H),7.89-7.82(m,2H),7.57-7.47(m,1H),6.65(d,1H),4.51(p,1H),3.80- 3.66(m,2H),3.25-2.99(m,2H),2.16-1.77(m,2H),1.54(dq,1H),1.43(dd,7H);LC-MS:m / z 359.2(MH+).

[0230] Scheme 4, Repair of compound (III)*g: 4-(4-fluoro-4-methylpiperidine-1-carbonyl)-3-(1-propan-2-ylpyrazol-3-yl)benzonitrile [ka] The synthesis of this compound was carried out in the same manner as the synthesis of compound 3- (1-isopropylpyrazol-3-yl) -4- (4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile, and instead of 3-bromo-4- (4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile, 3-bromo-4- (4-fluoro-4-methylpiperidine-1-carbonyl) benzonitrile was used. The title compound was obtained in a yield of 100% (204 mg). 1H NMR(400MHz,DMSO) δ8.22-8.08(m,1H),7.89-7.78(m,2H),7.47(dd,1H),6.67-6.51(m,1H),4.52 (h,1H),4.33-4.17(m,1H),3.13-2.88(m,3H),1.84-1.12(m,13H);LC-MS:m / z 355.2(MH+).

[0231] Scheme 4, Preparation of compound (III)*h: 3-(1-propan-2-ylpyrazol-3-yl)-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile was replaced with 3-bromo-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile. The title compound was obtained in a yield of 100% (220 mg). 1 H NMR(400MHz,DMSO) δ8.25-8.06(m,1H),7.88-7.77(m,2H),7.56-7.40(m,1H),6.67-6.47(m,1H),4.62(s,1 LC-MS:m / z 391.3(MH+).

[0232] Scheme 4, Preparation of compound (III)*i: 4-(6-azaspiro[2.5]octane-6-carbonyl)-3-(1-propan-2-ylpyrazol-3-yl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile, except that 4-(6-azaspiro[2.5]octane-6-carbonyl)-3-bromobenzonitrile was used instead of 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile. The title compound was obtained in a yield of 80% (130 mg). 1 H NMR(400MHz,DMSO-d6) δ8.16(d,1H),7.85(d,1H),7.81(dd,1H),7.45(d,1H),6.60(d,1H),4.60-4.45(m,1H),3.76-3.49(m,2H),3.15-2.85(m, 2H),1.50-1.40(m,7H),1.37-1.30(m,1H),1.22-1.12(m,1H),0.93-0.85(m,1H),0.40-0.13(m,4H);LC-MS:349.2(MH+).

[0233] Scheme 4, Preparation of compound (III)*j: 4-(4,4-difluoropiperidine-1-carbonyl)-3-(2-ethylpyrazol-3-yl)benzonitrile [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of compound 3- (1-isopropylpyrazol-3-yl) -4- (4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile, and instead of 3-bromo-4- (4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile and 1- (propan-2-yl) -3- (tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-pyrazole, 3-bromo-4- (4,4-difluoropiperidine-1-carbonyl) benzonitrile and 1-ethyl-5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) pyrazole, respectively. The title compound was obtained in a yield of 30% (76 mg). 1H NMR(400MHz,DMSO-d6) δ ppm 8.06-7.99(m,2H),7.77-7.70(m,1H),7.52(d,1H),6.26(d,1H),4.10-3.93(m,2H) ,3.71-3.42(m,2H),3.26-2.95(m,2H),2.12-1.64(m,4H),1.30(t,3H);LC-MS:m / z 345.24(MH+).

[0234] Scheme 4, Preparation of compound (III)*k: 3-[1-(2-methylpropyl)pyrazol-3-yl]-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of compound 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile, except that 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile and 1-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole were replaced with 3-bromo-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile and 1-(2-methylpropyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (see Scheme 12, compound (III)*e), respectively. The title compound was obtained in a yield of 35% (12 mg). 1 H NMR(400MHz,DMSO) δ8.26-8.11(m,1H),7.87-7.76(m,2H),7.59-7.40(m,1H),6.62(dd,1H),4.73-4.54(m,1H),3.93(dd,2H) ),3.27-2.53(m,4H),2.11(dq,1H),1.97-1.80(m,1H),1.70-0.89(m,3H),0.90-0.76(m,6H);LC-MS:m / z 405.2(MH+).

[0235] Scheme 4, Preparation of compound (III)*l: 4-(4,4-difluoropiperidine-1-carbonyl)-3-(1-methylpyrazol-3-yl)benzonitrile [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of compound 3- (1-isopropylpyrazol-3-yl) -4- (4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile, and instead of 3-bromo-4- (4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile and 1- (propan-2-yl) -3- (tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-pyrazole, 3-bromo-4- (4,4-difluoropiperidine-1-carbonyl) benzonitrile and 1-methyl-1H-pyrazole-3-boronic acid pinacol ester were used, respectively. The title compound was obtained in a yield of 56% (56 mg). 1 H NMR(400MHz,DMSO-d6) δ8.20(d,1H),7.85(dd,1H),7.80(d,1H),7.51(d,1H),6.67(d,1H),3.97-3.84(m,4H),3.59(d dd,1H),3.24-3.05(m,2H),2.21-1.97(m,2H),1.94-1.79(m,1H),1.78-1.59(m,1H);LC-MS:m / z 331.12(MH+).

[0236] Scheme 4, Preparation of compound (III)*m: 3-(1-cyclobutylpyrazol-3-yl)-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of compound 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile, except that 3-bromo-4-(4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile and 1-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole were replaced with 3-bromo-4-[4-(trifluoromethyl)piperidine-1-carbonyl] benzonitrile and 1-cyclobutyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) pyrazole (see Scheme 12, compound (III)*a), respectively. The title compound was obtained in a yield of 79% (165 mg). 1 H NMR(400MHz,DMSO) δ8.17(dd,1H),7.92(q,1H),7.84(ddd,1H),7.49(dd,1H),6.60(dd,1H),4.84(p,1H),4.62(d,1H),3.21-3.1 1(m,1H),3.03-2.69(m,2H),2.57(d,1H),2.44-2.30(m,3H),1.97-1.65(m,4H),1.56-1.12(m,3H);LC-MS:m / z 403.2(MH+).

[0237] Scheme 4, Preparation of compound (III)*n: 4-(6-azaspiro[2.5]octane-6-carbonyl)-3-(1-propan-2-ylpyrazol-4-yl)benzonitrile [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of compound 3- (1-isopropylpyrazol-3-yl) -4- (4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile, except that 3-bromo-4- (4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile and 1- (propan-2-yl) -3- (tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-pyrazole were replaced with 4- (6-azaspiro [2.5] octane-6-carbonyl) -3-bromobenzonitrile and 1-isopropyl-4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) -1H-pyrazole, respectively. The title compound was obtained in a yield of 78% (85 mg). 1 H NMR(400MHz,DMSO) δ8.08(d,1H),8.03(d1H),7.74(dd,1H),7.72(d,1H),7.45(d,1H),4.57(p,1H),3.95-3.82(m,1H),3.43(ddd,1H),3.13-2.93(m,1H) ),2.93-2.83(m,1H),1.44(dd,6H),1.41-1.33(m,1H),1.27(s,1H),0.99-0.90(m,1H),0.71(td,1H),0.37-0.14(m,4H);LC-MS:m / z 349.18(MH+).

[0238] Scheme 4, Preparation of compound (IV)*a: [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxy-4-methyl-1-piperidyl)methanone [ka] Example 39 A mixture of 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile (120.0 mg, 0.330 mmol), dicesium carbonate (320.08 mg, 0.980 mmol), ethanimidamide hydrochloride (46.44 mg, 0.490 mmol), and CuBr (2.35 mg, 0.020 mmol) in DMSO (3.713 mL) was stirred at 120 °C for 8 h. After this time, the reaction was cooled to room temperature, HO was added, and the mixture was then extracted three times with AcOEt. The aqueous phase was acidified with HCl 1 M to pH = 5 and extracted three times with AcOEt. The combined organic fractions were washed with brine, dried over Na2SO4, filtered, concentrated in vacuo, and purified by flash chromatography on an NH column (100% DCM to 95:5 DCM / MeOH) to give the product of formula [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxy-4-methyl-1-piperidyl)methanone. Yield 63mg 1 H NMR(400MHz,DMSO) δ13.78(s,1H),8.33(dd,1H),7.93(ddd,1H),7.82(dd,1H),7.30(dd,1H),6.43(dd,1H),4.55(dp,1H),4.28 -3.96(m,1H),3.15-2.86(m,6H),2.41(s,3H),1.72(t,1H),1.53-1.20(m,9H),1.14-0.87(m,3H);LC-MS:m / z 423.5(MH+).

[0239] Preparation: (4-tert-butyl-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]methanone [ka] Example 40 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxy-4-methyl-1-piperidyl)methanone in Example 39, except that 4-(4-tert-butylpiperidine-1-carbonyl)-3-(1-isopropylpyrazol-3-yl)benzonitrile was used instead of 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile. The title compound was obtained in a yield of 20% (22 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 8.37(s,1H),7.98-7.90(m,1H),7.79(s,1H),7.36-7.23(m,1H),6.44-6.36(m,1H),4.74-4.45(m,2H),3.28-3.18(m,2H), 2.85-2.55(m,2H),2.41(s,3H),1.83-1.41(m,7H),1.29-0.93(m,3H),0.88-0.66(m,9H),0.29-0.15(m,1H);435.38(MH+).

[0240] Preparation: [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(1-oxa-7-azaspiro[3.5]nonan-7-yl)methanone [ka] Example 41 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxy-4-methyl-1-piperidyl)methanone in Example 39, except that 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile was replaced with 3-(1-isopropylpyrazol-3-yl)-4-(1-oxa-7-azaspiro[3.5]nonane-7-carbonyl)benzonitrile. The title compound was obtained in a yield of 50% (37 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 8.35-8.28(m,1H),7.98-7.91(m,1H),7.84-7.76(m,1H),7.32-7.26( m,1H),6.46-6.39(m,1H),4.60-4.48(m,1H),4.43-4.28(m,2H),3.75 LC-MS:m / z 421.48(MH+).

[0241] Preparation: (4-ethoxy-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]methanone [ka] Example 42 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxy-4-methyl-1-piperidyl)methanone in Example 39, except that 4-(4-ethoxypiperidine-1-carbonyl)-3-(1-isopropylpyrazol-3-yl)benzonitrile was used instead of 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile. The title compound was obtained in a yield of 38% (80 mg). 1 H NMR(400MHz,DMSO) δ13.79(s,1H),8.33(dd,1H),7.93(dt,1H),7.81(dd,1H),7.30(dd,1H),6.42(t,1H),4.53(dp,1H),4.05-3.91(m,1H),3.48-3.36(m ,2H),3.28-3.05(m,3H),2.95-2.74(m,1H),2.41(s,3H),1.79(d,1H),1.55-1.32(m,8H),1.29-1.18(m,1H),1.06(dt,3H);LC-MS:m / z 423.3(MH+).

[0242] Preparation: (4-Fluoro-4-methylpiperidin-1-yl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-(1-propan-2-ylpyrazol-3-yl)phenyl]methanone [ka] Example 43 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2- (1-isopropylpyrazol-3-yl) -4- (5-methyl-4H-1,2,4-triazol-3-yl) phenyl] -(4-methoxy-4-methyl-1-piperidyl) methanone in Example 39, and 3- (1-isopropylpyrazol-3-yl) -4- (4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile was replaced with 4- (4-fluoro-4-methylpiperidine-1-carbonyl) -3- (1-propan-2-ylpyrazol-3-yl) benzonitrile. The title compound was obtained in a yield of 75% (32 mg). 1 H NMR(400MHz,DMSO) δ13.80(s,1H),8.33(dd,1H),7.94(td,1H),7.82(dd,1H),7.33(t,1H),6.43(dd,1H),4.55(dp,1H), 4.40-4.13(m,1H),3.19-2.86(m,3H),2.41(s,3H),1.86-1.40(m,10H),1.37-1.13(m,3H);LC-MS:m / z 411.6(MH+).

[0243] Preparation: (4,4-Difluoropiperidin-1-yl)-[2-(2-ethylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]methanone [ka] Example 44 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxy-4-methyl-1-piperidyl)methanone in Example 39, except that 4-(4,4-difluoropiperidine-1-carbonyl)-3-(2-ethylpyrazol-3-yl)benzonitrile was used instead of 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile. The title compound was obtained in a yield of 60% (53 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 8.15-8.08(m,1H),7.96(d,1H),7.52(d,2H),6.26(d,1H),4.01(d,2H),3.68-3.49 (m,2H),3.25-3.01(m,3H),2.41(s,3H),2.10-1.64(m,4H),1.32(t,3H);LC-MS:m / z 401.23(MH+).

[0244] Preparation: [2-[1-(2-methylpropyl)pyrazol-3-yl]-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)piperidin-1-yl]methanone [ka] Example 45 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxy-4-methyl-1-piperidyl)methanone in Example 39, except that 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile was replaced with 3-[1-(2-methylpropyl)pyrazol-3-yl]-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile. The title compound was obtained in a yield of 10% (4 mg). 1 H NMR(400MHz,DMSO) δ13.80(s,1H),8.36(dd,1H),7.95(ddd,1H),7.77(dd,1H),7.39-7.25(m,1H),6.52-6.37(m,1H),4.75-4.58(m,1H),3.99-3 .91(m,2H),3.02-2.55(m,3H),2.41(s,3H),2.21-2.06(m,1H),1.97-1.79(m,1H),1.73-0.89(m,4H),0.88(s,6H);LC-MS:m / z 461.2(MH+).

[0245] Preparation: (4,4-Difluoropiperidin-1-yl)-[2-(1-methylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]methanone [ka] Example 46 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl) phenyl]-(4-methoxy-4-methyl-1-piperidyl) methanone in Example 39, except that 4-(4,4-difluoropiperidine-1-carbonyl)-3-(1-methylpyrazol-3-yl) benzonitrile was used instead of 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile. The title compound was obtained in a yield of 36% (23 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 13.93-13.69(m,1H),8.34(d,1H),7.95(dd,1H),7.77(d,1H),7.37(d,1H),6.49(d,1H),3.88(s,4H) ,3.64-3.49(m,1H),3.25-3.09(m,2H),2.41(s,3H),2.17-1.77(m,3H),1.69-1.49(m,1H);LC-MS:m / z 387.19(MH+).

[0246] Preparation: [2-(1-cyclobutylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)piperidin-1-yl]methanone [ka] Example 47 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxy-4-methyl-1-piperidyl)methanone in Example 39, except that 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile was replaced with 3-(1-cyclobutylpyrazol-3-yl)-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile. The title compound was obtained in a yield of 36% (67 mg). 1 H NMR(400MHz,DMSO) δ13.80(s,1H),8.33(dd,1H),7.96(ddd,1H),7.86(dd,1H),7.35(dd,1H),6.46(t,1H),4.87(p,1H),4.66(d,1H),3.40(d,1H), 3.21(d,1H),3.03-2.70(m,2H),2.56(d,1H),2.47-2.31(m,6H),2.03-1.63(m,3H),1.56-1.18(m,2H),0.40(qd,1H);LC-MS:m / z 459.48(MH+).

[0247] Preparation: [4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-(1-propan-2-ylpyrazol-3-yl)phenyl]-[4-(trifluoromethyl)piperidin-1-yl]methanone [ka] Example 48 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxy-4-methyl-1-piperidyl)methanone in Example 39, except that 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile was replaced with 3-(1-propan-2-ylpyrazol-3-yl)-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile. The title compound was obtained in a yield of 27% (67 mg). 1 H NMR(400MHz,DMSO) δ13.80(s,1H),8.43-8.23(m,1H),7.95(ddd,1H),7.81(dd,1H),7.39-7.27(m,1H),6.42(d,1H),4.66(d,1 LC-MS:m / z 447.2(MH+).

[0248] Preparation: 6-Azaspiro[2.5]octan-6-yl-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-(1-propan-2-ylpyrazol-4-yl)phenyl]methanone [ka] Example 49 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxy-4-methyl-1-piperidyl)methanone in Example 39, except that 4-(6-azaspiro[2.5]octane-6-carbonyl)-3-(1-propan-2-ylpyrazol-4-yl)benzonitrile was used instead of 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile. The title compound was obtained in a yield of 19% (18 mg). 1 H NMR(400MHz,DMSO) δ13.77(s,1H),8.09(d,1H),7.97(s,1H),7.88(dd,1H),7.64(s,1H),7.32(d,1H),4.58(hept,1H),3.96-3.80(m,1H),3.41(ddd,1H),3 .09-2.88(m,2H),2.41(s,3H),1.45(dd,6H),1.38(ddd,1H),1.23(dt,1H),0.92(dt,1H),0.71(ddd,1H),0.38-0.13(m,4H);LC-MS:m / z 405.57(MH+).

[0249] Preparation: 6-Azaspiro[2.5]octan-6-yl-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-(1-propan-2-ylpyrazol-3-yl)phenyl]methanone [ka] Example 50 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxy-4-methyl-1-piperidyl)methanone in Example 39, except that 4-(6-azaspiro[2.5]octane-6-carbonyl)-3-(1-propan-2-ylpyrazol-3-yl)benzonitrile was used instead of 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile. The title compound was obtained in a yield of 39% (31 mg). 1 H NMR(400MHz,DMSO-d6) δ13.80(s,1H),8.35(d,1H),7.94(dd,1H),7.84(d,1H),7.32(d,1H),6.46(d,1H),4.57(p,1H),3.77-3.54(m,2H),3.0 4(dddd,2H),2.42(s,3H),1.47(dd,6H),1.35(q,2H),1.16-1.06(m,1H),0.85(ddd,1H),0.44-0.05(m,4H);LC-MS:m / z 405.24(MH+).

[0250] Preparation: (4,4-Difluoropiperidin-1-yl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-(1-propan-2-ylpyrazol-3-yl)phenyl]methanone [ka] Example 51 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxy-4-methyl-1-piperidyl)methanone in Example 39, except that 4-(4,4-difluoropiperidine-1-carbonyl)-3-(1-propan-2-ylpyrazol-3-yl)benzonitrile was used instead of 3-(1-isopropylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile. The title compound was obtained in a yield of 48% (50 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 14.61-12.76(m,1H),8.31(d,1H),7.96(dd,1H),7.84(d,1H),7.38(d,1H),6.48(d,1H),4.54(spt,1H),3.97-3.78(m, LC-MS:m / z 415.3(MH+).

[0251] Preparation: (6,6-Difluoro-2-azaspiro[3.3]heptan-2-yl)-[2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]methanone [ka] Example 52 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2- (1-isopropylpyrazol-3-yl) -4- (5-methyl-4H-1,2,4-triazol-3-yl) phenyl] - (4-methoxy-4-methyl-1-piperidyl) methanone in Example 39, and 3- (1-isopropylpyrazol-3-yl) -4- (4-methoxy-4-methyl-piperidine-1-carbonyl) benzonitrile was replaced with 4- (6,6-difluoro-2-azaspiro [3.3] heptane-2-carbonyl) -3- (1-isopropylpyrazol-3-yl) benzonitrile. The title compound was obtained in a yield of 35% (21 mg). 1 H NMR(400MHz,DMSO-d6) δ13.73(s,1H),8.30(d,1H),7.93(d,1H),7.84(d,1H),7.33(d,1H),6.48(d,1H),4.56(p ,1H),4.06(s,2H),3.69(s,2H),2.89-2.56(m,4H),2.42(s,3H),1.47(d,6H);LC-MS:m / z 427.30

[0252] Scheme 4, Preparation of compound (V)*a: [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethoxy)piperidin-1-yl]methanone [ka] A mixture of 3-bromo-4-[4-(trifluoromethoxy)piperidine-1-carbonyl]benzonitrile (268.0 mg, 0.710 mmol), dicesium carbonate (694.56 mg, 2.13 mmol), ethanimidamide hydrochloride (100.77 mg, 1.07 mmol) and CuBr (5.1 mg, 0.040 mmol) in DMSO (3.5 mL) was stirred at 120° C. for 7 h. After this time, the reaction was cooled and directly purified by reverse-phase flash chromatography using acidic conditions (elution from 5:95 CHCN / HO+0.1% HCOOH to 50:50 CHCN / HO+0.1% HCOOH) to give the product of formula [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethoxy)piperidin-1-yl]methanone. Yield: 34 mg 1 H NMR(400MHz,DMSO) δ13.88(s,1H),8.18(d,1H),8.05-7.98(m,1H),7.54-7.39(m,1H),4.74(dt,1H),4.08-3.9 8(m,1H),3.50-3.37(m,2H),3.30-3.11(m,1H),2.41(s,3H),2.14-1.59(m,4H);LC-MS:m / z 433.07,435.05(MH+).

[0253] Scheme 4, Preparation of compound (V)*b: [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methylpiperidin-1-yl)methanone [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethoxy)piperidin-1-yl]methanone, except that 3-bromo-4-[4-(trifluoromethoxy)piperidine-1-carbonyl]benzonitrile was replaced with 3-bromo-4-(4-methylpiperidine-1-carbonyl)benzonitrile. The title compound was obtained in a yield of 61% (65 mg). 1 H NMR(400MHz,DMSO) δ13.82(s,1H),8.17(d,1H),8.00(ddd,1H),7.35(d,1H),4.46(s,1H),3.23(s,1H),3.08-2.92( LC-MS:m / z 363.10,365.12(MH+).

[0254] Scheme 4, Preparation of compound (V)*c: [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxypiperidin-1-yl)methanone [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethoxy)piperidin-1-yl]methanone, except that 3-bromo-4-[4-(trifluoromethoxy)piperidine-1-carbonyl]benzonitrile was replaced with 3-bromo-4-(4-methoxypiperidine-1-carbonyl)benzonitrile. The title compound was obtained in a yield of 52% (120 mg). 1H NMR(400MHz,DMSO) δ13.86(s,1H),8.17(d,1H),8.00(dd,1H),7.41(t,1H),3.93(d,1H),3.44(d,1H),3.39-3.32(m,2H),3. 25(s,3H),3.10-2.96(m,1H),2.41(s,3H),1.96-1.86(m,1H),1.79(s,1H),1.56-1.32(m,2H);LC-MS:m / z 379.36,381.36(MH+).

[0255] Scheme 4, Preparation of compound (V)*d: [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)piperidin-1-yl]methanone [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethoxy)piperidin-1-yl]methanone, except that 3-bromo-4-[4-(trifluoromethoxy)piperidine-1-carbonyl]benzonitrile was replaced with 3-bromo-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile. The title compound was obtained in a yield of 54% (252 mg). 1 H NMR(400MHz,DMSO) δ13.87(s,1H),8.18(dd,1H),8.01(dt,1H),7.51(dd,1H),4.62(s,1H),3.36(d,1H),3.19-3.03(m,1H),2 .83(t,1H),2.71-2.61(m,1H),2.41(s,3H),1.94(s,1H),1.84-1.71(m,1H),1.57-1.27(m,2H);LC-MS:m / z 417.05,419.07(MH+).

[0256] Scheme 4, Preparation of compound (V)*e: [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4,4-difluoropiperidin-1-yl)methanone [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethoxy)piperidin-1-yl]methanone, except that 3-bromo-4-[4-(trifluoromethoxy)piperidine-1-carbonyl]benzonitrile was replaced with 3-bromo-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile. The title compound was obtained in a yield of 53% (268 mg). 1 H NMR(400MHz,DMSO-d6) δ13.88(s,1H),8.20(d,1H),8.03(dd,1H),7.52(d,1H),3.92-3.81(m,1H),3. 74-3.63(m,1H),3.30-3.14(m,2H),2.42(s,3H),2.17-1.92(m,4H);LC-MS:m / z 385.05,387.06(MH+).

[0257] Preparation: [2-(1-tert-butylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)-1-piperidyl]methanone [ka] Example 53 A mixture of tripotassium phosphate (154.67 mg, 0.730 mmol), X-Phos amonobiphenyl palladium chloride precatalyst (15.07 mg, 0.020 mmol), 1-tert-butyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (95 mg, 0.380 mmol), and [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)piperidin-1-yl]methanone (80.0 mg, 0.190 mmol) in 1,2-dimethoxyethane (2.128 mL) / water (0.142 mL) was degassed with N for 5 min, then degassed three times with N / vacuum cycles. The reaction was stirred at 90 °C overnight. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 times). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and the solvent removed under vacuum. The mixture was purified by NH column flash chromatography (eluting with 100% DCM to 95:5 DCM / MeOH) and then purified again by reverse-phase flash chromatography using acidic conditions (eluting with 5:95 CH3CN / HO + 0.1% HCOOH to 60:40 CH3CN / HO + 0.1% HCOOH) to give the product of formula [2-(1-tert-butylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)-1-piperidyl]methanone. Yield: 35mg 1 H NMR(400MHz,DMSO) δ13.80(s,1H),8.30(dd,1H),7.95(ddd,1H),7.86(t,1H),7.33(dd,1H),6.60-6.26(m,1H),4.65(d,1H),3.45-3.16 (m,1H),2.93-2.67(m,2H),2.49(d,1H),2.41(s,3H),1.97-1.63(m,1H),1.55(d,9H),1.47-0.09(m,3H);LC-MS:m / z 461.3(MH+).

[0258] Preparation: [2-(1-tert-butylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4,4-difluoropiperidin-1-yl)methanone [ka] Example 54 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [2- (1-tert-butylpyrazol-3-yl) -4- (5-methyl-4H-1,2,4-triazol-3-yl) phenyl] - [4- (trifluoromethyl) -1-piperidyl] methanone in Example 53, and [2-bromo-4- (5-methyl-4H-1,2,4-triazol-3-yl) phenyl] - [4- (trifluoromethyl) piperidin-1-yl] methanone instead of [2-bromo-4- (5-methyl-4H-1,2,4-triazol-3-yl) phenyl] - (4,4-difluoropiperidin-1-yl) methanone was used. The title compound was obtained in a yield of 61% (68 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 8.29(d,1H) 7.92-7.98(m,1H) 7.89(d,1H) 7.34-7.43(m,1H) 6.44-6.50(m,1H) 3.67-3.77(m,2H) 3.00-3.25(m,2H) 2.41(s,3H) 1.75-2.15(m,3H) 1.55(s,9H) 1.25-1.37(m,2H);LC-MS:m / z 429.29(MH+).

[0259] Preparation: [2-(1-cyclobutylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4,4-difluoropiperidin-1-yl)methanone [ka] Example 55 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound in Example 53, [2-(1-tert-butylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)-1-piperidyl]methanone, and the resulting mixture was [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)piperidin-1-yl]methanone and 1-tert-butyl-3- Instead of (4,4,5,5-tetramethyl-1,3,2-dioxaborazol-2-yl)pyrazole, [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4,4-difluoropiperidin-1-yl)methanone and 1-cyclobutyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (see Scheme 12, compound (III)*a) were used, respectively. The title compound was obtained in a yield of 37% (29 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 13.91-13.70(m,1H),8.31(d,1H),7.99-7.94(m,1H),7.88(d,1H),7.39(d,1H),6.51(d,1H),4.87(p,1H), 3.82-3.68(m,2H),3.26-3.09(m,2H),2.48-2.35(m,6H),2.15-1.75(m,6H),1.56-1.38(m,1H);LC-MS:m / z 427.27(MH+).

[0260] Preparation: 1-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[1-(propan-2-yl)-1H-pyrazol-3-yl]benzoyl]-4-(trifluoromethoxy)piperidine [ka] Example 56 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound in Example 53, [2-(1-tert-butylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)-1-piperidyl]methanone, and the resulting mixture was [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)piperidin-1-yl]methanone and 1-t Instead of ert-butyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole, [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethoxy)piperidin-1-yl]methanone and 1-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole were used, respectively. The title compound was obtained in a yield of 29% (10 mg). 1 H NMR(400MHz,DMSO) δ13.78(s,1H),8.33(dd,1H),7.95(ddd,1H),7.88-7.78(m,1H),7.35(dd,1H),6.45(dd,1H),4.69-4.4 9(m,2H),4.15-4.00(m,1H),3.26-2.90(m,3H),2.42(s,3H),1.96(d,1H),1.80-0.82(m,9H);LC-MS:m / z 463.5(MH+).

[0261] Preparation: [2-[1-(1-cyclopropylethyl)pyrazol-3-yl]-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4,4-difluoro-1-piperidyl)methanone [ka] Example 57 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound in Example 53, [2-(1-tert-butylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)-1-piperidyl]methanone, and the resulting mixture was [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)piperidin-1-yl]methanone and 1-te Instead of rt-butyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole, [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4,4-difluoropiperidin-1-yl)methanone and 1-(1-cyclopropylethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole were used, respectively. The title compound was obtained as a racemic mixture in 30% (34 mg) yield. 1 H NMR (400 MHz, DMSO-d6) δ8.32(t,1H),8.00-7.93(m,1H),7.87(t,1H),7.39(d,1H),6.48(dd,1H),3 .93-3.79(m,1H),3.75-3.64(m,1H),3.64-3.48(m,1H),3.22-3.04(m,2H), 2.42(s,3H),2.14-1.97(m,1H),1.97-1.72(m,1H),1.58-1.47(m,3H),1.44 -1.15(m,1H),0.71-0.56(m,1H),0.46-0.37(m,1H),0.34(t,2H);LC-MS:m / z 441.25(MH+).

[0262] The racemic mixture (Example 57) was then separated into single enantiomers (Examples 57a and 57b) by chiral semi-preparative HPLC. [Table 2]

[0263] Preparation: (4-Methoxypiperidin-1-yl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-(1-propan-2-ylpyrazol-3-yl)phenyl]methanone [ka] Example 58 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound in Example 53, [2-(1-tert-butylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)-1-piperidyl]methanone, and Instead of [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxypiperidin-1-yl)methanone and 1-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole, [4-methoxypiperidin-1-yl]methanone and 1-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole were used, respectively. The title compound was obtained in 41% yield (55 mg). 1 H NMR(400MHz,DMSO) δ13.72(s,1H),8.34(dd,1H),7.93(dt,1H),7.81(dd,1H),7.30(s,1H),6.42(t,1H),4.54(pd,1H),4.05-3.84(m ,1H),3.30(s,2H),3.24-3.05(m,4H),2.96-2.76(m,1H),2.41(s,3H),1.81(s,1H),1.58-0.68(m,9H);LC-MS:m / z 409.2(MH+).

[0264] Preparation: (4,4-Difluoro-1-piperidyl)-[2-(1-ethylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]methanone [ka] Example 59 The synthesis of the title compound was carried out in a manner similar to the synthesis of the compound in Example 53, [2-(1-tert-butylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)-1-piperidyl]methanone, and the resulting mixture was 1-tert-butyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (383.71 mg, 0.380 mmol) and [2-bromo- Instead of 4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)piperidin-1-yl]methanone, 1-ethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole and [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4,4-difluoropiperidin-1-yl)methanone were used, respectively. The title compound was obtained in a yield of 24% (12 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 8.33(d,1H),7.96(dd,1H),7.82(d,1H),7.37(d,1H),6.48(d,1H),4.17(q,2H),3.90(br d,1H),3.56(m,1H),3.24-3.08(m,2H),2.41(s,3H),2.17-1.75(m,4H),1.39(t,4H);LC-MS:m / z 401.31(MH+).

[0265] Preparation: (4,4-Difluoro-1-piperidyl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[1-(oxetan-3-yl)pyrazol-3-yl]phenyl]methanone [ka] Example 60 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound in Example 53, [2-(1-tert-butylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)-1-piperidyl]methanone, and 1-tert-butyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole and [2-bromo-4-(5-methyl-4H-1, Instead of [2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)piperidin-1-yl]methanone, 1-(oxetan-3-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole and [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4,4-difluoropiperidin-1-yl)methanone were used, respectively. The title compound was obtained in 55% (42 mg) yield. 1 H NMR(400MHz,DMSO-d6) δ ppm 8.36(d,1H),8.02-7.91(m,2H),7.42(d,1H),6.60(d,1H),5.68-5.58(m,1H),5.00-4.84(m,4H),3.86 -3.65(m,2H),3.23-3.11(m,2H),2.45-2.35(m,3H),2.17-1.83(m,4H),1.67-1.50(m,1H);LC-MS:m / z 429.38(MH+).

[0266] Preparation: (4-Methylpiperidin-1-yl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-(1-propan-2-ylpyrazol-3-yl)phenyl]methanone [ka] Example 61 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound in Example 53, [2-(1-tert-butylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)-1-piperidyl]methanone, and 1-tert-butyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole and [2-bromo-4-(5-methyl-4 Instead of [4-(trifluoromethyl)piperidin-1-yl]methanone, 1-(propan-2-yl)-3-(tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole and [2-bromo-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methylpiperidin-1-yl)methanone were used, respectively. The title compound was obtained in 60% (22 mg) yield. 1 H NMR(400MHz,DMSO) δ13.79(s,1H),8.42-8.28(m,1H),7.93(ddd,1H),7.81(dd,1H),7.28(dd,1H),6.42(td,1H),4.63-4.45(m,2H),3.2 6-3.08(m,1H),2.89-2.57(m,2H),2.41(s,3H),1.76-1.32(m,9H),1.24-0.94(m,2H),0.92-0.70(m,3H);LC-MS:m / z 393.57(MH+). [ka]

[0267] Step 1 Compounds of formula II can be obtained by Miyaura borylation between compounds of formula I (commercially available from Astatech) and B2Pin2 in the presence of a suitable transition metal catalyst, such as Pd(dppf)Cl2, a suitable base, such as potassium acetate, in a suitable solvent, such as 1,4-dioxane, typically at 100° C. The reaction takes about 3 to about 12 hours to complete.

[0268] Step 2 Compounds of formula III can be obtained by Suzuki coupling between compounds of formula II and the desired heteroaryl halide in a suitable solvent, such as a 1,2-dimethoxyethane / water mixture, in the presence of a suitable precatalyst, such as XPhos Pd G2, a suitable base, such as K3PO4, typically at 100° C. The reaction takes from about 1 hour to about 12 hours to complete.

[0269] Step 3 Compounds of formula IV can be obtained by hydrolyzing compounds of formula III with LiOH in the presence of a suitable solvent, such as a mixture of MeOH / THF / water, typically at room temperature, and the reaction takes about 12 hours to complete.

[0270] Step 4 The compound of formula V can be obtained from the compound of formula IV by coupling with an appropriate amine in the presence of a coupling agent such as HATU and an organic base such as DIPEA. The reaction is typically carried out at room temperature in a suitable solvent such as DMF. The reaction takes about 3 hours to about 12 hours to complete.

[0271] Step 5 The compound of formula VI can be obtained by nitrile cyclization of the compound of formula V with ethanimidamide hydrochloride in the presence of a suitable catalyst, such as CuBr, a suitable base, such as CsCO, in a suitable solvent, such as DMSO, typically at 120° C. The reaction takes about 3 hours to about 12 hours to complete.

[0272] Scheme 5. Preparation of compound (II): methyl 4-cyano-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate [ka] A suspension of [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (0.07 g, 0.080 mmol) complexed with dichloromethane, potassium acetate (1.24 g, 12.5 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (1.27 g, 5 mmol), and methyl 2-bromo-4-cyanobenzoate (1.0 g, 4.17 mmol) in 1,4-dioxane (30.41 mL) was degassed under a nitrogen flux for 10 min and heated to 100 °C overnight. The next day, the reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 x 100 °C). The organic layers were collected together, washed with brine, dried over NaSO, filtered, and the solvent was removed in vacuo to give the product of formula methyl 4-cyano-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate, which was used in the next step without further purification. Yield: 1.19g. LC-MS: m / z 288.14 (MH+).

[0273] Scheme 5, Preparation of compound (III)*a: Methyl 4-cyano-2-[4-(trifluoromethyl)thiazol-2-yl]benzoate [ka] A mixture of 2-bromo-4-(trifluoromethyl)thiazole (169.7 mg, 0.730 mmol), methyl 4-cyano-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (210.0 mg, 0.730 mmol), X-Phos Pd G2 (0.06 g, 0.070 mmol), and potassium phosphate tribasic (0.47 g, 2.19 mmol) in water (0.336 mL) and 1,2-dimethoxyethane (3.356 mL) was degassed under nitrogen flux for 10 min and heated to 100 °C for 2 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 times). The organic layers were collected together, washed with brine, dried over Na2SO4, filtered, and the solvent was removed in vacuo. The crude material was purified by flash chromatography on silica gel (eluting with 100% cHex to 90:10 cHex / EtOAc) to give the product of formula methyl 4-cyano-2-[4-(trifluoromethyl)thiazol-2-yl]benzoate. Yield: 52 mg 1 H NMR(400MHz,DMSO-d6) δ ppm 8.70(d,1H),8.43(d,1H),8.15(dd,1H),7.91(d,1H),3.72(s,3H);LC-MS:m / z 313.09(MH+).

[0274] Scheme 5, Preparation of compound (III)*b: methyl 4-cyano-2-(6-cyclopropyl-2-pyridyl)benzoate [ka] The synthesis of the title compound was carried out similarly to the compound methyl 4-cyano-2-[4-(trifluoromethyl)thiazol-2-yl]benzoate, except that 2-bromo-6-cyclopropylpyridine was used instead of 2-bromo-4-(trifluoromethyl)thiazole. The title compound was obtained in 45% (303.7 mg) yield. 1H NMR(400MHz,DMSO-d6) δ ppm 8.20(d,1H),7.98(dd,1H),7.81-7.76(m,2H),7.59(dd,1H),7.34(dd,1H),3.66(s,3H),2.17-2.09(m,1H),0.98-0.83(m,4H);LC-MS:m / z 279.22(MH+).

[0275] Scheme 5, Preparation of compound (III)*c: methyl 2-(1-tert-butylpyrazol-3-yl)-4-cyano-benzoate [ka] The synthesis of the title compound was carried out similarly to the compound methyl 4-cyano-2-[4-(trifluoromethyl)thiazol-2-yl]benzoate, except that 1-tert-butyl-3-iodopyrazole was used instead of 2-bromo-4-(trifluoromethyl)thiazole. The title compound was obtained in 12% (60 mg) yield. 1 H NMR(400MHz,DMSO-d6) δ ppm 8.20(d,1H),7.90(d,1H),7.84(dd,1H),7.65(d,1H),6.73(d,1H),3.77(s,3H) 1.53(s,9H);LC-MS:m / z 284.20(MH+).

[0276] Scheme 5, Preparation of compound (IV)*a: 4-cyano-2-[4-(trifluoromethyl)thiazol-2-yl]benzoic acid [ka] To a solution of methyl 4-cyano-2-[4-(trifluoromethyl)thiazol-2-yl]benzoate (53.0 mg, 0.170 mmol) in THF (1.178 mL) in methanol (0.294 mL) was added a solution of lithium hydroxide (8.13 mg, 0.255 mmol) in water (0.294 mL). The reaction was stirred at room temperature overnight. After this time, the solution was evaporated under reduced pressure, and the residue was then taken up in water. The aqueous phase was washed with DCM, acidified with HCl 1N solution to pH = 4, and extracted with EtOAc (6 times). The combined organic fractions were dried over Na2SO4, filtered, and concentrated in vacuo to give the product of formula 4-cyano-2-[4-(trifluoromethyl)thiazol-2-yl]benzoic acid. Yield: 44.7 mg. 1 H NMR(400MHz,DMSO-d6) δ ppm 13.71(br s,1H),8.68(s,1H),8.30(d,1H),8.12(dd,1H),7.93(d,1H);LC-MS:m / z 299.07(MH+).

[0277] Scheme 5, Preparation of compound (IV)*b: 4-cyano-2-(6-cyclopropyl-2-pyridyl)benzoic acid [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of the compound 4-cyano-2-[4-(trifluoromethyl)thiazol-2-yl]benzoic acid, except that methyl 4-cyano-2-[4-(trifluoromethyl)thiazol-2-yl]benzoate was replaced with methyl 4-cyano-2-(6-cyclopropyl-2-pyridyl)benzoate. The title compound was obtained in a yield of 93% (269.5 mg). 1H NMR(400MHz,DMSO-d6) δ ppm 13.04(br s,1H),8.13(d,1H),7.94(dd,1H),7.78-7.71(m,2H),7.55(d,1H),7.34(d,1H),2.16-2.06(m,1H),1.05-0.87(m,4H);LC-MS:m / z 265.22(MH+).

[0278] Scheme 5, Preparation of compound (IV)*c: 2-(1-tert-butylpyrazol-3-yl)-4-cyano-benzoic acid [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of compound 4-cyano-2-[4-(trifluoromethyl)thiazol-2-yl]benzoic acid, except that methyl 4-cyano-2-[4-(trifluoromethyl)thiazol-2-yl]benzoate was replaced with methyl 2-(1-tert-butylpyrazol-3-yl)-4-cyanobenzoate. The title compound was obtained in a yield of 100% (58 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 13.19(br s,1H),8.15(d,1H),7.88(d,1H),7.81(dd,1H),7.62(d,1H),6.65(d,1H),1.55(s,9H);LC-MS:m / z 270.22(MH+).

[0279] Scheme 5, Preparation of compound (V)*a: 4-(4-methylpiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile [ka] To a stirred solution of 4-cyano-2-[4-(trifluoromethyl)thiazol-2-yl]benzoic acid (44.7 mg, 0.150 mmol) in DMF (1.041 mL) was added N,N-diisopropylethylamine (0.08 mL, 0.450 mmol) and HATU (85.48 mg, 0.220 mmol). The reaction was stirred at room temperature for 15 minutes. 4-Methylpiperidine (14.86 mg, 0.150 mmol) was then added, and the reaction mixture was stirred at room temperature overnight. The next day, saturated NaHCO3 solution was added to the reaction mixture, and the aqueous phase was extracted with EtOAc (3 times). The organic portion was collected, washed with brine, and residual water was removed by adding Na2SO4, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (eluting with 100% cHex to 70:30 cHex / EtOAc) to give the product of formula 4-(4-methylpiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile. Yield: 46.8 mg. 1 H NMR(400MHz,DMSO-d6) δ ppm 8.71-8.66(m,1H),8.45-8.34(m,1H),8.07(dd,1H),7.62(dd,1H),4.46-4 .35(m,1H),3.27(s,2H),3.06-2.97(m,1H),2.81-2.58(m,8H);LC-MS:m / z 380.20(MH+).

[0280] Scheme 5, Preparation of compound (V)*b: 3-(6-cyclopropyl-2-pyridyl)-4-(4-methylpiperidine-1-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound 4-(4-methylpiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile, except that 4-cyano-2-[4-(trifluoromethyl)thiazol-2-yl]benzoic acid was replaced with 4-cyano-2-(6-cyclopropyl-2-pyridyl)benzoic acid. The title compound was obtained in a yield of 85% (55.3 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 8.42-8.25(m,1H),8.14-8.06(m,1H),7.92(q,1H),7.75-7.60(m,2H),7.49(dd,1H),4.61-4.50(m,1H),2.96-2.71 (m,2H),2.37-2.23(m,1H),1.88-1.49(m,3H),1.43-1.04(m,6H),0.97-0.79(m,3H),0.18-0.09(m,1H);LC-MS:m / z 346.25(MH+).

[0281] Scheme 5, Preparation of compound (V)*c: 3-(1-tert-butylpyrazol-3-yl)-4-(4-methylpiperidine-1-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound 4- (4-methylpiperidine-1-carbonyl) -3- [4- (trifluoromethyl) thiazol-2-yl] benzonitrile, except that 2- (1-tert-butylpyrazol-3-yl) -4-cyano-benzoic acid was used instead of 4-cyano-2- [4- (trifluoromethyl) thiazol-2-yl] benzoic acid. The title compound was obtained in a yield of 84% (60 mg). 1H NMR(400MHz,DMSO-d6) δ ppm 8.15(dd,1H),7.90(dd,1H),7.81(ddd,1H),7.43(dd,1H),6.56(dd,1H),4.55-4.41(m,1H),3.99-2.23( LC-MS:m / z 351.35(MH+).

[0282] Scheme 5, Preparation of compound (V)*d: 3-(6-cyclopropyl-2-pyridyl)-4-(4-fluoro-4-methyl-piperidine-1-carbonyl)benzonitrile [ka] The synthesis of title compound is carried out similarly to the synthesis of compound 4- (4-methylpiperidine-1-carbonyl) -3- [4- (trifluoromethyl) thiazol-2-yl] benzonitrile, and instead of 4-methylpiperidine, 4-fluoro-4-methyl-piperidine hydrochloride is used, and instead of 4-cyano-2- [4- (trifluoromethyl) thiazol-2-yl] benzoic acid, 4-cyano-2- (6-cyclopropyl-2-pyridyl) benzoic acid is used. The title compound was obtained with a yield of 29% (13 mg). LC-MS: m / z 364.35(MH+).

[0283] Scheme 5, Preparation of compound (V)*e: 3-(1-tert-butylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of compound 4- (4-methylpiperidine-1-carbonyl) -3- [4- (trifluoromethyl) thiazol-2-yl] benzonitrile, except that 4-methylpiperidine was replaced with 4-methoxy-4-methyl-piperidine hydrochloride, and 4-cyano-2- [4- (trifluoromethyl) thiazol-2-yl] benzoic acid was replaced with 2- (1-tert-butylpyrazol-3-yl) -4-cyano-benzoic acid. The title compound was obtained in a yield of 81% (41 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 8.15(dd,1H),7.90(dd,1H),7.84-7.78(m,1),7.45(dd,1H),6.58(dd,1H),4.19-4.05(m,1H),3.1 4-2.77(m,6H),1.84-1.66(m,1H),1.54(d,11H),1.11-0.89(m,3H),0.57-0.43(m,1H);LC-MS:m / z 381.36(MH+).

[0284] Scheme 5, Preparation of compound (V)*f: 4-(4-methoxy-4-methyl-piperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 4-(4-methylpiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile, except that 4-methoxy-4-methyl-piperidine hydrochloride was used instead of 4-methylpiperidine. The title compound was obtained in a yield of 65% (88.8 mg). 1H NMR(400MHz,DMSO-d6) δ ppm 8.71-8.65(m,1H),8.45-8.35(m,1H),8.12-8.03(m,1H),7.69-7.57(m,1H),4.19-4.01(m,1H) ,3.29(s,3H),3.26-2.95(m,3H),1.81-1.70(m,1H),1.60-1.20(m,3H),1.04(s,3H);LC-MS:m / z 410.27(MH+).

[0285] Scheme 5, Preparation of compound (VI)*a: (4-methyl-1-piperidyl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[4-(trifluoromethyl)thiazol-2-yl]phenyl]methanone [ka] Example 62 A mixture of dicesium carbonate (120.57 mg, 0.370 mmol), ethanimidamide hydrochloride (17.49 mg, 0.190 mmol), CuBr (0.88 mg, 0.010 mmol), and 4-(4-methylpiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile (46.8 mg, 0.120 mmol) in DMSO (1.199 mL) was stirred at 120 °C for 4 h. After this time, the reaction was cooled to room temperature, and HO was added. The mixture was then extracted three times with AcOEt. The aqueous phase was diluted with a saturated solution of potassium sodium tartrate and extracted five times with EtOAc and THF. The combined organic fractions were dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on an NH column (eluting with 100% DCM to 95:5 DCM / MeOH) to give the product of formula (4-methyl-1-piperidyl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[4-(trifluoromethyl)thiazol-2-yl]phenyl]. Yield: 26.6 mg. 1H NMR(400MHz,DMSO-d6) δ ppm 8.69-8.61(m,1H),8.54-8.38(m,1H),8.20-8.13(m,1H),7.56-7.40(m,1H),4.56-4.41( LC-MS:m / z 436.28(MH+).

[0286] Preparation: [2-(6-cyclopropyl-2-pyridyl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methyl-1-piperidyl)methanone [ka] Example 63 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound (4-methyl-1-piperidyl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[4-(trifluoromethyl)thiazol-2-yl]phenyl]methanone in Example 62, except that 3-(6-cyclopropyl-2-pyridyl)-4-(4-methylpiperidine-1-carbonyl)benzonitrile was used instead of 4-(4-methylpiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile. The title compound was obtained in a yield of 65% (42 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 8.23(br d,1H),8.03(d,1H),7.74(td,1H),7.47-7.25(m,3H),4.47-4.35(m,1H),2.84-2.53(m,3H) ),2.44-2.36(m,3H),2.20-2.06(m,1H),1.74-0.62(m,12H),0.32-0.25(m,1H);LC-MS:m / z 402.36(MH+).

[0287] Preparation: [2-(1-tert-butylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methyl-1-piperidyl)methanone [ka] Example 64 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound (4-methyl-1-piperidyl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[4-(trifluoromethyl)thiazol-2-yl]phenyl]methanone in Example 62, except that 3-(1-tert-butylpyrazol-3-yl)-4-(4-methylpiperidine-1-carbonyl)benzonitrile was used instead of 4-(4-methylpiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile. The title compound was obtained in a yield of 68% (47.3 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 8.30(dd,1H),7.98-7.79(m,2H),7.28(t,1H),6.42(dd,1H),4.49(br d,1H),2.85-2.57(m,2H),2.40(s,3H),1.55(d,11H),1.30-0.67(m,7H),0.11-0.09(m,1H);LC-MS:m / z 407.47(MH+).

[0288] Preparation: [2-(6-cyclopropyl-2-pyridyl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-fluoro-4-methyl-1-piperidyl)methanone [ka] Example 65 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound (4-methyl-1-piperidyl) - [4- (5-methyl-4H-1,2,4-triazol-3-yl) -2- [4- (trifluoromethyl) thiazol-2-yl] phenyl] methanone in Example 62, and 4- (4-methylpiperidine-1-carbonyl) -3- [4- (trifluoromethyl) thiazol-2-yl] benzonitrile was replaced with 3- (6-cyclopropyl-2-pyridyl) -4- (4-fluoro-4-methyl-piperidine-1-carbonyl) benzonitrile. The title compound was obtained in a yield of 53% (8 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 8.27-8.21(m,1H),8.07-8.00(m,1H),7.79-7.71(m,1H),7.49-7.40(m,2H),7.33-7.26(m,1H),4.29-4.13( LC-MS:m / z 420.37(MH+).

[0289] Preparation: [2-(1-tert-butylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4-methoxy-4-methyl-1-piperidyl)methanone [ka] Example 66 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound (4-methyl-1-piperidyl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[4-(trifluoromethyl)thiazol-2-yl]phenyl]methanone in Example 62, except that 3-(1-tert-butylpyrazol-3-yl)-4-(4-methoxy-4-methyl-piperidine-1-carbonyl)benzonitrile was used instead of 4-(4-methylpiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile. The title compound was obtained in a yield of 40% (19 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 8.31(dd,1H),7.98-7.85(m,2H),7.30(dd,1H),6.44(dd,1H),4.22-4.07(m,1H),3.05(d,6H),2.41(s,3 LC-MS:m / z 437.48(MH+).

[0290] Preparation: (4-Methoxy-4-methyl-1-piperidyl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[4-(trifluoromethyl)thiazol-2-yl]phenyl]methanone [ka] Example 67 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound (4-methyl-1-piperidyl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[4-(trifluoromethyl)thiazol-2-yl]phenyl]methanone in Example 62, except that 4-(4-methylpiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile was replaced with 4-(4-methoxy-4-methyl-piperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile. The title compound was obtained in a yield of 25% (27.3 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 8.62(s,1H),8.52-8.35(m,1H),8.15(dd,1H),7.53-7.42(m,1H),4.22-3.98(m,1H),3.23-2 .95(m,6H),2.42(s,3H),1.83-1.69(m,1H),1.58-1.36(m,3H),1.25-0.99(m,4H);LC-MS:m / z 466.29(MH+). [ka]

[0291] Step 1 Compounds of formula II can be obtained from compounds of formula I (commercially available from Astatech) by coupling with an appropriate amine in the presence of a coupling agent, such as HATU, and a suitable organic base, such as DIPEA. The reaction is typically carried out at room temperature in a suitable solvent, such as DMF. The reaction takes about 3 to about 12 hours to complete.

[0292] Step 2 Compounds of formula III can be obtained by Miyaura borylation between compounds of formula II and B2Pin2 in the presence of a suitable transition metal catalyst, such as Pd(dppf)Cl2, a suitable base, such as potassium acetate, in a suitable solvent, such as 1,4-dioxane, typically at 95° C. The reaction takes about 12 hours to complete.

[0293] Step 3 Compounds of formula IV can be obtained by Suzuki coupling between compounds of formula III and commercially available heteroaryl halides in a suitable solvent mixture such as 1,2-dimethoxyethane / water in the presence of a suitable catalyst, e.g., palladium tetrakistriphenylphosphine, a suitable inorganic base, NaCO, typically at 95° C. The reaction takes about 3 to about 12 hours to complete.

[0294] Step 4 Compounds of formula V can be obtained by nitrile cyclization of compounds of formula IV with ethanimidamide hydrochloride in the presence of a suitable catalyst, such as CuBr, a suitable base, such as CsCO, in a suitable solvent, such as DMSO, typically at 120° C. The reaction takes about 3 hours to about 12 hours to complete.

[0295] Scheme 6, Preparation of compound (II)*a: 3-bromo-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile [ka] To a solution of HATU (1.14 g, 2.99 mmol), 2-bromo-4-cyanobenzoic acid (450.0 mg, 1.99 mmol), and 4-(trifluoromethyl)piperidine hydrochloride (415.24 mg, 2.19 mmol) in DMF (9 mL) was added N,N-diisopropylethylamine (2.03 mL, 11.95 mmol). The reaction was stirred at room temperature for 5 hours. After this time, the reaction was diluted with HO and then extracted three times with AcOEt. The combined organic fractions were washed with brine, dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluting with 100% cHex to 60:40 AcOEt / cHex) to give the product of formula 3-bromo-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile. Yield: 560mg 1 H NMR(400MHz,DMSO) δ8.29(dd,1H),7.95(ddd,1H),7.71-7.50(m,1H),4.60(t,1H),3.26(d,1H),3.09(dtd,1H) ,2.83(tdd,1H),2.66(d,1H),1.94(t,1H),1.82-1.65(m,1H),1.55-1.29(m,2H);LC-MS:m / z 361.07,363.10(MH+).

[0296] Scheme 6, Preparation of compound (III)*a: 4-(4,4-difluoropiperidine-1-carbonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile [ka] 3-Bromo-4-(4,4-difluoropiperidine-1-carbonyl)benzonitrile (950.0 mg, 2.8 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (2.13 g, 8.4 mmol), potassium acetate (832.78 mg, 8.4 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (68.76 mg, 0.080 mmol) were placed in a vial and suspended in 1,4-dioxane (25 mL). The mixture was degassed by passing through an N2-vacuum cycle (3 times). The mixture was stirred overnight at 90 °C under N2 protection. After this time, the reaction was cooled, filtered through a pad of Celite, and then washed with EtOAc. The organic phase was washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to give the product of formula 4-(4,4-difluoropiperidine-1-carbonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile, which was used in the next step without further purification. Yield: 1.0g LC-MS: m / z 377.26 (MH+).

[0297] Scheme 6, Preparation of compound (III)*b: 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile [ka] 3-Bromo-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile (750.0 mg, 2.08 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (1.58 g, 6.23 mmol), potassium acetate (617.7 mg, 6.23 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (34.0 mg, 0.040 mmol) were suspended in 1,4-dioxane (20 mL), and the mixture was degassed by passing it through three N2-vacuum cycles. The mixture was stirred overnight at 95 °C under N2 protection. After this time, complete consumption of the starting material was observed, so the mixture was cooled to room temperature, filtered through a pad of Celite, and washed with EtOAc. The organic phase was washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to give the product of formula 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile. The product was used in the next step without further purification. Yield: 800mg LC-MS: m / z 409.16 (MH+).

[0298] Scheme 6, Preparation of compound (IV)*a: 4-(4,4-difluoropiperidine-1-carbonyl)-3-(6-isopropyl-2-pyridyl)benzonitrile [ka] Palladium tetrakistriphenylphosphine (80.17 mg, 0.070 mmol) and 2-bromo-6-isopropylpyridine (277.62 mg, 1.39 mmol) were suspended in 1,2-dimethoxyethane (13.88 mL), followed by the addition of a 2 M aqueous solution of NaCO (2.08 mL, 4.16 mmol). The mixture was degassed with five nitrogen / vacuum cycles, and 4-(4,4-difluoropiperidine-1-carbonyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (0.5 g, 1.39 mmol) was added. The reaction mixture was degassed again with five nitrogen / vacuum cycles and then heated to 95 °C for 8 h. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 times). The organic layers were collected together, washed with brine, dried over NaSO, filtered, and the solvent was removed under vacuum. The mixture was purified by reverse-phase flash chromatography using acidic conditions (elution from 5:95 CHCN / HO+0.1% HCOOH to 60:460 CHCN / HO+0.1% HCOOH) to give the product of formula 4-(4,4-difluoropiperidine-1-carbonyl)-3-(6-isopropyl-2-pyridyl)benzonitrile. Yield: 160mg 1 H NMR(400MHz,DMSO-d6) δ8.25(d,1H),7.98(dd,1H),7.89-7.85(m,1H),7.72-7.62(m,2H),7.33(dd,1H),4.06-3.97(m,1H),3.40-3.2 4(m,2H),3.14-3.05(m,1H),2.99(p,1H),2.23-1.84(m,3H),1.71-1.51(m,1H),1.29-1.20(m,6H);LC-MS:m / z 370.31(MH+).

[0299] Scheme 6, Preparation of compound (IV)*b: 4-(4,4-difluoropiperidine-1-carbonyl)-3-[6-(trifluoromethyl)pyridin-2-yl]benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 4-(4,4-difluoropiperidine-1-carbonyl)-3-(6-isopropyl-2-pyridyl)benzonitrile, except that 2-bromo-6-(trifluoromethyl)pyridine was used instead of 2-bromo-6-isopropyl-pyridine. The title compound was obtained in a yield of 40% (130 mg). 1 H NMR(400MHz,DMSO) δ8.37(d,1H),8.26(t,1H),8.20(d,1H),8.06(dd,1H),7.95(dd,1H),7.75(d,1H),4.04-3.93( LC-MS:m / z 396.26(MH+).

[0300] Scheme 6, Preparation of compound (IV)*c: 3-[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile [ka] Palladium tetrakistriphenylphosphine (42.46 mg, 0.040 mmol) and 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile (0.33 g, 0.730 mmol) were suspended in 1,2-dimethoxyethane (7.349 mL), followed by the addition of a 2 M aqueous solution of NaCO (1.1 mL, 2.2 mmol). The reaction mixture was degassed with five nitrogen / vacuum cycles, and 2-chloro-4-methyl-6-(trifluoromethyl)pyrimidine (158.9 mg, 0.810 mmol) was added. The reaction mixture was again degassed with five nitrogen / vacuum cycles and then heated to 95 °C for 8 h. After this time, the reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 times). The organic layers were collected together, washed with brine, dried over NaSO, filtered, and the solvent was removed under vacuum. The residue was purified by flash chromatography on silica gel (eluting with 5:95 AcOEt / cHex to 60:40 AcOEt / cHex) and again by reverse-phase flash chromatography using acidic conditions (eluting with 5:95 CHCN / H2O + 0.1% HCOOH to 40:60 CH3CN / H2O + 0.1% HCOOH) to give the product of formula 3-[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile. Yield: 34 mg 1 H NMR(400MHz,DMSO) δ8.60-8.42(m,1H),8.10(dd,1H),7.99(s,1H),7.73-7.59(m,1H),4.54(d,1H) ),3.30(s,3H),2.68(s,4H),1.97(d,1H),1.73(d,1H),1.47(d,2H);LC-MS:m / z 443.4(MH+).

[0301] Scheme 6, Preparation of compound (IV)*d: 3-(4-cyclopropylthiazol-2-yl)-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 3-[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile, except that 2-bromo-4-cyclopropylthiazole was used instead of 2-chloro-4-methyl-6-(trifluoromethyl)pyrimidine. The title compound was obtained in a yield of 11% (33 mg). 1 H NMR(400MHz,DMSO) δ8.33-8.22(m,1H),7.98(td,1H),7.65-7.53(m,1H),7.47(d,1H),4.58(s,1H),3.28(s,1 LC-MS:m / z 406.47(MH+).

[0302] Scheme 6, Preparation of compound (IV)*e: 3-(6-propan-2-ylpyridin-2-yl)-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 3-[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile, except that 2-bromo-6-propan-2-ylpyridine was used instead of 2-chloro-4-methyl-6-(trifluoromethyl)pyrimidine. The title compound was obtained in a yield of 37% (47 mg). 1H NMR(400MHz,DMSO) δ8.27-8.11(m,1H),7.96(ddd,1H),7.84(td,1H),7.64(dd,1H),7.59-7.49(m,1H),7. 37-7.26(m,1H),4.52(d,1H),3.30(s,4H),2.50(p,1H),1.94-0.02(m,10H);LC-MS:m / z 402.28(MH+).

[0303] Scheme 6, Preparation of compound (IV)*f: 3-(6-cyclopropylpyridin-2-yl)-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound 3-[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile, except that 2-bromo-6-cyclopropylpyridine was used instead of 2-chloro-4-methyl-6-(trifluoromethyl)pyrimidine. The title compound was obtained in a yield of 34% (90 mg). 1 H NMR(400MHz,DMSO-d6) δ8.25-8.09(m,1H),8.01-7.86(m,1H),7.82-7.72(m,1H),7.64-7.46(m,2H),7.35-7.25(m,1H),4.54(d, LC-MS:m / z 400.47(MH+).

[0304] Scheme 6, Preparation of compound (IV)*g: 4-[4-(trifluoromethyl)piperidine-1-carbonyl]-3-[4-(trifluoromethyl)-1,3-thiazol-2-yl]benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound 3-[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile, except that 2-bromo-4-(trifluoromethyl)thiazole was used instead of 2-chloro-4-methyl-6-(trifluoromethyl)pyrimidine. The title compound was obtained in a yield of 23% (67 mg). LC-MS: m / z 434.38(MH+).

[0305] Scheme 6, Preparation of compound (IV)*h: 4-[4-(trifluoromethyl)piperidine-1-carbonyl]-3-[6-(trifluoromethyl)pyridin-2-yl]benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound 3-[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile, except that 2-bromo-6-(trifluoromethyl)pyridine was used instead of 2-chloro-4-methyl-6-(trifluoromethyl)pyrimidine. The title compound was obtained in a yield of 17% (77 mg). LC-MS: m / z 428.10(MH+).

[0306] Scheme 6, Preparation of compound (V)*a: [4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]phenyl]-[4-(trifluoromethyl)-1-piperidyl]methanone [ka] Example 68 A mixture of 3-[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]-4-[4-(trifluoromethyl)piperidine-1-carbonyl]benzonitrile (35.0 mg, 0.080 mmol), dicesium carbonate (77.34 mg, 0.240 mmol), ethanimidamide hydrochloride (11.22 mg, 0.120 mmol), and CuBr (0.57 mg, 0 mmol) in DMSO (0.791 mL) was stirred at 120 °C for 2 h. After this time, the reaction was cooled to room temperature and HO was added. The mixture was then extracted three times with AcOEt, washed with brine, dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on an NH column (eluting with 100% DCM to 95:5 DCM / MeOH) to give the product of formula [4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]phenyl]-[4-(trifluoromethyl)-1-piperidyl]methanone. Yield: 3 mg 1 H NMR(400MHz,MeOD) δ9.18-8.88(m,1H),8.24(d,1H),7.72(s,1H),7.53(d,1H),4.75(d,1H),3.68(d,1H),3.29 -2.77(m,3H),2.72(s,3H),2.52(s,3H),2.06(t,1H),1.83(d,1H),1.64(p,2H);LC-MS:m / z 499.39(MH+).

[0307] Preparation: [2-(4-cyclopropylthiazol-2-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)-1-piperidyl]methanone [ka] Example 69 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [4- (5-methyl-4H-1,2,4-triazol-3-yl) -2- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] phenyl] - [4- (trifluoromethyl) -1-piperidyl] methanone in Example 68, and 3- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] -4- [4- (trifluoromethyl) piperidine-1-carbonyl] benzonitrile was used instead of 3- (4-cyclopropylthiazol-2-yl) -4- [4- (trifluoromethyl) piperidine-1-carbonyl] benzonitrile. The title compound was obtained in a yield of 48% (18 mg). 1 H NMR(400MHz,DMSO) δ13.87(s,1H),8.34(dd,1),8.12-8.03(m,1H),7.56-7.29(m,2H),4.62(s,1H),3.41(d,1H),3.07-2.57(m,3H),2 .42(s,3H),2.11(tt,1H),2.02-1.84(m,1H),1.74-1.53(m,1H),1.52-1.01(m,2H),0.99-0.66(m,4H);LC-MS:m / z 462.22(MH+).

[0308] Preparation: [2-(6-isopropyl-2-pyridyl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)-1-piperidyl]methanone [ka] Example 70 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [4- (5-methyl-4H-1,2,4-triazol-3-yl) -2- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] phenyl] - [4- (trifluoromethyl) -1-piperidyl] methanone in Example 68, and 3- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] -4- [4- (trifluoromethyl) piperidine-1-carbonyl] benzonitrile was used instead of 3- (6-propan-2-ylpyridin-2-yl) -4- [4- (trifluoromethyl) piperidine-1-carbonyl] benzonitrile. The title compound was obtained in a yield of 47% (25 mg). 1 H NMR(400MHz,DMSO) δ13.83(s,1H),8.31-8.25(m,1H),8.10-8.02(m,1H),7.82(t,1H),7.58-7.39(m,2H),7.34-7.23(m,1H),4.5 5(d,1H),3.61-2.55(m,4H),2.41(s,4H),1.97-1.33(m,3H),1.30-1.20(m,6H),0.98-0.13(m,1H);LC-MS:m / z 458.48(MH+).

[0309] Preparation: [2-(6-cyclopropylpyridin-2-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethyl)piperidin-1-yl]methanone [ka] Example 71 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [4- (5-methyl-4H-1,2,4-triazol-3-yl) -2- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] phenyl] - [4- (trifluoromethyl) -1-piperidyl] methanone in Example 68, and 3- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] -4- [4- (trifluoromethyl) piperidine-1-carbonyl] benzonitrile was used instead of 3- (6-cyclopropylpyridin-2-yl) -4- [4- (trifluoromethyl) piperidine-1-carbonyl] benzonitrile. The title compound was obtained in a yield of 17% (17 mg). 1 H NMR(400MHz,DMSO-d6) δ13.83(s,1H),8.30-8.15(m,1H),8.06(dt,1H),7.76(td,1H),7.51-7.35(m,2H),7.28(dd,1H),4.57(d, LC-MS:m / z 456.22(MH+).

[0310] Preparation: [4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[4-(trifluoromethyl)-1,3-thiazol-2-yl]phenyl]-[4-(trifluoromethyl)piperidin-1-yl]methanone [ka] Example 72 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [4- (5-methyl-4H-1,2,4-triazol-3-yl) -2- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] phenyl] - [4- (trifluoromethyl) -1-piperidyl] methanone in Example 68, and 3- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] -4- [4- (trifluoromethyl) piperidine-1-carbonyl] benzonitrile was used instead of 4- [4- (trifluoromethyl) piperidine-1-carbonyl] -3- [4- (trifluoromethyl) -1,3-thiazol-2-yl] benzonitrile. The title compound was obtained in a yield of 48% (37 mg). 1 H NMR(400MHz,DMSO) δ13.91(s,1H),8.65(d,1H),8.44(d,1H),8.18(dd,1H),7.53(dd,1H),4.62(d,1H),3.49(d,1H) ,3.12(t,1H),2.80(t,1H),2.60(s,1H),2.44(s,3H),2.05-1.29(m,3H),1.03(d,1H);LC-MS:m / z 490.13(MH+).

[0311] Preparation: [4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[6-(trifluoromethyl)pyridin-2-yl]phenyl]-[4-(trifluoromethyl)piperidin-1-yl]methanone [ka] Example 73 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [4- (5-methyl-4H-1,2,4-triazol-3-yl) -2- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] phenyl] - [4- (trifluoromethyl) -1-piperidyl] methanone in Example 68, and 3- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] -4- [4- (trifluoromethyl) piperidine-1-carbonyl] benzonitrile was used instead of 4- [4- (trifluoromethyl) piperidine-1-carbonyl] -3- [6- (trifluoromethyl) pyridin-2-yl] benzonitrile. The title compound was obtained in a yield of 36% (31 mg). 1 H NMR(400MHz,DMSO) δ13.86(s,1H),8.32(d,1H),8.23(t,1H),8.13(dd,1H),8.06(d,1H),7.92(s,1H),7.52(d,1H),4.51(d,1 LC-MS:m / z 484.13(MH+).

[0312] Preparation: 4,4-Difluoro-1-piperidyl)-[2-(6-isopropyl-2-pyridyl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]methanone [ka] Example 74 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [4- (5-methyl-4H-1,2,4-triazol-3-yl) -2- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] phenyl] - [4- (trifluoromethyl) -1-piperidyl] methanone in Example 68, and 3- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] -4- [4- (trifluoromethyl) piperidine-1-carbonyl] benzonitrile was replaced with 4- (4,4-difluoropiperidine-1-carbonyl) -3- (6-isopropyl-2-pyridyl) benzonitrile. The title compound was obtained in a yield of 50% (80 mg). 1 H NMR(400MHz,DMSO-d6) δ13.75(bs,1H),8.30(d,1H),8.07(dd,1H),7.85(t,1H),7.54(dd,2H),7.30(d,1H),3.93-3.83(m,1H),3.45-3.37( LC-MS:m / z 426.35(MH+).

[0313] Preparation: (4,4-Difluoropiperidin-1-yl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[6-(trifluoromethyl)pyridin-2-yl]phenyl]methanone [ka] Example 75 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound [4- (5-methyl-4H-1,2,4-triazol-3-yl) -2- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] phenyl] - [4- (trifluoromethyl) -1-piperidyl] methanone, and 3- [4-methyl-6- (trifluoromethyl) pyrimidin-2-yl] -4- [4- (trifluoromethyl) piperidine-1-carbonyl] benzonitrile was replaced with 4- (4,4-difluoropiperidine-1-carbonyl) -3- [6- (trifluoromethyl) pyridin-2-yl] benzonitrile. The title compound was obtained in a yield of 26% (25 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 8.33(d,1H),8.28-8.20(m,1H),8.17-8.08(m,2H),7.92(d,1H),7.59(d,1H),3 .96-3.83(m,2H),3.58-3.34(m,3H),2.42(s,3H),2.18-1.71(m,4H);LC-MS:m / z 452.20(MH+). [ka]

[0314] Step 1 Compounds of formula II can be obtained from compounds of formula I (commercially available from Astatech) by coupling with an appropriate amine in the presence of a coupling agent, such as HATU, and an organic base, such as DIPEA. The reaction is typically carried out at room temperature in a suitable solvent, such as DMF. The reaction takes about 3 to about 12 hours to complete.

[0315] Step 2 Compounds of formula III can be obtained by Miyaura borylation between compounds of formula II (commercially available from Astatech) and 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane in a suitable solvent such as 1,4-dioxane in the presence of a suitable transition metal catalyst such as Pd(dppf)Cl2 and a suitable base such as potassium acetate, typically at 95° C. The reaction takes about 12 hours to complete.

[0316] Step 3 Compounds of formula IV can be obtained by Suzuki coupling between compounds of formula III and commercially available heteroaryl halides in the presence of a suitable palladium catalyst, such as palladium tetrakistriphenylphosphine, a suitable inorganic base, NaCO, in a suitable solvent mixture of 1,2-dimethoxyethane / water, typically at 95° C. The reaction takes about 3 to about 12 hours to complete.

[0317] Step 4 Compounds of formula V can be obtained by nitrile cyclization of compounds of formula IV with ethanimidamide hydrochloride in the presence of a suitable catalyst, such as CuBr, a suitable base, such as CsCO, in a suitable solvent, such as DMSO, typically at 120° C. The reaction takes about 3 hours to about 12 hours to complete.

[0318] Scheme 7, Preparation of compound (II)*a: 3-bromo-4-(4,4-difluoropiperidine-1-carbonyl)benzonitrile [ka] To a solution of [dimethylamino(3-triazolo[4,5-b]pyridinyloxy)methylidene]-dimethylammonium hexafluorophosphate HATU (1.14 g, 2.99 mmol), 2-bromo-4-cyanobenzoic acid (450.0 mg, 1.99 mmol), and N,N-diisopropylethylamine (2.03 mL, 11.95 mmol) in DMF (13.27 mL) was added 4,4-difluoropiperidine hydrochloride (376.49 mg, 2.39 mmol). The reaction was stirred at room temperature for 3 hours. After this time, saturated NaHCO3 solution was added to the reaction mixture, and the aqueous phase was extracted with EtOAc (x3). The organic portion was collected, washed with brine, and residual water was removed by adding Na2SO4, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (eluting with 100% cHex to 65:35 cHexAcOEt / ) to give the product of formula 3-bromo-4-(4,4-difluoropiperidine-1-carbonyl)benzonitrile. Yield: 500mg 1 H NMR(400MHz,DMSO-d6) δ ppm 8.31(d,1H) 7.98(dd,1H) 7.66(d,1H) 3.82-3.93(m,1H) 3.60-3.73(m,1H) 3.22(t,2H) 1.88-2.22(m,4H);LC-MS:m / z 329.00,331.00(MH+).

[0319] Scheme 7, Preparation of compound (II)*b: 3-bromo-4-[4-(trifluoromethoxy)piperidine-1-carbonyl]benzonitrile [ka] To a solution of [dimethylamino(3-triazolo[4,5-b]pyridinyloxy)methylidene]-dimethylammonium hexafluorophosphate HATU (630.83 mg, 1.66 mmol), 2-bromo-4-cyanobenzoic acid (250.0 mg, 1.11 mmol), and 4-(trifluoromethoxy)piperidine hydrochloride (272.9 mg, 1.33 mmol) in DMF (5.821 mL) was added N,N-diisopropylethylamine (1.13 mL, 6.64 mmol). The reaction was stirred at room temperature for 6 hours. After this time, the reaction was diluted with HO. The mixture was then extracted three times with AcOEt. The combined organic fractions were washed with brine, dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluting with 5:95 to 60:40 AcOEt:cHex) to give the product of formula 3-bromo-4-[4-(trifluoromethoxy)piperidine-1-carbonyl]benzonitrile. Yield: 260mg 1 H NMR(400MHz,DMSO) δ8.29(dd,1H),7.96(ddd,1H),7.72-7.49(m,1H),4.74(dt,1H),4.02(td,1H),3.42(ddd d,1H),3.30-3.06(m,2H),2.09-1.97(m,1H),1.90(s,1H),1.84-1.56(m,2H);LC-MS:m / z 377.36,379.26(MH+).

[0320] Scheme 7, Preparation of compound (III)*a: [5-cyano-2-(4,4-difluoropiperidine-1-carbonyl)phenyl]boronic acid [ka] Potassium acetate (40.67 mg, 0.410 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (5.6 mg, 0.010 mmol), 3-bromo-4-(4,4-difluoropiperidine-1-carbonyl)benzonitrile (45.0 mg, 0.140 mmol), and 2-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)-5,5-dimethyl-1,3,2-dioxaborinane (46.33 mg, 0.210 mmol) were suspended in 1,4-dioxane (1 mL). The mixture was then degassed three times via N2-vacuum cycles. The vial was sealed, and the mixture was stirred at 90 °C for 3 h. After this time, the reaction was cooled and filtered through a pad of Celite, washing with EtOAc. The organic phase was washed with saturated NaHCO solution, brine, dried over NaSO, filtered, and concentrated in vacuo to give the product of formula [5-cyano-2-(4,4-difluoropiperidine-1-carbonyl)phenyl]boronic acid, which was used in the next step without further purification. Yield: 40mg LC-MS: m / z 295.24 (MH+).

[0321] Scheme 7, Preparation of compound (III)*b: [5-cyano-2-[4-(trifluoromethoxy)piperidine-1-carbonyl]phenyl]boronic acid [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound [5-cyano-2-(4,4-difluoropiperidine-1-carbonyl)phenyl]boronic acid, except that 3-bromo-4-[4-(trifluoromethoxy)piperidine-1-carbonyl]benzonitrile was used instead of 3-bromo-4-(4,4-difluoropiperidine-1-carbonyl)benzonitrile. The title compound was obtained in a yield of 61% (145 mg). LC-MS: m / z 343.20(MH+).

[0322] Scheme 7, Preparation of compound (IV)*a: 4-(4,4-difluoropiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile [ka] Palladium tetrakistriphenylphosphine (15.72 mg, 0.010 mmol) and [5-cyano-2-(4,4-difluoropiperidine-1-carbonyl)phenyl]boronic acid (80.0 mg, 0.270 mmol) were suspended in 1,2-dimethoxyethane (2 mL), followed by the addition of a 2 M aqueous solution of Na2CO3 (86.5 mg, 0.820 mmol). The mixture was degassed with five nitrogen / vacuum cycles, followed by 2-bromo-4-(trifluoromethyl)thiazole (69.43 mg, 0.300 mmol). The reaction mixture was degassed again with five nitrogen / vacuum cycles and heated to 100 °C overnight. After this time, the reaction was cooled to room temperature, diluted with water, and extracted with EtOAc (3 times). The organic layers were collected together, washed with brine, dried over Na2SO4, filtered, and the solvent removed in vacuo. The mixture was purified by flash chromatography on silica gel (eluting with 100% cHex to 50:50 cHex:EtOAc) to give the product of formula 4-(4,4-difluoropiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile. Yield: 35mg 1 H NMR(400MHz,DMSO-d6) δ8.69(d,1H),8.44(d,1H),8.11(dd,1H),7.70(d,1H),3.87-3.78(m,1H),3.63-3.53(m,1H),2.20-1.85(m,6H);LC-MS:m / z 402.15(MH+).

[0323] Scheme 7, Preparation of compound (IV)*b: 4-(4,4-difluoropiperidine-1-carbonyl)-3-[4-(trifluoromethyl)pyrimidin-2-yl]benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound 4-(4,4-difluoropiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile, except that 2-chloro-4-(trifluoromethyl)pyrimidine was used instead of 2-bromo-4-(trifluoromethyl)thiazole. The title compound was obtained in a yield of 40% (44 mg). 1 H NMR(400MHz,DMSO-d6) δ9.33(d,1H),8.58(d,1H),8.15(dd,1H),8.09-8.04(m,1H),7.76(dd,1H),4.17-3.86(m,1H),2.21-1.92(m,6H);LC-MS:m / z 397.21(MH+).

[0324] Scheme 7, Preparation of compound (IV)*c: 3-(6-cyclopropyl-2-pyridyl)-4-(4,4-difluoropiperidine-1-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound 4-(4,4-difluoropiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile, except that 2-bromo-6-cyclopropylpyridine was used instead of 2-bromo-4-(trifluoromethyl)thiazol. The title compound was obtained in a yield of 47% (28 mg). 1 H NMR(400MHz,DMSO) δ8.22(d,1H),7.96(td,2H),7.79(t,1H),7.67(dd,2H),3.93(d,1H),3.74(s,1H),3. 41(t,1H),2.98(d,1H),2.20-1.81(m,6H),1.41(s,1H),1.00-0.91(m,2H);LC-MS:m / z 368.22(MH+).

[0325] Scheme 7, Preparation of compound (IV)*d: 3-(6-tert-butyl-2-pyridyl)-4-(4,4-difluoropiperidine-1-carbonyl)benzonitrile [ka] The synthesis of the title compound was carried out similarly to the synthesis of compound 4-(4,4-difluoropiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile, except that 2-bromo-6-tert-butyl-pyridine was used instead of 2-bromo-4-(trifluoromethyl)thiazol. The title compound was obtained in a yield of 82% (94 mg). 1 H NMR(400MHz,DMSO) δ8.22(d,1H),7.99(dd,1H),7.87(t,1H),7.73(d,1H),7.61(dd,1H),7.47(dd,1H),4.11-3.96(m,1H) ,3.25-3.14(m,2H),3.06-2.90(m,1H),2.19-1.77(m,3H),1.56-1.38(m,1H),1.30(s,9H);LC-MS:m / z 384.47(MH+).

[0326] Scheme 7, Preparation of compound (IV)*e: 3-(1-tert-butylpyrazol-3-yl)-4-[4-(trifluoromethoxy)piperidine-1-carbonyl]benzonitrile [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of compound 4- (4,4-difluoropiperidine-1-carbonyl) -3- [4- (trifluoromethyl) thiazol-2-yl] benzonitrile, [5-cyano-2- (4,4-difluoropiperidine-1-carbonyl) phenyl] boronic acid and 2-bromo-4- (trifluoromethyl) thiazole were replaced with [5-cyano-2- [4- (trifluoromethoxy) piperidine-1-carbonyl] phenyl] boronic acid and 1-tert-butyl-3-iodopyrazole, respectively. The title compound was obtained in a yield of 33% (96 mg). 1 H NMR(400MHz,DMSO) δ8.22-8.12(m,1H),7.96-7.88(m,1H),7.82(td,1H),7.50(dd,1H),6.61(dd,1H),4.65(dt,1 LC-MS:m / z 421.23(MH+).

[0327] Scheme 7, Preparation of compound (V)*a: (4,4-difluoro-1-piperidyl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[4-(trifluoromethyl)thiazol-2-yl]phenyl]methanone [ka] Example 76 A mixture of 4-(4,4-difluoropiperidine-1-carbonyl)-3-[4-(trifluoromethyl)thiazol-2-yl]benzonitrile (35.0 mg, 0.070 mmol), CuBr (0.52 mg, 0 mmol), dicesium carbonate (94.33 mg, 0.290 mmol), and ethanimidamide hydrochloride (13.69 mg, 0.140 mmol) in DMSO (1.334 mL) was stirred at 120 °C for 2 h. After this time, the reaction was cooled to room temperature. HO was added, and the mixture was then extracted three times with AcOEt. The combined organic fractions were washed with brine, dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by NH column flash chromatography (eluting with 100% DCM to 95:5 DCM:MeOH) and again by reverse-phase flash chromatography using acidic conditions (eluting with 5:95 CHCN / HO+0.1% HCOOH to 55:45 CHCN / HO+0.1% HCOOH) to give the product of formula (4,4-difluoro-1-piperidyl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[4-(trifluoromethyl)thiazol-2-yl]phenyl]methanone. Yield: 14 mg 1 H NMR(400MHz,DMSO-d6) δ8.65(d,1H),8.43(d,1H),8.19(dd,1H),7.56(d,1H),3.94-3.82(m,1H),3.6 7-3.52(m,1H),3.38-3.30(m,2H),2.44(s,3H),2.20-1.79(m,4H);LC-MS:m / z 458.38(MH+).

[0328] Preparation: (4,4-Difluoro-1-piperidyl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[4-(trifluoromethyl)pyrimidin-2-yl]phenyl]methanone [ka] Example 77 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound (4,4-difluoro-1-piperidine) - [4- (5-methyl-4H-1,2,4-triazol-3-yl) -2- [4- (trifluoromethyl) thiazol-2-yl] phenyl] methanone in Example 76, and 4- (4,4-difluoropiperidine-1-carbonyl) -3- [4- (trifluoromethyl) thiazol-2-yl] benzonitrile was replaced with 4- (4,4-difluoropiperidine-1-carbonyl) -3- [4- (trifluoromethyl) pyrimidin-2-yl] benzonitrile. The title compound was obtained in a yield of 11% (5 mg). 1 H NMR(400MHz,DMSO-d6) δ9.30(d,1H),8.86(d,1H),8.19(dd,1H),8.01(d,1H),7.56(d,1H),3.95-3.82(m,1H),3.58-3.40(m,2H) 2.55-2.52(m,2H),2.43(s,3H),2.20-1.90(m,4H);LC-MS:m / z 453.26(MH+).

[0329] Preparation: [2-(6-cyclopropyl-2-pyridyl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4,4-difluoro-1-piperidyl)methanone [ka] Example 78 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound (4,4-difluoro-1-piperidyl) - [4- (5-methyl-4H-1,2,4-triazol-3-yl) -2- [4- (trifluoromethyl) thiazol-2-yl] phenyl] methanone in Example 76, and 4- (4,4-difluoropiperidine-1-carbonyl) -3- [4- (trifluoromethyl) thiazol-2-yl] benzonitrile was replaced with 3- (6-cyclopropyl-2-pyridyl) -4- (4,4-difluoropiperidine-1-carbonyl) benzonitrile. The title compound was obtained in a yield of 33% (8 mg). 1H NMR(400MHz,DMSO-d6) δ13.80(bs,1H),8.26(d,1H),8.06(dd,1H),7.78(t,1H),7.56-7.46(m,2H),7.30(dd,1H),3.92-3.80(m,1H),3 .54-3.45(m,2H),3.08-2.93(m,1H),2.42(s,3H),2.19-1.80(m,3H),1.36(s,1H),1.12-0.69(m,4H);LC-MS:m / z 424.31(MH+).

[0330] Preparation: [2-(6-tert-butyl-2-pyridyl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-(4,4-difluoro-1-piperidyl)methanone [ka] Example 79 The synthesis of the title compound was carried out in the same manner as in Example 76 (4,4-difluoro-1-piperidyl) - [4- (5-methyl-4H-1,2,4-triazol-3-yl) -2- [4- (trifluoromethyl) thiazol-2-yl] phenyl] methanone, and 4- (4,4-difluoropiperidine-1-carbonyl) -3- [4- (trifluoromethyl) thiazol-2-yl] benzonitrile was replaced with 3- (6-tert-butyl-2-pyridyl) -4- (4,4-difluoropiperidine-1-carbonyl) benzonitrile. The title compound was obtained in a yield of 35% (38 mg). 1 H NMR(400MHz,DMSO) δ13.85(s,1H),8.29(d,1H),8.07(dd,1H),7.86(t,1H),7.62-7.49(m,2H),7.45(dd,1H), 3.93(d,1H),3.41(s,2H),3.01(t,1H),2.42(s,3H),1.93(d,3H),1.32(s,10H);LC-MS:m / z 440.31(MH+)

[0331] Preparation of [2-(1-tert-butylpyrazol-3-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-[4-(trifluoromethoxy)-1-piperidyl]methanone [ka] Example 80 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound (4,4-difluoro-1-piperidine) - [4- (5-methyl-4H-1,2,4-triazol-3-yl) -2- [4- (trifluoromethyl) thiazol-2-yl] phenyl] methanone in Example 76, and 4- (4,4-difluoropiperidine-1-carbonyl) -3- [4- (trifluoromethyl) thiazol-2-yl] benzonitrile was replaced with 3- (1-tert-butylpyrazol-3-yl) -4- [4- (trifluoromethoxy) piperidine-1-carbonyl] benzonitrile. The title compound was obtained in a yield of 3.5% (4 mg). 1 H NMR(400MHz,DMSO) δ13.73(s,1H),8.30(dd,1H),8.01-7.81(m,2H),7.33(d,1H),6.53-6.43(m,1H),4.67-4.55(m,1H),4.14-3 .95(m,1H),3.29-2.85(m,3H),2.42(s,3H),1.99-1.88(m,1H),1.74-1.61(m,1H),1.56(d,11H);LC-MS:m / z 477.49(MH+). [ka]

[0332] Step 1 Compounds of formula II can be obtained from compounds of formula I (synthesized according to Scheme 7) by Suzuki coupling with 2-bromo-4-thiazocarboxylic acid ethyl ester in the presence of a suitable precatalyst, such as XPhos Pd G2, a suitable base, such as K3PO4, in a suitable solvent, such as a 1,2-dimethoxyethane / water mixture, typically at 90° C. The reaction takes about 5 hours to complete.

[0333] Step 2 Compounds of formula III can be obtained by nitrile cyclization of compounds of formula II with ethanimidamide hydrochloride in the presence of a suitable catalyst, such as CuBr, a suitable base, such as CsCO, in a suitable solvent, such as DMSO, typically at 120° C. The reaction takes about 3 hours to about 12 hours to complete.

[0334] Step 3 Compounds of formula IV can be obtained from compounds of formula III by hydrolysis, for example, using LiOH, in a mixture of a suitable solvent such as MeOH / THF / HO, typically at 50° C. The reaction takes about 12 hours to complete.

[0335] Scheme 8. Preparation of compound (II): ethyl 2-[5-cyano-2-(4,4-difluoropiperidine-1-carbonyl)phenyl]thiazole-4-carboxylate [ka] Example 81 In a suitable vial, 2-bromo-4-thiazolecarboxylic acid ethyl ester (134.88 mg, 0.570 mmol), [5-cyano-2-(4,4-difluoropiperidine-1-carbonyl)phenyl]boronic acid (560.0 mg, 0.380 mmol), X-phos aminobiphenyl palladium chloride precatalyst (29.93 mg, 0.040 mmol), and tripotassium phosphate (242.54 mg, 1.14 mmol) were suspended in a mixture of water (0.6 mL) and 1,2-dimethoxyethane (5.7 mL). The resulting suspension was degassed with nitrogen and heated to 90 °C for 5 h. After this time, the reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3 times). The organic layers were collected together, washed with brine, dried over Na2SO4, filtered, and the solvent removed in vacuo. The crude material was purified by flash chromatography on silica gel (eluting with 95:5 cHex / EtOAc to 50:50 cHex / EtOAc) to give the product of formula ethyl 2-[5-cyano-2-(4,4-difluoropiperidine-1-carbonyl)phenyl]thiazole-4-carboxylate. Yield: 115mg 1 H NMR(400MHz,DMSO) δ8.70(s,1H),8.42(d,1H),8.09(dd,1H),7.68(d,1H),4.40-4.26(m,2H),3.97-3.83(m ,1H),3.68-3.52(m,1H),3.43-3.33(m,2H),2.29-1.86(m,4H),1.32(t,3H);LC-MS:m / z 406.37(MH+).

[0336] Scheme 8. Preparation of compound (III): Ethyl 2-[2-(4,4-difluoropiperidine-1-carbonyl)-5-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]thiazole-4-carboxylate [ka] Example 82 A mixture of ethyl 2-[5-cyano-2-(4,4-difluoropiperidine-1-carbonyl)phenyl]thiazole-4-carboxylate (115.0 mg, 0.280 mmol), CuBr (2.03 mg, 0.010 mmol), dicesium carbonate (277.26 mg, 0.850 mmol), and ethanimidamide hydrochloride (40.23 mg, 0.430 mmol) in DMSO (3.618 mL) was stirred at 120 °C for 90 min. After this time, the reaction was cooled to room temperature and HO was added. The mixture was then extracted three times with AcOEt. The combined organic fractions were washed with brine, dried over NaSO, filtered, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluting with 100% DCM to 90:10 DCM:EtOH) to give the product of formula ethyl 2-[2-(4,4-difluoropiperidine-1-carbonyl)-5-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]thiazole-4-carboxylate. Yield: 30 mg 1 H NMR(400MHz,DMSO-d6) δ13.90(bs,1H),8.66(s,1H),8.42(d,1H),8.16(dd,1H),7.54(d,1H),4.34(q,2H),4.01-3.92(m, 1H),3.65-3.55(m,1H),3.41-3.36(m,2H),2.44(s,3H),2.29-1.83(m,4H),1.33(t,3H);LC-MS:m / z 462.38(MH+).

[0337] Scheme 8. Preparation of compound (IV): 2-[2-(4,4-difluoropiperidine-1-carbonyl)-5-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]thiazole-4-carboxylic acid [ka] Example 83 To a solution of ethyl 2-[2-(4,4-difluoropiperidine-1-carbonyl)-5-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]thiazole-4-carboxylate (23.0 mg, 0.040 mmol) in methanol (0.142 mL) / THF (0.712 mL) was added a solution of lithium hydroxide (1.61 mg, 0.070 mmol) in water (0.142 mL). The reaction was stirred at 50° C. overnight. The next day, the reaction was cooled to room temperature, acidified with HCl 1N until pH=1, and directly purified by reverse-phase flash chromatography using acidic conditions (elution from CHCN / HO+0.1% FA 5:95+0.1% FA to CHCN / HO+0.1% FA 35:65) to give the product of formula 2-[2-(4,4-difluoropiperidine-1-carbonyl)-5-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]thiazole-4-carboxylic acid. Yield: 6mg 1 H NMR(400MHz,DMSO) δ13.86(s,1H),8.71-8.30(m,2H),8.14(dd,1H),7.50(d,1H),4.17-4.03(m,1H),3.52-3.29(m,3H),2.45(s,3H),2.31-1.78(m,4H). [ka]

[0338] Step 1 Compounds of formula II can be obtained from compounds of formula I (commercially available from Enamine) by coupling with 4,4-difluoropiperidine hydrochloride in the presence of a coupling agent such as HATU and an organic base such as DIPEA. The reaction is typically carried out at room temperature in a suitable solvent such as DMF. The reaction takes about 12 hours to complete.

[0339] Step 2 Compounds of formula III can be obtained by Suzuki coupling between compounds of formula II and 1-(1-methylethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (commercially available from Enamine) in the presence of a suitable precatalyst, such as XPhos Pd G2, a suitable base, such as K3PO4, in a suitable solvent, such as a 1,2-dimethoxyethane / water mixture, typically at 95° C. The reaction takes about 3 hours to complete.

[0340] Step 3 Compounds of formula IV can be obtained by Stille coupling reaction between compounds of formula III and an appropriate THP-protected stannane in a suitable solvent, such as 1,4-dioxane, in the presence of a suitable palladium precatalyst, such as palladium tri-tert-butylphosphine, a suitable base, such as CsF, typically at 100° C. The reaction takes about 3 to about 5 hours to complete.

[0341] Step 4 Compound V can be obtained from compound of formula IV by removing the THP protecting group under acidic conditions, for example, HCl 6N solution, typically at 50° C. The reaction takes about 3 hours to complete.

[0342] Scheme 9. Preparation of compound (II): (2-bromo-4-chlorophenyl)-(4,4-difluoropiperidin-1-yl)methanone [ka] To a solution of HATU (1.45 g, 3.82 mmol), 2-bromo-4-chlorobenzoic acid (600.0 mg, 2.55 mmol), and N,N-diisopropylethylamine (2.66 mL, 15.29 mmol) in DMF (16.99 mL) was added 4,4-difluoropiperidine hydrochloride (481.89 mg, 3.06 mmol). The reaction was stirred at room temperature overnight. The next day, saturated NaHCO3 solution was added to the reaction mixture, and the aqueous phase was extracted with EtOAc (3 times). The organic portion was collected and washed with brine. Residual water was removed by adding Na2SO4, and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (eluting with 100% cHex to 30:70 cHex:AcOEt) to give the product of formula (2-bromo-4-chlorophenyl)-(4,4-difluoropiperidin-1-yl)methanone. Yield: 715mg 1 H NMR(400MHz,DMSO) δ7.87(d,1H),7.58(dd,1H),7.48(d,1H),3.86(dt,1H),3.66(ddd,1H),3.24(t,2H),2.31-1.85(m,4H);LC-MS:m / z 338.00,340.03(MH+).

[0343] Scheme 9. Preparation of compound (III): [4-chloro-2-(1-propan-2-ylpyrazol-3-yl)phenyl]-(4,4-difluoropiperidin-1-yl)methanone [ka] In a suitable vial, a mixture of X-phos aminobiphenyl palladium chloride precatalyst (162.46 mg, 0.210 mmol), tripotassium phosphate (1316.58 mg, 6.2 mmol), (2-bromo-4-chlorophenyl)-(4,4-difluoropiperidin-1-yl)methanone (700.0 mg, 2.07 mmol), and 1-(1-methylethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (390.53 mg, 1.65 mmol) in water (0.952 mL) and 1,2-dimethoxyethane (14.95 mL) was degassed by bubbling N for 10 minutes. The mixture was then subjected to a N-vacuum cycle and then stirred at 95 °C for 3 hours. After this time, the reaction was cooled to room temperature. Water was added to the mixture, and the aqueous phase was extracted with AcOEt three times. The organic phases were combined, washed with brine, dried over Na2SO4, and concentrated under vacuum. The residue was purified by flash chromatography on silica gel (eluting with 100% cHex to 40:60 cHex: EtOAc) to obtain the product of formula [4-chloro-2-(1-propan-2-ylpyrazol-3-yl)phenyl]-(4,4-difluoropiperidin-1-yl)methanone. Yield: 450 mg, 1 H NMR(400MHz,DMSO-d6) δ7.84(d,1H),7.76(d,1H),7.45(dd,1H),7.34(d,1H),6.55(d,1H),4.51(hept,1H) ,3.82-3.61(m,2H),3.24-3.02(m,2H),2.16-1.72(m,4H),1.43(dd,6H);LC-MS:m / z 368.36(MH+).

[0344] Scheme 9, Preparation of compound (IV)*a: (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-[1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazol-3-yl]phenyl]methanone [ka] Palladium tritert-butylphosphine (4.42 mg, 0.010 mmol) and cesium fluoride (72.21 mg, 0.480 mmol) were placed in an appropriate vial and subjected to three N2-vacuum cycles. A solution of trimethyl-[1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazol-3-yl]stannane (283.73 mg, 0.260 mmol) and [4-chloro-2-(1-propan-2-ylpyrazol-3-yl)phenyl]-(4,4-difluoropiperidin-1-yl)methanone (85.0 mg, 0.220 mmol) in 1,4-dioxane (3 mL) was then added. The resulting suspension was degassed by bubbling N2 for 5 minutes, followed by five N2-vacuum cycles. The mixture was stirred at 100 °C for 4 hours. After this time, the mixture was cooled to room temperature, diluted with EtOAc, filtered through a pad of Celite, washed with EtOAc, and concentrated under high vacuum. The crude material was purified by reverse-phase flash chromatography using acidic conditions (elution from 5:95 CHCN / HO + 0.1% HCOOH to 65:35 CHCN / HO + 0.1% HCOOH) to give the product of formula (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-[1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazol-3-yl]phenyl]methanone. Yield: 51 mg 1 H NMR (400 MHz, DMSO) δ7.98(dd,1H),7.90-7.81(m,1H),7.63-7.53(m,1H),7.49(dd,1H),7.12(d, 1H),6.54(t,1H),5.46-5.37(m,1H),4.52(p,1H),4.11-3.95(m,1H),3.89-3. 76(m,1H),3.75-3.49(m,2H),3.26-3.21(m,1H),3.21-3.11(m,1H),2.43-2.3 5(m,1H),2.18-1.80(m,5H),1.74-1.47(m,5H),1.47-1.33(m,6H);LC-MS:m / z 552.29(MH+)

[0345] Scheme 9, Preparation of compound (IV)*b: (4,4-Difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-(5-isopropyl-1-tetrahydropyran-2-yl-pyrazol-3-yl)phenyl]methanone [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of the compound (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-[1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazol-3-yl]phenyl]methanone, and instead of trimethyl-[1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazol-3-yl]stannane, (5-isopropyl-1-tetrahydropyran-2-yl-pyrazol-3-yl)-trimethyl-stannane was used. The title compound was obtained in a yield of 59% (55 mg). 1 H NMR(400MHz,DMSO) δ8.07(d,1H),7.85(d,1H),7.80(d,1H),7.32(d,1H),6.70(s,1H),6.54 (d,1H),5.45(d,1H),4.54(p,1H),3.97-3.80(m,2H),3.76-3.62(m,1H), 3.62-3.51(m,1H),3.15-3.04(m,2H),2.45-2.36(m,1H),2.15-2.01(m, 3H),1.98-1.67(m,6H),1.64-1.51(m,5H),1.48-1.39(m,8H);LC-MS:m / z 526.33(MH+).

[0346] Scheme 9, Preparation of compound (IV)*c: (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-1-tetrahydropyran-2-yl-pyrazol-3-yl)phenyl]methanone [ka] The synthesis of the title compound was carried out in the same manner as the synthesis of the compound (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-[1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazol-3-yl]phenyl]methanone, and instead of trimethyl-[1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazol-3-yl]stannane, trimethyl-[5-methyl-1-tetrahydropyran-2-yl-pyrazol-3-yl]stannane was used. The title compound was obtained in a yield of 40% (24 mg). 1 H NMR(400MHz,DMSO) δ8.05(d,1H),7.84(d,1H),7.77(d,1H),7.32(d,1H),6.65(s,1H),6.51(d,1H),5.43(d,1H),4.53(p,1H),3.92(d,2H),3.69( d,1H),3.57(s,1H),3.23-3.04(m,2H),2.40-2.31(m,3H),2.12-2.01(m,2H),1.97-1.51(m,7H),1.46-1.42(m,7H);LC-MS:m / z 498.49(MH+).

[0347] Scheme 9, Preparation of compound (V)*a: (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-[5-(trifluoromethyl)-1H-pyrazol-3-yl]phenyl]methanone [ka] Example 84 To a solution of (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-[1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazol-3-yl]phenyl]methanone (50.0 mg, 0.090 mmol) in ethanol (2 mL) was added 6N aqueous HCl (45.33 μL, 0.270 mmol). The mixture was stirred at 60° C. for 2 hours. After this time, the reaction mixture was cooled to room temperature, saturated NaHCO3 solution was added, and the mixture was extracted with EtOAc (3 times). The organic portions were combined, washed with brine, dried over Na2SO4, and concentrated in vacuo. The crude material was purified by reverse-phase flash chromatography using acidic conditions (elution from 5:95 CHCN / HO+0.1% HCOOH to 55:45 CHCN / HO+0.1% HCOOH) to give the product of formula (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-[5-(trifluoromethyl)-1H-pyrazol-3-yl]phenyl]methanone. Yield: 20 mg 1 H NMR(400MHz,DMSO) δ14.19(s,1H),8.15(d,1H),7.87(d,1H),7.82(dd,1H),7.42(d,1H),7.33(s,1H),6.62(d,1H),4 .52(hept,1H),3.86-3.58(m,2H),3.23-3.07(m,2H),2.17-1.75(m,3H),1.44(dd,7H);LC-MS:m / z 468.22(MH+).

[0348] Preparation: (4,4-Difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-(5-isopropyl-1H-pyrazol-3-yl)phenyl]methanone [ka] Example 85 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound (4,4-difluoro-1-piperidyl) - [2- (1-isopropylpyrazol-3-yl) -4- [5- (trifluoromethyl) -1H-pyrazol-3-yl] phenyl] methanone in Example 84, and (4,4-difluoro-1-piperidyl) - [2- (1-isopropylpyrazol-3-yl) -4- [1-tetrahydropyran-2-yl-5- (trifluoromethyl) pyrazol-3-yl] phenyl] methanone was used instead of (4,4-difluoro-1-piperidyl) - [2- (1-isopropylpyrazol-3-yl) -4- (5-isopropyl-1-tetrahydropyran-2-yl-pyrazol-3-yl) phenyl] methanone. The title compound was obtained in a yield of 40% (15 mg). 1 H NMR(400MHz,DMSO) δ12.67(s,1H),8.07(s,1H),7.84(d,1H),7.76(d,1H),7.30(d,1H),6.56(d,2H),4.52(hept,1H),3.95-3. 79(m,1H),3.65-3.57(m,1H),3.23-2.92(m,3H),2.18-1.72(m,3H),1.44(dd,7H),1.28(d,6H);LC-MS:m / z 442.48(MH+).

[0349] Preparation: (4,4-Difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-1H-pyrazol-3-yl)phenyl]methanone [ka] Example 86 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound (4,4-difluoro-1-piperidyl) - [2- (1-isopropylpyrazol-3-yl) -4- [5- (trifluoromethyl) -1H-pyrazol-3-yl] phenyl] methanone in Example 84, (4,4-difluoro-1-piperidyl) - [2- (1-isopropylpyrazol-3-yl) -4- [1-tetrahydropyran-2-yl-5- (trifluoromethyl) pyrazol-3-yl] phenyl] methanone instead of (4,4-difluoro-1-piperidyl) - [2- (1-isopropylpyrazol-3-yl) -4- (5-methyl-1-tetrahydropyran-2-yl) pyrazol-3-yl) phenyl] methanone was used. The title compound was obtained in a yield of 66% (14 mg). 1 H NMR(400MHz,DMSO) δ12.63(s,1H),8.07(s,1H),7.84(d,1H),7.74(d,1H),7.30(d,1H),6.53(d,2H),4.52(hept,1H),3.92-3. 75(m,1H),3.73-3.52(m,1H),3.24-3.06(m,2H),2.29(s,3H),2.15-1.71(m,3H),1.44(dd,7H);LC-MS:m / z 414.47(MH+). [ka]

[0350] Step 1 The compound of formula II can be obtained by Stille coupling reaction between the compound of formula I (synthesized according to Scheme 9) and trimethyl-[2-[(5-methyl-2-trimethylstannyl-imidazol-1-yl)methoxy]ethyl]silane in a suitable solvent, such as 1,4-dioxane, in the presence of a suitable catalyst, such as palladium tri-tert-butylphosphine, a suitable base, such as CsF, typically at 100° C. The reaction takes about 5 hours to complete.

[0351] Step 2 Compounds of formula III can be obtained from compounds of formula II by removing the SEM protecting group under acidic conditions, for example, HCl 6N solution, typically at 75° C. The reaction takes about 16 hours to complete.

[0352] Scheme 10, Preparation of compound (II)*a: (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-[5-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-2-yl]phenyl]methanone and (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-[4-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-2-yl]phenyl]methanone [ka] An appropriate vial was charged with tri-tert-butylphosphine palladium (3.21 mg, 0.010 mmol) and cesium fluoride (69.96 mg, 0.460 mmol) and subjected to three N2-vacuum cycles. A solution of trimethyl-[2-[(5-methyl-2-trimethylstannyl-imidazol-1-yl)methoxy]ethyl]silane / trimethyl-[2-[(4-methyl-2-trimethylstannyl-imidazol-1-yl)methoxy]ethyl]silane (78.54 mg, 0.210 mmol) and [4-chloro-2-(1-propan-2-ylpyrazol-3-yl)phenyl]-(4,4-difluoropiperidin-1-yl)methanone (77.0 mg, 0.210 mmol) in 1,4-dioxane (2.093 mL) was then added. The resulting suspension was degassed by bubbling N for 5 min, followed by five cycles of N-vacuum. The mixture was stirred at 100° C. for 5 h. After this time, the mixture was cooled to room temperature, diluted with EtOAc, filtered over a pad of Celite, washed with EtOAc, and concentrated under high vacuum. The crude material was purified by reverse-phase flash chromatography using acidic conditions (elution from 5:95 CHCN / HO + 0.1% HCOOH to 45:55 CHCN / HO + 0.1% HCOOH) to give the products of formula (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-[5-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-2-yl]phenyl]methanone and (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-[4-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-2-yl]phenyl]methanone as a mixture of regioisomers. The mixture of regioisomers was used in the next step without further purification. Yield: 18mg LC-MS: m / z 544.57(MH+).

[0353] Scheme 10, Preparation of compound (III)*a: (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-1H-imidazol-2-yl)phenyl]methanone [ka] Example 87 To a solution of (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-[5-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-2-yl]phenyl]methanone / (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-[4-methyl-1-(2-trimethylsilylethoxymethyl)imidazol-2-yl]phenyl]methanone (mixture of regioisomers) (17.0 mg, 0.030 mmol) in ethanol (1 mL) was added 6N aqueous HCl (15.63 μL, 0.090 mmol). The mixture was stirred at 75° C. for 16 hours. After this time, the mixture was cooled, saturated NaHCO solution was added to the solution, and the mixture was extracted with EtOAc (3 times). The organic portions were combined, washed with brine, dried over NaSO, and concentrated in vacuo. The crude material was purified by reverse-phase flash chromatography using acidic conditions (elution from 5:95 CHCN / HO+0.1% HCOOH to 30:70 CHCN / HO+0.1% HCOOH) to give the product of formula (4,4-difluoro-1-piperidyl)-[2-(1-isopropylpyrazol-3-yl)-4-(5-methyl-1H-imidazol-2-yl)phenyl]methanone. Yield: 8mg 1 H NMR(400MHz,DMSO) δ12.18(d,1H),8.01(d,1H),7.82(d,1H),7.69-7.57(m,2H),7.28(d,1H),6.45(d,1H),4.52(hept,1H),3.98 -3.80(m,1H),3.68-3.48(m,1H),3.23-3.07(m,2H),2.45(s,3H),2.16-1.71(m,3H),1.44(dd,7H);LC-MS:m / z 414.28(MH+). [ka]

[0354] Step 1 Compounds of formula II can be obtained by Suzuki coupling between compounds of formula I (synthesized according to Scheme 3) and the desired boronic ester, such as 2-(cyclopenten-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, in the presence of a suitable catalyst, such as palladium tetrakistriphenylphosphine, a suitable base, such as Na2CO3, and in a suitable solvent, such as a mixture of toluene / ethanol / water, typically at 100° C. The reaction takes about 2 to 12 hours to complete.

[0355] Step 2 Compounds of formula III can be obtained by reducing the double bond of compounds of formula II under catalytic hydrogenation conditions, typically using Pd / C in a suitable solvent such as ethanol at room temperature. The reaction takes about 2 hours to complete.

[0356] Preparation: N-[3-(cyclopenten-1-yl)-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide [ka] Example 88 Palladium tetrakistriphenylphosphine (11.55 mg, 0.010 mmol), sodium carbonate (369.78 mg, 3.49 mmol), and 2-(cyclopenten-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (96.73 mg, 0.500 mmol) were sequentially added to the vial. The solid was suspended in a mixture of ethanol (1.7 mL), toluene (1.7 mL), and water (0.500 mL), and the resulting suspension was degassed using a shlenk line. N-[3-bromo-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide (200.0 mg, 0.500 mmol) was added under nitrogen flux. The mixture was again degassed and heated to 100 °C for 2 h. After this time, the reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc. The organic layers were collected together, washed with brine, dried over NaSO, filtered, and the solvent removed under vacuum. The crude material was purified by reverse-phase flash chromatography using acidic conditions (elution from 5:95 CHCN / HO + 0.1% HCOOH to 40:60 CHCN / HO + 0.1% HCOOH) to give the product of formula N-[3-(cyclopenten-1-yl)-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide. Yield: 23 mg 1 H NMR(400MHz,DMSO-d6) δ10.31(s,1H),7.61(d,1H),7.56(dd,1H),7.28(d,1H),5.88(p,1H),4.28(s,1H),3.73(s,1H),3.47(d,3H),3.14( LC-MS:m / z 389.2(MH+).

[0357] Preparation: N-[3-(cyclopenten-1-yl)-4-(4-methyl-2-phenylpiperazine-1-carbonyl)phenyl]cyclopropanecarboxamide [ka] Example 89 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[3-(cyclopenten-1-yl)-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide in Example 88, except that N-[3-bromo-4-(4-methyl-2-phenylpiperazine-1-carbonyl)phenyl]cyclopropanecarboxamide was used instead of N-[3-bromo-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide. The title compound was obtained in a yield of 51% (30 mg). 1 H NMR(400MHz,DMSO-d6) δ10.42-10.17(m,1H),7.70-7.53(m,3H),7.50-6.93(m,5H),6.16-4.25(m,2H),3.5 3-3.33(m,1H),3.09-2.50(m,5H),2.38-1.51(m,10H),0.92-0.70(m,4H);LC-MS:m / z 430.27(MH+).

[0358] Preparation: N-[3-cyclopentyl-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide [ka] Example 90 A mixture of N-[3-(cyclopenten-1-yl)-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide (23.0 mg, 0.060 mmol) and Pd—C 10% (6.3 mg, 0.010 mmol) in MeOH (5 mL) was stirred under a H atmosphere (1 atm) at room temperature for 2 hours. After this time, the reaction was filtered and concentrated in vacuo. The residue was purified by reverse-phase flash chromatography using acidic conditions (elution from 5:95 CHCN / HO + 0.1% HCOOH to 60:40 CHCN / HO + 0.1% HCOOH) to give the product of formula N-[3-cyclopentyl-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide. Yield: 7.6 mg 1 H NMR(400MHz,DMSO-d6) δ10.24(s,1H),7.63(d,1H),7.48(dd,1H),7.26(d,1H),4.46(d,1H),3.71-3.44(m,3H),3.20(d,3H) ,2.93(p,2H),1.94(dt,2H),1.75(td,3H),1.61(q,2H),1.47(dq,2H),0.84-0.74(m,4H);LC-MS:m / z 391.5(MH+).

[0359] Preparation: N-[3-cyclopentyl-4-(4-methyl-2-phenylpiperazine-1-carbonyl)phenyl]cyclopropanecarboxamide [ka] Example 91 The synthesis of the title compound was carried out in the same manner as the synthesis of the compound N-[3-cyclopentyl-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide in Example 90, except that N-[3-(cyclopenten-1-yl)-4-(4-methyl-2-phenylpiperazine-1-carbonyl)phenyl]cyclopropanecarboxamide was used instead of N-[3-(cyclopenten-1-yl)-4-(1,1-dioxo-1,4-thiazinane-4-carbonyl)phenyl]cyclopropanecarboxamide. The title compound was obtained in a yield of 54% (16 mg). 1 H NMR(400MHz,DMSO-d6) δ10.22(s,1H),7.76-7.53(m,3H),7.50-7.07(m,5H),5.95-4.29(m,1H),3.53-3.40(m,1H ),3.22-2.62(m,4H),2.42-2.13(m,4H),2.07-1.10(m,10H),0.86-0.70(m,4H);LC-MS:m / z 432.29(MH+) [ka]

[0360] Step 1 Compounds of formula II can be obtained from compounds of formula I (commercially available from Combi-Blocks) by the Mitsunobu-Tsunoda reaction in the presence of the desired alcohol. The reaction is typically carried out at 150°C in a suitable solvent, such as 1,4-dioxane, under microwave irradiation. The reaction takes about 30 minutes to complete. Alternatively, compounds of formula II can be obtained by N-alkylation of compounds of formula I with a suitable electrophile, such as an appropriate tosylate, in a suitable solvent, such as DMF, in the presence of a suitable base, such as NaH, typically at 50°C. The reaction takes about 12 hours to complete.

[0361] Step 2 Compounds of formula III can be obtained by Miyaura borylation between compounds of formula II and B2Pin2 in the presence of a suitable transition metal catalyst, such as Pd(dppf)Cl2, a suitable base, such as potassium acetate, in a suitable solvent, such as 1,4-dioxane, typically at 100° C. The reaction takes about 12 hours to complete.

[0362] Step 3 Compounds of formula III can be obtained from compounds of formula IV (commercially available from Activate Scientific) by Mitsunobu-Tsunoda reaction using the desired alcohol in 1',4-dioxane under microwave irradiation at 150° C. The reaction takes about 30 minutes to complete.

[0363] Scheme 12, Preparation of compound (II)*a: 1-cyclobutyl-3-iodopyrazole [ka] A mixture of 3-iodo-1H-pyrazole (1.0 g, 5.16 mmol), cyclobutanol (371.76 mg, 5.16 mmol), and 2-tributylphosphoranylideneacetonitrile (2.7 mL, 10.31 mmol) in 1,4-dioxane (17.78 mL) was stirred at 150° C. for 30 minutes under microwave irradiation. The mixture was diluted with water (20 mL) and extracted with EtOAc. The organic phase was washed with brine, dried over NaSO, filtered, and then concentrated under high vacuum. The crude material was purified by flash chromatography on silica gel (eluting with 100% cHex to 90:10 cHex / EtOAc) to give the product of formula 1-cyclobutyl-3-iodopyrazole. Yield: 295mg. 1 H NMR(400MHz,DMSO-d6) δ ppm 7.27(d,1H),6.40(d,1H),4.82-4.70(m,1H),2.61-2.39(m,4H),1.95-1.79(m,2H);LC-MS:m / z 249.06(MH+).

[0364] Scheme 12, Preparation of compound (II)*b: 1-(1-cyclopropylethyl)-3-iodopyrazole [ka] The synthesis of the title compound was carried out similarly to the synthesis of the compound 1-cyclobutyl-3-iodopyrazole, except that 1-cyclopropylethanol was used instead of cyclobutanol. The title compound was obtained in a yield of 44% (877 mg). 1 H NMR(400MHz,DMSO-d6) δ ppm 7.56(dd,1H),6.43(t,1H),3.81(dq,1H),1.46(dd,3H),1.40-1.29(m,1H),0.62-0.22(m,4H);LC-MS:m / z 263.1(MH+).

[0365] Scheme 12, Preparation of compound (II)*c: 1-tert-butyl-3-iodopyrazole [ka] To a solution of 3-iodo-1H-pyrazole (1.0 g, 5.16 mmol) in 2-methyl-2-propanol (5.08 mL, 53.1 mmol) was added 95-97% H2SO4 (0.35 mL, 6.19 mmol). The mixture was stirred at 100 °C overnight. After this time, the mixture was diluted with saturated NaHCO3 solution until pH = 7 and extracted with EtOAc. The organic phase was washed with brine, dried over Na2SO4, and concentrated to give the crude material, which was purified by flash chromatography on silica gel (eluting with 100% cHex to 80:20 cHex / EtOAc) to give the product of formula 1-tert-butyl-3-iodopyrazole. Yield: 713 mg. 1H NMR(400MHz,DMSO-d6) δppm 7.73(d,1H),6.43(d,1H),1.49(s,9H);LC-MS:m / z 251.00(MH+).

[0366] Scheme 12, Preparation of compound (II)*d: 3-iodo-1-(oxetan-3-yl)pyrazole [ka] To a solution of 3-iodo-1H-pyrazole (0.51 g, 2.63 mmol) in DMF (10 mL) was added sodium hydride (0.42 g, 10.52 mmol) at 0 °C, and the reaction was stirred at the same temperature for 10 minutes. After this, oxetan-3-yl 4-methylbenzenesulfonate (0.9 g, 3.94 mmol) was added. The reaction was allowed to reach room temperature and then stirred at 50 °C overnight. After this, the mixture was diluted with water and extracted with EtOAc. The organic phase was washed with brine, dried over Na SO , and concentrated under reduced pressure. The crude was purified by flash chromatography on an NH column (eluting with 100% cHex to 90:10 cHex / EtOAc) to give the product of formula 3-iodo-1-(oxetan-3-yl)pyrazole. Yield: 445mg. 1 H NMR(400MHz,DMSO-d6) δ ppm 7.80(d,1H),6.52(d,1H),5.57(tt,1H),4.91-4.81(m,4H);LC-MS:m / z 251.12(MH+).

[0367] Preparation: Oxetan-3-yl 4-methylbenzenesulfonate [ka] To a solution of 3-oxetanol (1.0 g, 13.5 mmol) in DCM (20 mL) was added pyridine (2.17 mL, 27 mmol), followed by DMAP (0.33 g, 2.7 mmol) and 4-methylbenzenesulfonyl chloride (2.83 g, 14.85 mmol). The reaction was stirred at room temperature overnight. After this time, the mixture was diluted with 1N aqueous HCl and extracted with DCM. The organic phase was washed with saturated NaHCO3 solution. The organic phase was dried and concentrated using a phase separator to give the crude material, which was purified by flash chromatography on silica gel (eluting with 100% cHex to 80:20 cHex / EtOAc) to give the product of formula oxetan-3-yl 4-methylbenzenesulfonate. Yield: 1.96g. 1 H NMR(400MHz,DMSO-d6) δ ppm 7.80(d,2H),7.49(d,2H),5.39-5.31(m,1H),4.71-4.63(m,2H),4.49-4.37(m,2H),2.42(s,3H);LC-MS:m / z 229.07(MH+).

[0368] Scheme 12, Preparation of compound (III)*a: 1-cyclobutyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole [ka] A mixture of 1-cyclobutyl-3-iodopyrazole (290.0 mg, 1.17 mmol), 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolane (356.25 mg, 1.4 mmol), potassium acetate (401.56 mg, 4.09 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane (382.82 mg, 0.470 mmol) in 1,4-dioxane (5 mL) was degassed with N for 5 minutes, followed by three vacuum / N cycles. The reaction was stirred at 100 °C overnight. The next day, the mixture was cooled to room temperature and diluted with water. The mixture was extracted three times with EtOAc. The combined organic fractions were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to give the product of formula 1-cyclobutyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (see Scheme 12, compound (III)*a). The product was used directly in the next step. Yield: 314.6 mg LC-MS: m / z 167.06 (MH+) mass of boronic acid.

[0369] Scheme 12, Preparation of compound (III)*b: 1-(1-cyclopropylethyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole [ka] The synthesis of the title compound was carried out in the same manner as in the synthesis of the compound (III)*a, 1-cyclobutyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole, except that 1-(1-cyclopropylethyl)-3-iodopyrazole was used instead of 1-cyclobutyl-3-iodopyrazole. The title compound was obtained in a yield of 76% (459 mg). 1H NMR(400MHz,DMSO-d6) δ ppm 7.79(d,1H),6.58(d,1H),4.20-4.09(m,1H),1.55-1.43(m,3H),1.25-1.20(m,1H),1.07(s,12H),0.63-0.17(m,4H);LC-MS:m / z 181.1(MH+) Mass of boronic acid.

[0370] Scheme 12, Preparation of compound (III)*c: 1-tert-butyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole [ka] The synthesis of the title compound was carried out in the same manner as in the synthesis of the compound (III)*a, 1-cyclobutyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole, except that 1-tert-butyl-3-iodopyrazole was used instead of 1-cyclobutyl-3-iodopyrazole. The title compound was obtained in quantitative yield (472 mg). LC-MS: m / z 167.06 (MH+) mass of boronic acid.

[0371] Scheme 12, Preparation of compound (III)*d: 1-(oxetan-3-yl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole [ka] The synthesis of the title compound was carried out in the same manner as in the synthesis of the compound (III)*a, 1-cyclobutyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole, except that 3-iodo-1-(oxetan-3-yl)pyrazole was used instead of 1-cyclobutyl-3-iodopyrazole. The title compound was obtained in quantitative yield (228 mg). LC-MS: m / z 247.18(MH+)

[0372] Scheme 12, Preparation of compound (III)*e: 1-(2-methylpropyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole [ka] A mixture of 2-methyl-1-propanol (0.57 mL, 6.18 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (1.2 g, 6.18 mmol), and 2-tributylphosphoranidolene acetonitrile (3.24 mL, 12.37 mmol) in 1,4-dioxane (12 mL) was stirred under microwave irradiation at 150° C. for 30 minutes. The reaction mixture was cooled to room temperature, diluted with water, and extracted with EtOAc (3×). The organic layers were collected together, washed with brine, dried over Na2SO4, filtered, and the solvent was removed under vacuum to give the product of formula 1-(2-methylpropyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole, which was used in the next step without further purification (see Scheme 12, compound (III)*e). Yield: 1g. 1 H NMR (400 MHz, MeOD) δ ppm 7.48 (d, 1H), 6.68 (d, 1H), 4.21 (d, 2H), 2.13 (dp, 1H), 1.35 (s, 12H), 0.86 (d, 6H); LC-MS: m / z 169.0 (MH+) mass of boronic acid.

[0373] Scheme 12, Preparation of compound (III)*f: 1-ethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole [ka] The synthesis of the title compound was carried out in the same manner as in the synthesis of the compound (III)*e, 1-(2-methylpropyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole, except that ethanol was used instead of 2-methyl-1-propanol. The title compound was obtained in quantitative yield (2.99 g). LC-MS: m / z 141.01 (MH+) mass of boronic acid. [ka]

[0374] Step 1 Compounds of formula II can be obtained by N-protecting compounds of formula I with 3,4-dihydro-2H-pyran in the presence of a catalytic amount of 4-toluenesulfonic acid in a suitable solvent, such as DCM, typically at room temperature, and the reaction takes about 12 hours to complete.

[0375] Step 2 Compounds of formula III can be obtained from compounds of formula II by reaction with trimethyl(trimethylstannyl)stannane in the presence of a suitable catalyst, such as palladium tetrakistriphenylphosphine, and a suitable solvent, such as toluene, typically at 100° C. The reaction takes about 1 to 20 hours to complete.

[0376] Scheme 13, Preparation of compound (II)*a: 3-bromo-1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazole [ka] To a stirred solution of 3-bromo-5-(trifluoromethyl)-1H-pyrazole (200.0 mg, 0.930 mmol) in DCM (9.304 mL) was added 3,4-dihydro-2H-pyran (126.5 μL, 1.4 mmol) and 4-toluenesulfonic acid (16.02 mg, 0.090 mmol). The mixture was stirred at room temperature overnight. After this time, the mixture was washed with saturated NaHCO solution, and the aqueous phase was back-extracted with DCM. The organic phases were combined, washed with brine, dried over a phase separator, and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel (eluting with 100% cHex to 85:15 cHex / EtOAc) to give the product of formula 3-bromo-1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazole (see Scheme 13, compound (II)*a). Yield: 218mg 1 H NMR(400MHz,DMSO-d6) δ7.14(d,1H),5.59(dd,1H),3.98-3.87(m,1H),3.72-3.58(m,1H),2.30 -2.15(m,1H),2.04-1.86(m,2H),1.81-1.64(m,1H),1.60-1.50(m,2H).

[0377] Scheme 13, Preparation of compound (II)*b: 3-iodo-1-(oxan-2-yl)-5-propan-2-ylpyrazole [ka] The synthesis of the title compound was carried out in the same manner as in the synthesis of the compound 3-bromo-1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazole in Scheme 13, Compound (II)*a, except that 3-iodo-5-propan-2-yl-1H-pyrazole was used instead of 3-bromo-5-(trifluoromethyl)-1H-pyrazole. The title compound was obtained in a yield of 94% (320 mg). LC-MS: m / z 321.07

[0378] Scheme 13, Preparation of compound (II)*c: 3-iodo-5-methyl-1-(oxan-2-yl)pyrazole [ka] The synthesis of the title compound was carried out in the same manner as in the synthesis of the compound 3-bromo-1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazole in Scheme 13, Compound (II)*a, except that 3-iodo-5-propan-2-yl-1H-pyrazole was used instead of 3-bromo-5-(trifluoromethyl)-1H-pyrazole. The title compound was obtained in a yield of 79% (560 mg). LC-MS: m / z 293.14 (MH+).

[0379] Scheme 13, Preparation of compound (III)*a: Trimethyl-[1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazol-3-yl]stannane [ka] In an appropriate vial, trimethyl(trimethylstannyl)stannane (178.87 uL, 0.860 mmol), 3-bromo-1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazole (215.0 mg, 0.720 mmol, see Scheme 13, compound (II)*a), and palladium tetrakistriphenylphosphine (16.61 mg, 0.010 mmol) were suspended in toluene (5 mL). The mixture was degassed by bubbling N for 5 minutes, followed by five cycles of N-vacuum. The mixture was stirred at 100 °C for 20 hours. After this time, the reaction was cooled to room temperature, filtered, and concentrated in vacuo. The residue was dissolved in EtOAc and washed with water. The aqueous phase was back-extracted with EtOAc (2 times). The combined organic portions were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo to give the product of formula trimethyl-[1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazol-3-yl]stannane, which was used in the next step without further purification. Yield: 270mg LC-MS: m / z 385.11 (MH+).

[0380] Scheme 13, Preparation of compound (III)*b: (5-isopropyl-1-tetrahydropyran-2-yl-pyrazol-3-yl)-trimethyl-stannane [ka] The synthesis of the title compound was carried out in the same manner as in the synthesis of the compound 3-bromo-1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazole of Scheme 13, Compound (II)*a, except that 3-iodo-1-(oxan-2-yl)-5-propan-2-ylpyrazole was used instead of 3-bromo-1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazole. The title compound was obtained in a yield of 83% (250 mg). LC-MS: m / z 359.18(MH+).

[0381] Scheme 13, Preparation of compound (III)*c: Trimethyl-(5-methyl-1-tetrahydropyran-2-yl-pyrazol-3-yl)stannane [ka] The synthesis of the title compound was carried out in the same manner as in the synthesis of the compound 3-bromo-1-tetrahydropyran-2-yl-5-(trifluoromethyl)pyrazole in Scheme 13, Compound (II)*a, except that 3-iod...

Claims

1. A compound of formula (IA), or a pharma- ceutically acceptable salt thereof, 【Chemistry 1】 During the ceremony, X 1 is selected from the group consisting of: 【Chemistry 2】 n a is an integer selected from the group of 0, 1, and 2; n b is an integer selected from the group of 0, 1, 2, 3, and 4, However, n a +n b The total must be between 2 and 4, or Or X 1 and Z 1 taken together form a fused ring system of formula (Ia) 【Chemistry 3】 R a is hydrogen and C 1 -C 3 is selected from the group of alkyl, X 2 is selected from the group consisting of: 【Chemistry 4】 Wavy lines in each case 【Chemistry 5】 But each X 1 and X 2 represents the bond to which the moiety is attached, Y 1 is selected from the group of C and N; Y 2 is selected from the group of C, N, S, and O, with the proviso that Y 2 When is O, R 4 does not exist, and Y 2 If S, then R 4 is absent or present one or two times, However, Y 1 and Y 2 Provided that two or more of the above are not C, n c is an integer selected from the group of 1, 2, and 3; n d is an integer selected from the group of 1, 2, and 3, However, n c +n d The total of the above must be between 2 and 6. Z 1 , Z 2 , and Z 3 are each independently selected from the group of C and N, with the proviso that Z 1 , Z 2 , and Z 3 But, R 2 or non-hydrogen R 2’ provided that, when it is bonded to, it is C; R 1 But, C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -NR x R y , phenyl, and benzyl; 1 -C 6 Alkyl groups, and the -(CH 2 ) n1 -C 3 -C 6 The rings of cycloalkyl, phenyl, and benzyl groups are free of halogen, OH, CF 3 , and -O-C 1 -C 3 substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl, R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 is selected from the group of alkyl, n1 is an integer selected from the group consisting of 0, 1, 2, and 3; R 2 is bonded through a carbon atom and contains 3, 4, 5, 6, 7, or 8 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from the group of N, S, and O, any of the foregoing being selected from C 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -CF 3 , halogen, oxo, cyano, -O-(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)OH, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), -(CH 2 ) n1 -heterocyclyl (including monocyclic heterocyclic rings or bicyclic or spirocyclic heterocyclic ring systems containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from the group N, S, and O), and phenyl, wherein R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 alkyl, with the proviso that -(CH 2 ) n1 -C 3 -C 6 When not substituted at least once by cycloalkyl or phenyl, R 2 is not pyridinyl, R 2 ’ Hydrogen, OH, halogen, C 1 -C 6 Alkyl, and -CF 3 is selected from the group R 3 is present one or more times and is independently selected from the group consisting of: ee) hydrogen, halogen, cyano, or OH; ff) -CO 2 H or -CO 2 - (C 1 -C 6 alkyl), gg) halogen, CF 3 C is substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group consisting of , and OH; 1 -C 6 Alkyl or -O-C 1 -C 6 Alkyl, hh) phenyl, benzyl, C 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Cycloalkyl is phenyl, benzyl, C 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Each ring of the cycloalkyl group is selected from the group consisting of OH, halogen, cyano, and C. 1 -C 6 substituted by 0, 1, 2, or 3 substituents selected from alkyl, 1 -C 6 The alkyl group is a halogen, -CF 3 phenyl, benzyl, C, each of which is further substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group consisting of phenyl, benzyl, C, and OH; 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Cycloalkyl, ii) a 5- or 6-membered heterocyclic ring containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, said 5- or 6-membered heterocyclic ring being selected from the group consisting of OH, halogen, benzyl, and C; 1 -C 6 substituted by 0, 1, 2, or 3 substituents selected from alkyl, 1 -C 6 a 5- or 6-membered heterocyclic ring in which the alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen and OH; jj) 2 R 3 forms a bridge between carbon atoms, said atoms of said bridge comprising 1, 2, or 3 atoms independently selected from the group of carbon, N, O, and S; R 4 occurs once or twice and is selected from H, halogen, oxo, C 1 -C 6 Alkyl, -(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -O-(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), phenyl, benzyl, or 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are independently selected from the group of heterocyclic rings selected from the group of N, O, and S, x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from alkyl 1 -C 6 is selected from the group of alkyl, Y 2 When is carbon, R 4 But -O-C 1 -C 6 It may also be alkyl, or two R 4 may form a spirocyclic carbocycle or a spirocyclic heterocycle, The R 4 C 1 -C 6 Alkyl, -C(=O)-O-C 1 -C 6 Alkyl, and —O—C 1 -C 6 Alkyl groups, and the -(CH 2 ) n2 -C 3 -C 6 Cycloalkyl and -O-(CH 2 ) n2 -C 3 -C 6 The rings of the cycloalkyl, phenyl, and benzyl groups are each independently selected from halogen, CF 3 , OH, heterocyclic rings having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, substituted or unsubstituted phenyl, and -O-C 1 -C 3 substituted by 0, 1, 2, or 3 substituents selected from the group consisting of alkyl, R 5 But H and C 1 -C 6 alkyl, wherein R 5 C 1 -C 6 The alkyl group is a halogen, -CF 3 , -NR x R y and OH; R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 is selected from the group of alkyl, R 6 But, H, C 1 -C 6 R is an alkyl group having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, a heterocyclic ring, phenyl, and benzyl; 6 C 1 -C 6 The alkyl group is a halogen, -CF 3 , -NR x R y and OH, wherein R 6 The rings of the phenyl and benzyl groups and the heterocyclic rings are 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, halogen, -CF 3 and OH, wherein R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from alkyl 1 -C 6 is selected from the group of alkyl, A compound, or a pharma- ceutically acceptable salt thereof, wherein n2 in each instance is an integer selected from the group of 0, 1, 2, and 3.

2. A compound of formula (IB) or a pharma- ceutically acceptable salt thereof, 【Chemistry 6】 During the ceremony, X 1 is selected from the group consisting of: 【Chemistry 7】 n a is an integer selected from the group of 0, 1, and 2; n b is an integer selected from the group of 0, 1, 2, 3, and 4, However, n a +n b The total must be between 2 and 4, or Or X 1 and Z 1 taken together form a fused ring system of formula (Ia) 【Chemistry 8】 R a is hydrogen and C 1 -C 3 is selected from the group of alkyl, X 2 is selected from the group consisting of: 【Chemistry 9】 Wavy lines in each case 【Chemistry 10】 But each X 1 and X 2 represents the bond to which the moiety is attached, Y 1 is selected from the group of C and N; Y 2 is selected from the group of C, N, S, and O, with the proviso that Y 2 When is O, R 4 does not exist, and Y 2 If S, then R 4 is absent or present one or two times, However, Y 1 and Y 2 Provided that two or more of the above are not C, n c is an integer selected from the group of 1, 2, and 3; n d is an integer selected from the group of 1, 2, and 3, However, n c +n d The total of the above must be between 2 and 6. Z 1 , Z 2 , and Z 3 are each independently selected from the group of C and N, with the proviso that Z 1 , Z 2 , and Z 3 But, R 2 or non-hydrogen R 2 ', provided that C; R 1 But, C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -NR x R y , phenyl, and benzyl; 1 -C 6 Alkyl groups, and the -(CH 2 ) n1 -C 3 -C 6 The rings of cycloalkyl, phenyl, and benzyl groups are free of halogen, OH, CF 3 , and -O-C 1 -C 3 substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl, R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 is selected from the group of alkyl, n1 is an integer selected from the group consisting of 0, 1, 2, and 3; R 2 is selected from the group of phenyl, pyridinyl, and a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system bonded through a carbon atom and containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 0, 1, 2, 3, or 4 additional ring heteroatoms selected from the group of N, S, and O, any of the foregoing being selected from C 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -CF 3 , halogen, oxo, cyano, -O-(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)OH, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), -(CH 2 ) n1 -heterocyclyl (including monocyclic heterocyclic rings or bicyclic or spirocyclic heterocyclic ring systems containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from the group N, S, and O), and phenyl, wherein R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 alkyl, with the proviso that -(CH 2 ) n1 -C 3 -C 6 When not substituted at least once by cycloalkyl or phenyl, R 2 is not pyridinyl, R 2 ' is OH, halogen, C 1 -C 6 Alkyl, and -CF 3 is selected from the group R 3 is present one or more times and is independently selected from the group consisting of: kk) hydrogen, halogen, cyano, or OH; ll) -CO 2 H or -CO 2 - (C 1 -C 6 alkyl), mm) Halogen, CF 3 C is substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group consisting of , and OH; 1 -C 6 Alkyl or -O-C 1 -C 6 Alkyl, nn) phenyl, benzyl, C 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Cycloalkyl is phenyl, benzyl, C 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Each ring of the cycloalkyl group is selected from the group consisting of OH, halogen, cyano, and C. 1 -C 6 substituted by 0, 1, 2, or 3 substituents selected from alkyl, 1 -C 6 The alkyl group is a halogen, -CF 3 phenyl, benzyl, C, each of which is further substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group consisting of phenyl, benzyl, C, and OH; 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Cycloalkyl, oo) a 5- or 6-membered heterocyclic ring containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, said 5- or 6-membered heterocyclic ring being selected from the group consisting of OH, halogen, benzyl, and C; 1 -C 6 substituted by 0, 1, 2, or 3 substituents selected from alkyl, 1 -C 6 a 5- or 6-membered heterocyclic ring in which the alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen and OH; pp) 2 R 3 forms a bridge between carbon atoms, said atoms of said bridge comprising 1, 2, or 3 atoms independently selected from the group of carbon, N, O, and S; R 4 occurs once or twice and is selected from H, halogen, oxo, C 1 -C 6 Alkyl, -(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -O-(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), phenyl, benzyl, or 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are independently selected from the group of heterocyclic rings selected from the group of N, O, and S, x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from alkyl 1 -C 6 is selected from the group of alkyl, Y 2 When is carbon, R 4 But -O-C 1 -C 6 It may also be alkyl, or two R 4 may form a spirocyclic carbocycle or a spirocyclic heterocycle, The R 4 C 1 -C 6 Alkyl, -C(=O)-O-C 1 -C 6 Alkyl, and —O—C 1 -C 6 Alkyl groups, and the -(CH 2 ) n2 -C 3 -C 6 Cycloalkyl and -O-(CH 2 ) n2 -C 3 -C 6 The rings of the cycloalkyl, phenyl, and benzyl groups are each independently selected from halogen, CF 3 , OH, heterocyclic rings having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, substituted or unsubstituted phenyl, and -O-C 1 -C 3 substituted by 0, 1, 2, or 3 substituents selected from the group consisting of alkyl, R 5 But H and C 1 -C 6 alkyl, wherein R 5 C 1 -C 6 The alkyl group is a halogen, -CF 3 , -NR x R y and OH; R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 is selected from the group of alkyl, R 6 But, H, C 1 -C 6 R is an alkyl group having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, a heterocyclic ring, phenyl, and benzyl; 6 C 1 -C 6 The alkyl group is a halogen, -CF 3 , -NR x R y and OH, wherein R 6 The rings of the phenyl and benzyl groups and the heterocyclic rings are 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, halogen, -CF 3 and OH, wherein R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from alkyl 1 -C 6 is selected from the group of alkyl, A compound, or a pharma- ceutically acceptable salt thereof, wherein n2 in each instance is an integer selected from the group of 0, 1, 2, and 3.

3. A compound of formula (IC) or a pharma- ceutically acceptable salt thereof, 【Chemistry 11】 During the ceremony, X 1 is selected from the group consisting of: 【Chemistry 12】 n a is an integer selected from the group of 0, 1, and 2; n b is an integer selected from the group of 0, 1, 2, 3, and 4, However, n a +n b The total must be between 2 and 4, or Or X 1 and Z 1 taken together form a fused ring system of formula (Ia) 【Chemistry 13】 R a is hydrogen and C 1 -C 3 is selected from the group of alkyl, X 2 is selected from the group consisting of: 【Chemistry 14】 Wavy lines in each case 【Chemistry 15】 But each X 1 and X 2 represents the bond to which the moiety is attached, Y 1 is selected from the group of C and N; Y 2 is selected from the group of C, N, S, and O, with the proviso that Y 2 When is O, R 4 does not exist, and Y 2 If S, then R 4 is absent or present one or two times, However, Y 1 and Y 2 Provided that two or more of the above are not C, n c is an integer selected from the group of 1, 2, and 3; n d is an integer selected from the group of 1, 2, and 3, However, n c +n d is 2, 3, 5, or 6, Z 1 , Z 2 , and Z 3 are each independently selected from the group of C and N, with the proviso that Z 1 , Z 2 , and Z 3 But, R 2 or non-hydrogen R 2 ', provided that C; R 1 But, C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -NR x R y , phenyl, and benzyl; 1 -C 6 Alkyl groups, and the -(CH 2 ) n1 -C 3 -C 6 The rings of cycloalkyl, phenyl, and benzyl groups are free of halogen, OH, CF 3 , and -O-C 1 -C 3 substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl, R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 is selected from the group of alkyl, n1 is an integer selected from the group consisting of 0, 1, 2, and 3; R 2 is selected from the group of phenyl, pyridinyl, and a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system bonded through a carbon atom and containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 0, 1, 2, 3, or 4 additional ring heteroatoms selected from the group of N, S, and O, any of the foregoing being selected from C 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -CF 3 , halogen, oxo, cyano, -O-(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)OH, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), -(CH 2 ) n1 -heterocyclyl (including monocyclic heterocyclic rings or bicyclic or spirocyclic heterocyclic ring systems containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from the group N, S, and O), and phenyl, wherein R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 alkyl, with the proviso that -(CH 2 ) n1 -C 3 -C 6 When not substituted at least once by cycloalkyl or phenyl, R 2 is not pyridinyl, R 2 ' is hydrogen, OH, halogen, C 1 -C 6 Alkyl, and -CF 3 is selected from the group R 3 is present one or more times and is independently selected from the group consisting of: qq) hydrogen, halogen, cyano, or OH; rr)-CO 2 H or -CO 2 - (C 1 -C 6 alkyl), ss) halogen, CF 3 C is substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group consisting of , and OH; 1 -C 6 Alkyl or -O-C 1 -C 6 Alkyl, tt) phenyl, benzyl, C 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Cycloalkyl is phenyl, benzyl, C 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Each ring of the cycloalkyl group is substituted with 0, 1, 2, or 3 substituents selected from OH, halogen, cyano, and C1-C6 alkyl; 1 -C 6 The alkyl group is a halogen, -CF 3 phenyl, benzyl, C, each of which is further substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group consisting of phenyl, benzyl, C, and OH; 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Cycloalkyl, uu) a 5- or 6-membered heterocyclic ring containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, said 5- or 6-membered heterocyclic ring being selected from the group consisting of OH, halogen, benzyl, and C; 1 -C 6 substituted by 0, 1, 2, or 3 substituents selected from alkyl, 1 -C 6 a 5- or 6-membered heterocyclic ring in which the alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen and OH; vv) 2 R 3 forms a bridge between carbon atoms, said atoms of said bridge comprising 1, 2, or 3 atoms independently selected from the group of carbon, N, O, and S; R 4 occurs once or twice and is selected from H, halogen, oxo, C 1 -C 6 Alkyl, -(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -O-(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), phenyl, benzyl, or 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are independently selected from the group of heterocyclic rings selected from the group of N, O, and S, x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from alkyl 1 -C 6 is selected from the group of alkyl, Y 2 When is carbon, R 4 But -O-C 1 -C 6 It may also be alkyl, or two R 4 may form a spirocyclic carbocycle or a spirocyclic heterocycle, The R 4 C 1 -C 6 Alkyl, -C(=O)-O-C 1 -C 6 Alkyl, and —O—C 1 -C 6 Alkyl groups, and the -(CH 2 ) n2 -C 3 -C 6 Cycloalkyl and -O-(CH 2 ) n2 -C 3 -C 6 The rings of the cycloalkyl, phenyl, and benzyl groups are each independently selected from halogen, CF 3 , OH, heterocyclic rings having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, substituted or unsubstituted phenyl, and -O-C 1 -C 3 substituted by 0, 1, 2, or 3 substituents selected from the group consisting of alkyl, R 5 But H and C 1 -C 6 alkyl, wherein R 5 C 1 -C 6 The alkyl group is a halogen, -CF 3 , -NR x R y and OH; R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 is selected from the group of alkyl, R 6 But, H, C 1 -C 6 R is an alkyl group having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, a heterocyclic ring, phenyl, and benzyl; 6 C 1 -C 6 The alkyl group is a halogen, -CF 3 , -NR x R y and OH, wherein R 6 The rings of the phenyl and benzyl groups and the heterocyclic rings are 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, halogen, -CF 3 and OH, wherein R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from alkyl 1 -C 6 is selected from the group of alkyl, A compound, or a pharma- ceutically acceptable salt thereof, wherein n2 in each instance is an integer selected from the group of 0, 1, 2, and 3.

4. A compound of formula (ID) or a pharma- ceutically acceptable salt thereof, 【Chemistry 16】 During the ceremony, X 1 is selected from the group consisting of: 【Chemistry 17】 n a is an integer selected from the group of 0, 1, and 2; n b is an integer selected from the group of 0, 1, 2, 3, and 4, However, n a +n b The total must be between 2 and 4, or Or X 1 and Z 1 taken together form a fused ring system of formula (Ia) 【Chemistry 18】 R a is hydrogen and C 1 -C 3 is selected from the group of alkyl, X 2 is selected from the group consisting of: 【Chemistry 19】 Wavy lines in each case 【Chemistry 20】 But each X 1 and X 2 represents the bond to which the moiety is attached, Y 1 is selected from the group of C and N; Y 2 is selected from the group of C, N, S, and O, with the proviso that Y 2 When is O, R 4 does not exist, and Y 2 If S, then R 4 is absent or present one or two times, However, Y 1 and Y 2 Provided that two or more of the above are not C, n c is an integer selected from the group of 1, 2, and 3; n d is an integer selected from the group of 1, 2, and 3, However, n c +n d The total of the above must be between 2 and 6. Z 1 , Z 2 , and Z 3 are each independently selected from the group of C and N, with the proviso that Z 1 , Z 2 , and Z 3 But, R 2 or non-hydrogen R 2 ', provided that C; R 1 But, C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -NR x R y , phenyl, and benzyl; 1 -C 6 Alkyl groups, and the -(CH 2 ) n1 -C 3 -C 6 The rings of cycloalkyl, phenyl, and benzyl groups are free of halogen, OH, CF 3 , and -O-C 1 -C 3 substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl, R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 is selected from the group of alkyl, n1 is an integer selected from the group consisting of 0, 1, 2, and 3; R 2 is selected from the group of phenyl, pyridinyl, and a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system bonded through a carbon atom and containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 0, 1, 2, 3, or 4 additional ring heteroatoms selected from the group of N, S, and O, any of the foregoing being selected from C 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -CF 3 , halogen, oxo, cyano, -O-(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)OH, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), -(CH 2 ) n1 -heterocyclyl (including monocyclic heterocyclic rings or bicyclic or spirocyclic heterocyclic ring systems containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from the group N, S, and O), and phenyl, wherein R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 alkyl, with the proviso that -(CH 2 ) n1 -C 3 -C 6 When not substituted at least once by cycloalkyl or phenyl, R 2 is not pyridinyl, R 2 ' is hydrogen, OH, halogen, C 1 -C 6 Alkyl, and -CF 3 is selected from the group R 3 is present one or more times and is independently selected from the group consisting of: ww) hydrogen, halogen, cyano, or OH; xx) -CO 2 H or -CO 2 - (C 1 -C 6 alkyl), yy) halogen, CF 3 C is substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group consisting of , and OH; 1 -C 6 Alkyl or -O-C 1 -C 6 Alkyl, zz) phenyl, benzyl, C 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Cycloalkyl is phenyl, benzyl, C 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Each ring of the cycloalkyl group is selected from the group consisting of OH, halogen, cyano, and C. 1 -C 6 substituted by 0, 1, 2, or 3 substituents selected from alkyl, 1 -C 6 The alkyl group is a halogen, -CF 3 phenyl, benzyl, C, each of which is further substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group consisting of phenyl, benzyl, C, and OH; 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Cycloalkyl, aaa) a 5- or 6-membered heterocyclic ring containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, said 5- or 6-membered heterocyclic ring being selected from the group consisting of OH, halogen, benzyl, and C; 1 -C 6 substituted by 0, 1, 2, or 3 substituents selected from alkyl, 1 -C 6 a 5- or 6-membered heterocyclic ring in which the alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen and OH; bbb) 2 R 3 forms a bridge between carbon atoms, said atoms of said bridge comprising 1, 2, or 3 atoms independently selected from the group of carbon, N, O, and S; R 4 occurs once or twice and is selected from H, halogen, oxo, C 1 -C 6 Alkyl, -(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -O-(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), phenyl, benzyl, or 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are independently selected from the group of heterocyclic rings selected from the group of N, O, and S, x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from alkyl 1 -C 6 is selected from the group of alkyl, Y 2 When is carbon, R 4 But -O-C 1 -C 6 It may also be alkyl, or two R 4 may form a spirocyclic carbocycle or a spirocyclic heterocycle, The R 4 C 1 -C 6 Alkyl, -C(=O)-O-C 1 -C 6 Alkyl, and —O—C 1 -C 6 Alkyl groups, and the -(CH 2 ) n2 -C 3 -C 6 Cycloalkyl and -O-(CH 2 ) n2 -C 3 -C 6 The rings of the cycloalkyl, phenyl, and benzyl groups are each independently selected from halogen, CF 3 , OH, heterocyclic rings having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, substituted or unsubstituted phenyl, and -O-C 1 -C 3 substituted by 0, 1, 2, or 3 substituents selected from the group consisting of alkyl, R 5 But H and C 1 -C 6 alkyl, wherein R 5 C 1 -C 6 The alkyl group is a halogen, -CF 3 , -NR x R y and OH; R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 is selected from the group of alkyl, R 6 But, H, C 1 -C 6 R is an alkyl group having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, a heterocyclic ring, phenyl, and benzyl; 6 C 1 -C 6 The alkyl group is a halogen, -CF 3 , -NR x R y and OH, wherein R 6 The rings of the phenyl and benzyl groups and the heterocyclic rings are 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, halogen, -CF 3 and OH, wherein R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from alkyl 1 -C 6 is selected from the group of alkyl, A compound, or a pharma- ceutically acceptable salt thereof, wherein n2 in each instance is an integer selected from the group of 0, 1, 2, and 3.

5. A compound of formula (IE), or a pharma- ceutically acceptable salt thereof, 【Chemistry 21】 During the ceremony, X 1 is selected from the group consisting of: 【Chemical 22】 n a is an integer selected from the group of 0, 1, and 2; n b is an integer selected from the group of 0, 1, 2, 3, and 4, However, n a +n b The total must be between 2 and 4, or Or X 1 and Z 1 taken together form a fused ring system of formula (Ia) 【Chemistry 23】 R a is hydrogen and C 1 -C 3 is selected from the group of alkyl, X 2 is selected from the group consisting of: 【Chemistry 24】 Wavy lines in each case 【Chemistry 25】 But each X 1 and X 2 represents the bond to which the moiety is attached, Y 1 is selected from the group of C and N; Y 2 is selected from the group of C, N, S, and O, with the proviso that Y 2 When is O, R 4 does not exist, and Y 2 If S, then R 4 is absent or present one or two times, However, Y 1 and Y 2 Provided that two or more of the above are not C, n c is an integer selected from the group of 1, 2, and 3; n d is an integer selected from the group of 1, 2, and 3, However, n c +n d The total of the above must be between 2 and 6. Z 1 , Z 2 , and Z 3 are each independently selected from the group of C and N, with the proviso that Z 1 , Z 2 , and Z 3 But, R 2 or non-hydrogen R 2 ', provided that C; R 1 But, C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -NR x R y , phenyl, and benzyl; 1 -C 6 Alkyl groups, and the -(CH 2 ) n1 -C 3 -C 6 The rings of cycloalkyl, phenyl, and benzyl groups are free of halogen, OH, CF 3 , and -O-C 1 -C 3 substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl, R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 is selected from the group of alkyl, n1 is an integer selected from the group consisting of 0, 1, 2, and 3; R 2 is selected from the group of phenyl, pyridinyl, and a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system bonded through a carbon atom and containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 0, 1, 2, 3, or 4 additional ring heteroatoms selected from the group of N, S, and O, any of the foregoing being selected from C 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -CF 3 , halogen, oxo, cyano, -O-(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)OH, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), -(CH 2 ) n1 -heterocyclyl (including a monocyclic heterocyclic ring or a bicyclic or spirocyclic heterocyclic ring system containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from the group of N, S, and O), and phenyl, with the proviso that -(CH 2 ) n1 -C 3 -C 6 When not substituted at least once by cycloalkyl or phenyl, R 2 is not pyridinyl, R 2 ' is hydrogen, OH, halogen, C 1 -C 6 Alkyl, and -CF 3 is selected from the group R 3 is present one or more times and is independently selected from the group consisting of: ccc) hydrogen, halogen, cyano, or OH; ddd)-CO 2 H or -CO 2 - (C 1 -C 6 alkyl), eee) halogen, CF 3 C is substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group consisting of , and OH; 1 -C 6 Alkyl or -O-C 1 -C 6 Alkyl, fff) phenyl, benzyl, C 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Cycloalkyl is phenyl, benzyl, C 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Each ring of the cycloalkyl group is selected from the group consisting of OH, halogen, cyano, and C. 1 -C 6 substituted by 0, 1, 2, or 3 substituents selected from alkyl, 1 -C 6 The alkyl group is a halogen, -CF 3 phenyl, benzyl, C, each of which is further substituted by 0, 1, 2, 3, 4, or 5 substituents selected from the group consisting of phenyl, benzyl, C, and OH; 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Cycloalkyl, ggg) a 5- or 6-membered heterocyclic ring containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, wherein the 5- or 6-membered heterocyclic ring is selected from the group consisting of OH, halogen, benzyl, and C. 1 -C 6 substituted by 0, 1, 2, or 3 substituents selected from alkyl, 1 -C 6 a 5- or 6-membered heterocyclic ring in which the alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group of halogen and OH; hhh) 2 R 3 forms a bridge between carbon atoms, said atoms of said bridge comprising 1, 2, or 3 atoms independently selected from the group of carbon, N, O, and S; R 4 occurs once or twice and is a halogen; R 5 But H and C 1 -C 6 alkyl, wherein R 5 C 1 -C 6 The alkyl group is a halogen, -CF 3 , -NR x R y and OH; R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 is selected from the group of alkyl, R 6 But, H, C 1 -C 6 R is an alkyl group having 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are selected from the group of N, O, and S, a heterocyclic ring, phenyl, and benzyl; 6 C 1 -C 6 The alkyl group is a halogen, -CF 3 , -NR x R y and OH, wherein R 6 The rings of the phenyl and benzyl groups and the heterocyclic rings are 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, halogen, -CF 3 and OH, wherein R x and R y each independently represents a halogen, OH, CF 3 , and -O-C 1 -C 3 H and C substituted by 0, 1, 2, or 3 substituents selected from alkyl 1 -C 6 is selected from the group of alkyl, n2 in each instance is an integer selected from the group of 0, 1, 2, and 3; However, the compound is not particularly limited to N-[4-(4,4-difluoropiperidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide, (4,4-difluoropiperidin-1-yl)-[4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-[3-(trifluoromethyl)pyrazol-1-yl]phenyl]methanone, [2-(3-cyclopropylpyrazol-1-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)- or a pharma- ceutically acceptable salt thereof, provided that the compound is not N-[4-(4-fluoropiperidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide, N-[4-(4-fluoropiperidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide, or N-[4-(4-fluoropiperidine-1-carbonyl)-3-pyrrolidin-1-ylphenyl]cyclopropanecarboxamide, or a pharma- ceutically acceptable salt thereof.

6. R 4 The compound of any one of claims 1 to 5, wherein is not unsubstituted benzyl.

7. R 4 The compound according to any one of claims 1 to 5, wherein is not an unsubstituted pyridinyl.

8. R 4 The compound of any one of claims 1 to 5, wherein is not substituted or unsubstituted phenyl.

9. R 3 The compound according to any one of claims 1 to 5, wherein is not H.

10. having the formula 【Chemistry 26】 During the ceremony, X 1 , X 2 , R 2 is as defined in any one of claims 1 to 9, Z 1 , Z 2 , and Z 3 is C, R 2 ', R 2 ' a and OH, halogen, C 1 -C 6 Alkyl, and -CF 3 10. The compound according to any one of claims 1 to 9, selected from the group consisting of:

11. having the formula 【Chemical 27】 During the ceremony, X 1 , X 2 , R 2 is as defined in any one of claims 1 to 9, Z 1 , Z 2 , and Z 3 is C, R 2 ', R 2 ' b and OH, halogen, C 1 -C 6 Alkyl, and -CF 3 10. The compound according to any one of claims 1 to 9, selected from the group consisting of:

12. having the formula 【Chemistry 28】 During the ceremony, X 1 , X 2 , R 2 is as defined in any one of claims 1 to 9, Z 1 , Z 2 , and Z 3 is C, R 2 ', R 2 ' c and hydrogen, OH, halogen, C 1 -C 6 Alkyl, and -CF 3 10. The compound according to any one of claims 1 to 9, selected from the group consisting of:

13. having the formula 【Chemical Formula 29】 In the formula, X 1 , Z 1 , Z 2 , Z 3 , Y 1 , Y 2 , R 2 , R 2 ', R 3 , and R 4 is as defined in claim 1, 2, or 4, or a pharma- ceutically acceptable salt thereof.

14. having the formula 【Chemistry 30】 In the formula, X 1 , Z 1 , Z 2 , Z 3 , R 2 , R 2 ', and R 3 is as defined in claim 1, 2, or 4, or a pharma- ceutically acceptable salt thereof.

15. having the formula 【Chemistry 31】 In the formula, X 1 , Z 1 , Z 2 , Z 3 , R 2 , R 2 ', and R 3 is as defined in claim 1, 2, or 4, or a pharma- ceutically acceptable salt thereof.

16. having the formula 【Chemistry 32】 In the formula, X 1 , Z 1 , Z 2 , Z 3 , R 2 , R 2 ', and R 4 is as defined in claim 1, 2, or 4, or a pharma- ceutically acceptable salt thereof.

17. having the formula 【Chemical 33】 In the formula, X 1 , Z 1 , Z 2 , Z 3 , R 2 , R 2 ', R 4 , R 5 , and R 6 is as defined in claim 1, 2, or 4, or a pharma- ceutically acceptable salt thereof.

18. having the formula 【Chemical Formula 34】 In the formula, X 1 , Z 1 , Z 2 , Z 3 , R 2 , R 2 ', and R 4 A compound according to any one of claims 1 to 4, or a pharma- ceutically acceptable salt thereof, wherein:

19. having the formula 【Chemistry 35】 In the formula, X 1 , Z 1 , Z 2 , Z 3 , R 2 , R 2 ', and R 4 A compound according to any one of claims 1 to 5, or a pharma- ceutically acceptable salt thereof, wherein:

20. having the formula 【Chemical 36】 During the ceremony, Z 1 , Z 2 , Z 3 , Y 1 , Y 2 , R a , R 1 , R 2 , R 2 ', R 3 , and R 4 3. The compound according to claim 1 or 2, wherein:

21. having the formula 【Chemical 37】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', and R 3 3. The compound according to claim 1 or 2, wherein:

22. having the formula 【Chemical Formula 38】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', and R 4 3. The compound according to claim 11 or 2, wherein:

23. having the formula 【Chemical Formula 39】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', and R 3 3. The compound according to claim 1 or 2, wherein:

24. having the formula 【Chemistry 40】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', R 5 , and R 6 3. The compound according to claim 1 or 2, wherein:

25. having the formula 【Chemistry 41】 During the ceremony, Z 1 , Z 2 , Z 3 , Y 1 , Y 2 , R a , R 1 , R 2 , R 2 ', R 3 , and R 4 3. The compound according to claim 1 or 2, wherein:

26. having the formula 【Chemistry 42】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', and R 3 3. The compound according to claim 1 or 2, wherein:

27. having the formula 【Chemistry 43】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', and R 4 3. The compound according to claim 1 or 2, wherein:

28. having the formula 【Chemistry 44】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', and R 4 3. The compound according to claim 1 or 2, wherein:

29. having the formula 【Chemistry 45】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', R 5 , and R 6 3. The compound according to claim 1 or 2, wherein:

30. having the formula 【Chemistry 46】 During the ceremony, Z 1 , Z 2 , Z 3 , Y 1 , Y 2 , R a , R 1 , R 2 , R 2 ', and R 4 3. The compound according to claim 1 or 2, wherein:

31. having the formula 【Chemistry 47】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', and R 3 3. The compound according to claim 1 or 2, wherein:

32. having the formula 【Chemistry 48】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', and R 4 3. The compound according to claim 1 or 2, wherein:

33. having the formula 【Chemistry 49】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', and R 3 3. The compound according to claim 1 or 2, wherein:

34. having the formula 【Chemistry 50】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', R 5 , and R 6 3. The compound according to claim 1 or 2, wherein:

35. having the formula 【Chemistry 51】 During the ceremony, Z 1 , Z 2 , Z 3 , Y 1 , Y 2 , R a , R 1 , R 2 , R 2 ', R 3 , and R 4 3. The compound according to claim 1 or 2, wherein:

36. having the formula 【Chemistry 52】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', and R 3 3. The compound according to claim 1 or 2, wherein:

37. having the formula 【Chemistry 53】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', and R 4 3. The compound according to claim 1 or 2, wherein:

38. having the formula 【Chemical 54】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', and R 3 3. The compound according to claim 1 or 2, wherein:

39. having the formula 【Chemistry 55】 During the ceremony, Z 1 , Z 2 , Z 3 , R a , R 1 , R 2 , R 2 ', R 5 , and R 6 3. The compound according to claim 1 or 2, wherein:

40. having the formula 【Chemistry 56】 During the ceremony, Z 1 , Z 2 , Z 3 , Y 1 , Y 2 , R 1 , R 2 , R 2 ', R 3 , and R 4 3. The compound according to claim 1 or 2, wherein:

41. having the formula 【Chemistry 57】 During the ceremony, Z 1 , Z 2 , Z 3 , R 1 , R 2 , R 2 ', and R 3 3. The compound according to claim 1 or 2, wherein:

42. having the formula 【Chemistry 58】 During the ceremony, Z 1 , Z 2 , Z 3 , R 1 , R 2 , R 2 ', and R 4 3. The compound according to claim 1 or 2, wherein:

43. having the formula 【Chemical Formula 59】 During the ceremony, Z 1 , Z 2 , Z 3 , R 1 , R 2 , R 2 ', and R 3 3. The compound according to claim 1 or 2, wherein:

44. having the formula 【Chemistry 60】 During the ceremony, Z 1 , Z 2 , Z 3 , Y 1 , Y 2 , R 1 , R 2 , R 2 ', R 3 , and R 4 3. The compound according to claim 1 or 2, wherein:

45. having the formula 【Chemistry 61】 During the ceremony, Z 1 , Z 2 , Z 3 , R 1 , R 2 , R 2 ', and R 3 3. The compound according to claim 1 or 2, wherein:

46. having the formula 【Chemistry 62】 During the ceremony, Z 1 , Z 2 , Z 3 , R 1 , R 2 , R 2 ', and R 4 3. The compound according to claim 1 or 2, wherein:

47. having the formula 【Chemistry 63】 During the ceremony, Z 1 , Z 2 , Z 3 , R 1 , R 2 , R 2 ', and R 3 3. The compound according to claim 1 or 2, wherein:

48. having the formula 【Chemistry 64】 During the ceremony, Z 1 , Z 2 , Z 3 , R 1 , R 2 , R 2 ', R 5 , and R 6 3. The compound according to claim 1 or 2, wherein:

49. having the formula 【Chemistry 65】 During the ceremony, Z 1 , Z 2 , Z 3 , Y 1 , Y 2 , R 2 , R 2 ', R 3 , R 4 , n a , and n b 3. The compound according to claim 1 or 2, wherein:

50. having the formula 【Chemistry 66】 During the ceremony, Z 1 , Z 2 , Z 3 , R 2 , R 2 ', R 3 , n a , and n b 3. The compound according to claim 1 or 2, wherein:

51. having the formula 【Chemistry 67】 During the ceremony, Z 1 , Z 2 , Z 3 , R 2 , R 2 ', R 4 , n a , and n b 3. The compound according to claim 1 or 2, wherein:

52. having the formula 【Chemistry 68】 During the ceremony, Z 1 , Z 2 , Z 3 , R 2 , R 2 ', R 3 , n a , and n b 3. The compound according to claim 1 or 2, wherein:

53. having the formula 【Chemistry 69】 During the ceremony, Z 1 , Z 2 , Z 3 , R 2 , R 2 ', R 5 , and R 6 3. The compound according to claim 1 or 2, wherein:

54. having the formula 【Chemistry 70】 During the ceremony, Z 1 , Z 2 , Z 3 , R 2 , R 2 ', and X 2 is as defined in claim 1, 2, 3, or 5, or a pharma- ceutically acceptable salt thereof.

55. having the formula 【Chemistry 71】 During the ceremony, Z 1 , Z 2 , Z 3 , R 2 , R 2 ', and X 2 is as defined in claim 1, 2, 3, or 5, or a pharma- ceutically acceptable salt thereof.

56. having the formula 【Chemical Formula 72】 During the ceremony, Z 1 , Z 2 , Z 3 , R 2 ', and X 2 is as defined in claim 1, 2, 3 or 5, R 7 is -OH, halogen, -C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -(CH 2 ) n1 -heterocycle (including monocyclic heterocyclic rings or bicyclic or spirocyclic heterocyclic ring systems containing 3, 4, 5, 6, 7, or 8 ring carbon atoms and 1, 2, 3, or 4 ring heteroatoms selected from the group of N, S, and O), cyano, -O-(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)OH, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), and -CF 3 or a pharma- ceutically acceptable salt thereof, having the formula: wherein any of said alkyl groups is further substituted with 0, 1, 2, 3, or 4 substituents selected from halogen and -OH; and n1 is an integer selected from the group of 0, 1, 2, and 3.

57. having the formula 【Chemical 73】 During the ceremony, Z 1 , Z 2 , Z 3 , R 2 ', and X 2 is as defined in any one of claims 1, 2, 3 or 5, R 7 is -OH, halogen, -C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -(CH 2 ) n1 -C 3 -C 6 Heterocycle (containing at least one heteroatom selected from the group of O, N, and S), cyano, -O-(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)OH, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), and -CF 3 or a pharma- ceutically acceptable salt thereof, having the formula: wherein any of said alkyl groups is further substituted with 0, 1, 2, 3, or 4 substituents selected from halogen and -OH; and n1 is an integer selected from the group of 0, 1, 2, and 3.

58. Z 1 , Z 2 , and Z 3 or a pharma- ceutically acceptable salt thereof. The compound of any one of claims 1 to 57, wherein each is C.

59. Z 1 , Z 2 , and Z 3 or a pharma- ceutically acceptable salt thereof.

58. The compound of any one of claims 1 to 57, wherein one of is N and the other is C; or a pharma- ceutically acceptable salt thereof.

60. Z 1 , Z 2 , and Z 3 and the other is C; or a pharma- ceutically acceptable salt thereof.

61. Z 1 , Z 2 , and Z 3 or a pharma- ceutically acceptable salt thereof. The compound according to any one of claims 1 to 57, wherein each is N.

62. Z 1 and Z 2 are each C, and Z 3 is N or Z 1 is N, and Z 2 and Z 3 or a pharma- ceutically acceptable salt thereof.

63. Z 1 and Z 3 are each C, and Z 2 or a pharma- ceutically acceptable salt thereof.

64. Z 1 and Z 3 are each N, and Z 2 or a pharma- ceutically acceptable salt thereof.

65. Z 1 and Z 2 are each N, and Z 3 or a pharma- ceutically acceptable salt thereof.

66. Z 2 and Z 3 are each N, and Z 1 or a pharma- ceutically acceptable salt thereof.

67. R 2 A compound according to any one of claims 1 and 6 to 66, or a pharma- ceutically acceptable salt thereof, wherein: 【Chemical 74】 【change】 During the ceremony, R 7 occurs once or twice, and is selected from hydrogen, —OH, halogen, —C 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -(CH 2 ) n1 -C 3 -C 6 Heterocycle (containing at least one heteroatom selected from O, N, and S), cyano, —O—(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)OH, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), and -CF 3 wherein any of said alkyl groups are further substituted with 0, 1, 2, 3, or 4 substituents selected from halogen and -OH, and n1 is an integer selected from the group of 0, 1, 2, and 3.

68. R 2 67. The compound of any one of claims 1 and 6 to 66, or a pharma- ceutically acceptable salt thereof, wherein is selected from the group consisting of: 【Chemistry 75】

69. R 2 is selected from the group consisting of: 【Chemical 76】 During the ceremony, R 5 and R 6 each independently represents hydrogen, —OH, halogen, —C 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -(CH 2 ) n1 -C 3 -C 6 Heterocycle (containing at least one heteroatom selected from the group of N, S, and O), cyano, -O-(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)OH, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), and -CF 3 wherein any of said alkyl groups are further substituted with 0, 1, 2, 3, or 4 substituents selected from halogen and -OH, and n1 is an integer selected from the group of 0, 1, 2, and 3.

70. R 2 is selected from the group consisting of: 【Chemical Formula 77】 During the ceremony, R 7 and R 8 each independently represents hydrogen, —OH, halogen, —C 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -(CH 2 ) n1 -C 3 -C 6 Heterocycle (containing at least one heteroatom selected from O, N, and S), cyano, —O—(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)OH, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), and -CF 3 wherein any of said alkyl groups is further substituted with 0, 1, 2, 3, or 4 substituents selected from halogen and -OH; and n1 is an integer selected from the group of 0, 1, 2, and 3; or a pharma- ceutically acceptable salt thereof.

71. R 2 is selected from the group consisting of: 【Chemical 78】 During the ceremony, R 5 and R 6 each independently represents hydrogen, —OH, halogen, —C 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, -(CH 2 ) n1 -C 3 -C 6 Cycloalkyl, -(CH 2 ) n1 -C 3 -C 6 Heterocycle (containing at least one heteroatom selected from the group of N, S, and O), cyano, -O-(CH 2 ) n2 -C 3 -C 6 Cycloalkyl, -C(=O)OH, -C(=O)-O-C 1 -C 6 Alkyl, -S(=O) 2 -C 1 -C 6 Alkyl, -C(=O)-NR x R y , -N(R x ) (S(=O) 2 -C 1 -C 6 alkyl), and -CF 3 wherein any of said alkyl groups is further substituted with 0, 1, 2, 3, or 4 substituents selected from halogen and -OH; and n1 is an integer selected from the group of 0, 1, 2, and 3; or a pharma- ceutically acceptable salt thereof.

72. R 2 is the group 【Chemical 79】 During the ceremony, R 5 and R 6 are each independently hydrogen, halogen, C 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, and -CF 3 67. The compound according to any one of claims 2 to 66, or a pharma- ceutically acceptable salt thereof, selected from:

73. R 2 is selected from the group consisting of: 【Chemistry 80】 During the ceremony, R 5 and R 6 are each independently hydrogen, halogen, C 1 -C 6 Alkyl, —O—C 1 -C 6 Alkyl, and -CF 3 67. The compound according to any one of claims 2 to 66, or a pharma- ceutically acceptable salt thereof, selected from:

74. R 5 and R 6 each independently represents hydrogen, C 1 -C 4 Alkyl, and C 1 -C 4 74. The compound according to any one of claims 1 to 73, selected from the group of alkoxy, or a pharma- ceutically acceptable salt thereof.

75. R 5 and R 6 each independently represents hydrogen, C 1 -C 3 Alkyl, and C 1 -C 3 75. The compound according to any one of claims 1 to 74, wherein the compound is selected from the group of alkoxy, or a pharma- ceutically acceptable salt thereof.

76. R 3 occurs 1 to 3 times, occurs 2 times, or occurs only 1 time, and optionally, R 3 is hydrogen, C 1 -C 4 Alkyl, C 3 -C 6 Cycloalkyl, -CF 3 , -C 1 -C 4 alkyl-OH, phenyl, benzyl, pyrazolyl, and thiophenyl, wherein the phenyl, pyrazolyl, and thiophenyl rings are selected from the group consisting of halogen, OH, CF 3 , C 1 -C 4 Alkyl, and C 1 -C 4 or R 3 But halogens, OH, CF 3 , C 1 -C 4 Alkyl, and C 1 -C 4 76. The compound of any one of claims 1 to 75, which is selected from the group of phenyl, benzyl, pyrazolyl, and thiophenyl, substituted with 0, 1, 2, or 3 substituents selected from the group of alkoxy, or a pharma- ceutically acceptable salt thereof.

77. Y 1 and Y 2 or a pharma- ceutically acceptable salt thereof. The compound of any one of claims 1 to 76, wherein each is N.

78. Y 1 is N and Y 2 or a pharma- ceutically acceptable salt thereof.

79. Y 1 is C and Y 2 is N; or a pharma- ceutically acceptable salt thereof.

80. R 1 But halogens, OH, CF 3 , and -O-C 1 -C 3 C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 80. The compound of any one of claims 1 to 79, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;

81. R 1 But halogens, OH, CF 3 , and -O-C 1 -C 3 C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 4 80. The compound of any one of claims 1 to 79, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;

82. R 1 But -(CH 2 ) n1 -C 3 -C 6 is selected from the group consisting of cycloalkyl, phenyl, and benzyl; 2 ) n1 -C 3 -C 6 The rings of the cycloalkyl, phenyl, and benzyl groups may be free of halogen, OH, CF 3 , and -O-C 1 -C 3 80. The compound of any one of claims 1 to 79, or a pharma- ceutically acceptable salt thereof, substituted with 0, 1, 2, or 3 substituents selected from the group alkyl.

83. R a is H; or a pharma- ceutically acceptable salt thereof.

84. R a But, C 1 -C 3 2. A compound according to any preceding claim, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;

85. R 3 is H; or a pharma- ceutically acceptable salt thereof.

86. R 3 But, C 1 -C 3 2. A compound according to any preceding claim, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;

87. R 3 But CO 2 H and -CO 2 - (C 1 -C 6 4. The compound according to any of the preceding claims, wherein the compound is selected from the group consisting of:

88. R 3 Phenyl, benzyl, C 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 cycloalkyl, selected from the group consisting of phenyl, benzyl, C 3 -C 6 Cycloalkyl and -CH 2 -C 3 -C 6 Each ring of the cycloalkyl group is selected from the group consisting of OH, halogen, and C. 1 -C 6 substituted by 0, 1, 2, or 3 substituents selected from alkyl, 1 -C 6 The alkyl group is a halogen, -CF 3 4. A compound according to any preceding claim, further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group:

89. R 3 is selected from the group of 5- or 6-membered heterocyclic rings containing 1, 2, or 3 ring heteroatoms independently selected from O, S, and N, said 5- or 6-membered heterocyclic rings being selected from the group of OH, halogen, and C 1 -C 6 substituted by 0, 1, 2, or 3 substituents selected from alkyl, 1 -C 6 10. A compound according to any preceding claim, or a pharma- ceutically acceptable salt thereof, wherein the alkyl group is further substituted with 0, 1, 2, 3, 4, or 5 substituents selected from the group halogen and OH.

90. n a +n b or a pharma- ceutically acceptable salt thereof.

2. The compound of claim 1, wherein the sum of

91. n a +n b or a pharma- ceutically acceptable salt thereof.

2. The compound of claim 1, wherein the sum of

92. R 4 But halogen, CF 3 , OH, and —O—C 1 -C 3 C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 6 2. A compound according to any preceding claim, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;

93. R 4 is halogen, CF3, OH, and -O-C 1 -C 3 C substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl 1 -C 4 2. A compound according to any preceding claim, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;

94. R 4 is substituted by 0, 1, 2 or 3 halogens and OH; 1 -C 4 2. A compound according to any preceding claim, or a pharma- ceutically acceptable salt thereof, wherein: R is an alkyl group;

95. R 4 But -(CH 2 ) n2 -C 3 -C 6 cycloalkyl, and the -(CH 2 ) n2 -C 3 -C 6 The cycloalkyl ring of the cycloalkyl group may be selected from the group consisting of halogen, CF 3 , OH, and —O—C 1 -C 3 4. A compound according to any preceding claim, wherein n is substituted by 0, 1, 2, or 3 substituents selected from the group of alkyl, and n2 is an integer selected from the group of 0, 1, 2, or 3, or a pharma- ceutically acceptable salt thereof.

96. R 4 is selected from the group of phenyl and benzyl, the rings of the phenyl and benzyl groups being free of halogen, CF 3 , OH, and —O—C 1 -C 3 2. A compound according to any preceding claim, substituted by 0, 1, 2 or 3 substituents selected from the group alkyl, or a pharma- ceutically acceptable salt thereof.

97. R 4 has 3, 4, 5, 6, 7, 8, 9, or 10 ring atoms, of which 1, 2, 3, or 4 ring atoms are heterocyclic or heteroaromatic rings selected from the group of N, O, and S, and the rings of the phenyl and benzyl groups are each independently selected from halogen, CF 3 , OH, and —O—C 1 -C 3 2. A compound according to any preceding claim, substituted by 0, 1, 2 or 3 substituents selected from the group alkyl, or a pharma- ceutically acceptable salt thereof.

98. Y 2 is C and R 4 H, -O-C 1 -C 6 Alkyl, and -O-(CH 2 ) n2 -C 3 -C 6 cycloalkyl, wherein said O—C 1 -C 6 The alkyl group and the -O-(CH 2 ) n2 -C 3 -C 6 The cycloalkyl rings of the cycloalkyl are each independently selected from halogen, CF 3 , OH, and —O—C 1 -C 3 or 2 R 4 But, C 3 -C 6 2. A compound according to any of the preceding claims, which either forms a cycloalkyl carbocyclic ring or a heterocyclic ring containing from 2 to 5 ring carbon atoms and 1 or 2 ring heteroatoms selected from the group of N and O, or a pharma- ceutically acceptable salt thereof.

99. Said-C 1 -C 6 The alkyl group and the -O-(CH 2 ) n2 -C 3 -C 6 2. A compound according to any preceding claim, wherein said cycloalkyl ring of the cycloalkyl is substituted with 0, 1, 2, or 3 substituents each independently selected from the group halogen and OH; or a pharma- ceutically acceptable salt thereof.

100. A pharmaceutical composition comprising a pharma- ceutically effective amount of a compound selected from any of the preceding claims, or from Examples 1-125, or a pharma- ceutically acceptable salt as described above, and a pharma- ceutically acceptable carrier or excipient.

101. 20. Use of a compound selected from any of the preceding claims, or from Examples 1 to 125, or a pharma- ceutically acceptable salt as defined in any of the foregoing, in the preparation of a medicament.

102. A compound selected from any of the preceding claims, a compound selected from Examples 1-125, a compound of formula (I'), or a pharma- ceutically acceptable salt as defined in any of the foregoing, for use as a medicament.

103. A method of inhibiting activity of GPR39 protein in a subject, comprising administering to said subject in need thereof a pharma- ceutically effective amount of a compound selected from any of the preceding claims, a compound selected from Examples 1-125, a compound of formula (I'), or a pharma- ceutically acceptable salt as defined above.

104. A method of treating hypertension in a human in need thereof, comprising administering to said human a pharma- ceutically effective amount of a compound selected from any of claims 1-102, a compound selected from Examples 1-125, a compound of formula (I'), or a pharma- ceutically acceptable salt of any of the foregoing.

105. 105. The method of claim 104, wherein the hypertension is primary hypertension.

106. 105. The method of claim 104, wherein the hypertension is secondary hypertension.

107. 105. The method of claim 104, wherein the hypertension is treatment-resistant or refractory hypertension.

108. 105. The method of claim 104, wherein the hypertension is pulmonary hypertension.

109. A method of treating heart failure in a human, comprising administering to said human in need thereof a pharma- ceutically effective amount of a compound selected from any of claims 1-102, a compound selected from any of Examples 1-125, a compound of formula (I'), or a pharma- ceutically acceptable salt of any of the foregoing.

110. A method of treating breast cancer in a human in need thereof, comprising administering to said human a pharma- ceutically effective amount of a compound selected from any of claims 1-102, a compound selected from any of Examples 1-125, a compound of formula (I'), or a pharma- ceutically acceptable salt thereof.

111. A method of treating gastric adenocarcinoma in a human in need thereof, comprising administering to said human a pharma- ceutically effective amount of a compound selected from any of claims 1-102, a compound selected from any of Examples 1-125, a compound of formula (I'), or a pharma- ceutically acceptable salt thereof.

112. A method of promoting or enhancing colonic epithelial function and tight junction barrier integrity in a human, comprising administering to said human in need thereof a pharma- ceutically effective amount of a compound selected from any of claims 1-102, a compound selected from any of Examples 1-125, a compound of formula (I'), or a pharma- ceutically acceptable salt of any of the foregoing.

113. A method of treating ulcerative colon disease in a human, comprising administering to said human in need thereof a pharma- ceutically effective amount of a compound selected from any of claims 1-102, a compound selected from any of Examples 1-125, a compound of formula (I'), or a pharma- ceutically acceptable salt thereof.

114. 114. The method of claim 113, wherein the ulcerative colon disease is ulcerative colitis.

115. 114. The method of claim 113, wherein the ulcerative colon disease is Crohn's disease.

116. A method of treating inflammatory bowel disease in a human, comprising administering to said human in need thereof a pharma- ceutically effective amount of a compound selected from any of claims 1-102, a compound selected from any of Examples 1-125, a compound of formula (I'), or a pharma- ceutically acceptable salt of any of the foregoing.

117. A method of treating diarrhea in a human, comprising administering to said human in need thereof a pharma- ceutically effective amount of a compound selected from any of claims 1-102, a compound selected from Examples 1-125, a compound of formula (I'), or a pharma- ceutically acceptable salt of any of the foregoing.

118. A method of enhancing delivery of an anesthetic agent to a human experiencing a microvascular complication, comprising administering to said human in need thereof a pharma- tically effective amount of a compound selected from any of claims 1-102, a compound selected from any of Examples 1-125, a compound of formula (I'), or a pharma- tically acceptable salt as defined above, and a pharma- tically effective amount of said anesthetic agent.

119. 119. The method of claim 118, wherein the human is experiencing a microvascular complication associated with or caused by prediabetes.

120. 119. The method of claim 118, wherein the human is experiencing a microvascular complication associated with or caused by diabetes.

121. A method of treating stroke in a human in need thereof, comprising administering to said human a pharma- ceutically effective amount of a compound selected from any of claims 1-102, a compound selected from any of Examples 1-125, a compound of formula (I'), or a pharma- ceutically acceptable salt thereof.

122. A kit comprising: a) one or more compositions, each of which comprises a pharma- ceutically effective amount of a compound selected from any of claims 1-102, a compound selected from any of Examples 1-125, or a pharma- ceutically acceptable salt as described above, and a pharma- ceutically acceptable carrier or excipient; and b) instructions for administering said one or more compositions to a human in need thereof.

123. A compound according to any one of Examples 1 to 125, or a pharma- ceutically acceptable salt thereof.

Citation Information

Patent Citations

  • Triazole compounds as antiviral agents

    JP2015525743A

  • Vasopressin receptor modulators with therapeutic potential

    JP2016513112A

  • Piperazine derivatives as MAGL inhibitors

    JP2021500322A

  • Substituted triazole diamine derivatives as kinase inhibitors

    WO2002057240A1

  • Antagonists of GPR39 protein

    WO2021222858A1